Preclinical Optimization of Treatment with Inhaled Argon to Improve Neurological Outcome and Survival After Cardiac Arrest by Fumagalli, Francesca Maria
Open Research Online
The Open University’s repository of research publications
and other research outputs
Preclinical Optimization of Treatment with Inhaled
Argon to Improve Neurological Outcome and Survival
After Cardiac Arrest
Thesis
How to cite:
Fumagalli, Francesca Maria (2018). Preclinical Optimization of Treatment with Inhaled Argon to Improve
Neurological Outcome and Survival After Cardiac Arrest. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2017 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
 
 
Preclinical Optimization of Treatment with 
Inhaled Argon to Improve Neurological Outcome 
and Survival After Cardiac Arrest 
 
 
Thesis submitted by the student 
Francesca Maria Fumagalli, MSc 
(Personal identifier: C7060029) 
 
for the degree of 
Doctor of Philosophy 
Discipline of Life and Biomolecular Sciences 
 
 
 
 
Open University Research School, UK 
IRCCS- Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy 
 
 
Director of Studies 
Dr. Roberto Latini 
 
External Supervisor 
Prof. Costanza Emanueli 
 
 
 
December 2017 
 
 
ABSTRACT 
Introduction. Treatment of post cardiac arrest (CA) syndrome represents a clinical 
priority. Inhalation of the noble gas Argon may represent an attractive option. The purpose 
of the current thesis is to determine the efficacy, safety and mechanisms of action of Argon 
in different experimental models.  
Methods. In order to assess the efficacy of argon treatment on post CA syndrome, a pig 
model of CA with underlying acute myocardial infarction and cardiopulmonary 
resuscitation (CPR) was used. Following resuscitation, animals were randomly assigned to 
receive ventilation with 70% Argon (Ar 70%) or 70% Nitrogen (N270%) in oxygen. Argon 
effects were studied in models of CA with different level of severity (i.e. short or long 
duration of untreated ventricular fibrillation). Furthermore, administration of low Argon 
concentration (i.e. 50%) was evaluated in a subset of animals. Hemodynamics, myocardial 
function, neurologic recovery, brain and cardiac histological injury and biomarkers 
together with survival were evaluated. The safety of Argon treatment was assessed in 
healthy pigs. In parallel, mechanisms of action were explored. Specifically, brain 
protection was investigated in a rat model of CA followed by CPR. After resuscitation, 
animals were randomized to receive Ar 70% or N270%. Brain glutamate, gamma-amino 
butyric acid, pyruvate and lactate were measured by in vivo micro-dialysis. In addition, 
myocardial protection by argon was explored in rats subjected to coronary artery occlusion 
followed by reperfusion and receiving Ar 70% or N2 70% during reperfusion. Six and 24 h 
after reperfusion, myocardial injury, plasma troponin T concentration and myocardial 
neutrophil infiltration were evaluated. 
Results. Efficacy of argon on preventing post CA brain injury has been demonstrated in 
swine. Indeed, a faster and complete neurologic recovery following CA and CPR was 
achieved in Argon-treated animals compared to controls, without detrimental effects on 
hemodynamics and respiratory gas exchanges. Beneficial effects of Argon tended to be 
higher at a concentration of 70% than of 50%. Results obtained in small rodents suggest 
that ventilation with Argon reduces brain lactate/ pyruvate level and troponin T release. 
However, further studies are needed in order explain the mechanism underpining Argon 
protective effects.  
Conclusion. The consistency of the results is highly suggestive to consider ventilation with 
Argon as a promising therapeutic approach after CA and CPR. 
 
  
 
 
ACKNOWLEDGEMENTS 
The student Francesca Fumagalli thanks the following colleagues for their precious help 
and support. Indeed, the experimental studies described in the thesis were possible thank to 
their collaboration and enthusiasm: 
 Dr. Giuseppe Ristagno, from the Mario Negri Institute, for having mentored FF and 
directed all the experiments described in the thesis; 
 Dr. Roberto Latini, for having supervised FF, with his impressive experience in the 
clinical and experimental cardiovascular medicine, during the 4 year course;  
 Prof Costanza Emanueli,  from the University of Bristol, UK, for the 4 year 
supervision; 
 Dr. Roberta Affatato, Sabina Ceriani, Davide Olivari, Deborah Novelli, from the 
Mario Negri Institute, for the help in running the experimental studies; 
 Dr. Francesca Nespoli, Simone Redaelli, Laura Ruggeri, from the Mario Negri 
Institute, for the help in conducting bibliographic research and in summarizing the 
study results; 
 Drs. Lidia Staszewsky, Ilaria Russo, Daria De Giorgio, from the Mario Negri 
Institute, for the echocardiographic examinations; 
 Dr. Serge Masson, from the Mario Negri Institute, for the  help in the interpretation 
of the findings related to circulating biomarkers; 
 Dr. William Invernizzi, from the Mario Negri Institute, for the microdyalisis study 
and HPLC analysis; 
 Prof. Eugenio Scanziani, from Università degli studi di Milano, performing 
histological analysis; 
 Drs. Michela Magnoli, from the Mario Negri Institute, for revision of statistics; 
 Dr. Gianni  Tognoni from the Mario Negri Institute, for the final revision of this 
thesis. 
 
 
DISCLOSURE 
Funding for the thesis work 
The experimental studies described in the thesis were possible thank to the following 
supports: 
 Italian Ministry of Health “Ricerca Finalizzata - Giovani Ricercatori”. Principal 
investigator: Dr. Giuseppe Ristagno. Period: 2014-2017. FF is the co-investigator, 
Responsible of the Research Unit for the project “Preclinical optimization of 
treatment with inhaled Argon to improve neurological outcome and survival after 
cardiac arrest”. 
 Fondazione Sestini. Principal investigator: Dr. Giuseppe Ristagno. Period: 2012-
2015. 
FF is the co-investigator for the projects: 
1. “Studi di Validazione degli Effetti Protettivi dell’Argon ed Ottimizzazione 
del Trattamento Inalatorio con Argon dopo Infarto Miocardico Acuto ed 
Arresto Cardiaco: Studio Preclinico sul Maiale”. 
2. “Studi sui meccanismi di azione dell’Argon su modello arresto cardiaco e 
rianimazione sul ratto e microdialisi cerebrale”. 
 
 
Conflict of Interest 
The student and supevisors declare no conflicts of interest. 
  
 
 
TABLE OF CONTENTS 
Major abbreviations ............................................................................................................................ 7 
Introduction ......................................................................................................................................... 9 
1 Cardiac arrest: a general overview. ............................................................................................. 9 
2 Post-CA syndrome. ................................................................................................................... 12 
2.1 Post CA brain injury ......................................................................................................... 16 
2.2 Post CA myocardial dysfunction ....................................................................................... 18 
2.3 Post CA systemic inflammatory response ......................................................................... 23 
3 Circulating biomarkers in CA ................................................................................................... 27 
3.1 Circulating biomarkers of cardiac injury ......................................................................... 29 
3.2 Circulating biomarkers of brain injury ............................................................................. 32 
4 Post CA syndrome current treatments ...................................................................................... 35 
4.1 Hemodynamic management ............................................................................................. 35 
4.2 Oxygen and carbon dioxide target ................................................................................... 36 
4.3 Temperature control ......................................................................................................... 37 
5 Medical uses of noble gases ...................................................................................................... 41 
5.1 Organ protection by xenon ............................................................................................... 42 
5.2 Argon................................................................................................................................. 48 
5.2.1 In vitro studies ........................................................................................................... 49 
5.2.2 In vivo studies ........................................................................................................... 50 
5.2.3 Clinical uses of Argon ............................................................................................... 51 
6 Aims and hypothesis ................................................................................................................. 54 
Material and methods ........................................................................................................................ 55 
1 Experimental design .................................................................................................................. 55 
2 Pig model of short duration CA and CPR- Experiment 1 ......................................................... 58 
2.1 Animal preparation ........................................................................................................... 58 
2.2 Measurements ................................................................................................................... 60 
2.3 Statistical analyses ............................................................................................................ 62 
3 Pig model of prolonged CA and CPR- Experiment 2 ............................................................... 63 
3.1 Animal preparation ........................................................................................................... 63 
3.2 Experimental procedures .................................................................................................. 63 
3.3 Measurements ................................................................................................................... 65 
3.4 Statistical analysis ............................................................................................................ 66 
4 Safety- Experiment 3 ................................................................................................................ 67 
4.1 Animal preparation ........................................................................................................... 67 
4.2 Experimental procedures and measurements ................................................................... 67 
5 Rat model of CA and CPR- Experiment 4 ................................................................................ 68 
 
 
5.1 Animal preparation ........................................................................................................... 68 
5.2 Experimental procedures .................................................................................................. 68 
5.3 Microdialysis procedure ................................................................................................... 69 
5.4 Statistical analysis ............................................................................................................ 71 
6 Rat model of myocardial ischemia-reperfusion injury- Experiment 5 ...................................... 73 
6.1 Animal preparation and experimental procedures ........................................................... 73 
6.2 Statistical analysis ............................................................................................................ 74 
Results ............................................................................................................................................... 75 
1 Pig model of short duration CA and CPR- Experiment 1 ......................................................... 75 
2 Pig model of prolonged CA and CPR- Experiment 2 ............................................................... 82 
3 Safety- Experiment 3 ................................................................................................................ 92 
4 Rat model of CA and CPR- Experiment 4 ................................................................................ 95 
5 Rat model of myocardial ischemia-reperfusion injury- Experiment 5 .................................... 101 
Discussion ....................................................................................................................................... 103 
1 Main findings .......................................................................................................................... 103 
2 Hemodynamic effects and safety ............................................................................................ 107 
3 Cardioprotection by Argon ..................................................................................................... 108 
4 Limitations .............................................................................................................................. 110 
5 Conclusions ............................................................................................................................. 111 
References ....................................................................................................................................... 112 
Appendices ...................................................................................................................................... 142 
Student’s backgroud ........................................................................................................................ 174 
 
 
 
 
 
 
  
7 
 
Major abbreviations 
ALT, serum alanine aminotransferase  
ANOVA, analysis of variance 
ATP, adenosine triphosphate  
BBB, blood–brain barrier  
CA, cardiac arrest 
Ca2+, calcium ion 
CBF, cerebral blood fluid 
CO, cardiac output  
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hs-cTnT, high sensitivity cardiac troponin T  
HT, hematocrit  
IL, interleukin 
INaL, late Na
+ current  
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LAD, left anterior descending  
LV, left ventricle 
MAP, mean arterial pressure 
Na+, sodium ion  
NDS, neurological deficit score 
NMDA, N-Methyl-D-Aspartate  
NO, nitric oxide  
NSA, neurological alertness score 
NSE, neuron specific enolase  
OPC, overall performance cartegory 
RAP, right atrium pressure 
RMS, root mean square 
ROC, receiver operator characteristic 
ROS, reactive oxygen species 
ROSC, return of spontaneous circulation 
SAP, systolic blood pressure  
TH, therapeutic hypothermia  
TNFa, tumor necrosis factor alpha 
TTC, tetrazolium chloride 
TTM, targeted temperature management  
VF, ventricular fibrillation  
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Introduction 
1 Cardiac arrest: a general overview. 
Cardiac arrest (CA) refers to the sudden cessation of cardiac activity with hemodynamic 
collapse, occurring usually with no premonitory symptoms. Victims of CA become 
unconscious within seconds to minutes because of insufficient cerebral blood flow. CA 
usually causes death if it is not treated within minutes. 
CA is often due to a cardiac arrhythmia and ventricular fibrillation (VF) appear to be 
responsible for 22.2% of patients (Gräsner 2016); however, the incidence of VF is probably 
higher. This could be explained by the fact that the exact mechanism of collapse is often 
difficult to establish because cardiac activity is not being monitored at the time of collapse, 
and asystole is often the first rhythm observed. However, asystole correlates with the 
duration of the arrest and may be the result of VF that has been present for several minutes 
and then leads to the loss of all electrical activity because of hypoxia, acidosis, and death 
of myocardial tissue (Tovar 2000). 
The most common cause of CA is coronary heart disease, occurring in 71% of the patients, 
of whom 48% had an occluded coronary artery (Deo 2012, Spaulding 1997). Among the main 
cardiac causes of CA, there are other types of structural heart disease (e.g., congenital 
coronary artery anomalies, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic 
right ventricular cardiomyopathy) and arrhythmias occurring in the absence of structural 
heart disease (Long QT syndrome, Brugada syndrome). Fifteen to 25 percent of CA are 
non-cardiac in origin. The causes include trauma, bleeding, drug intoxication, intracranial 
hemorrhage, pulmonary embolism, drowning and central airway obstruction (Eckart 2004). 
All the causes of CA are summarized in table 1. 
10 
 
 
Table 1. Causes of CA. From Yousuf 2015.  
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The cornerstones of survival from CA are early recognition and treatment, specifically, 
immediate initiation of good quality cardiopulmonary resuscitation (CPR), including chest 
compression and ventilation, and early defibrillation (DF). Chest compressions with 
minimized interruptions are the most important element of CPR, maintaining adequate 
coronary perfusion pressure (CPP) while the DF is performed. CPP is the aortic- right 
atrium gradient during the relaxation phase of cardiac cycle and it represents a predictor of 
ROSC (Paradis 1990). DF in patients with ventricular fibrillation (VF )represents the single 
most important intervention to reset cardiac rhythm and restore spontaneous circulation 
(Perkins 2015).     
Despite the development of CPR, electrical DF and the implementation of resuscitative 
techniques over the last 50 years, the overall percentage of return of spontaneous 
circulation (ROSC) is low, with 28.6% of successful resuscitated victims with extreme 
variability between different European countries (from 10 to 50% according to the 
differences in EMS structures and CPR practices in different countries). For this reason, 
CA is still considered one of the major causes of death in Europe, with an incidence rate of 
84 per 100.000 population  (Gräsner 2016). Therefore, improvement of CA treatment is a 
clinical priority. This represents the overall purpose of this thesis work.  
12 
 
2 Post-CA syndrome. 
Although successful ROSC is the first step of cardiac resuscitation, most of resuscitated 
patients die within 72 h. Indeed, only 33% of the patients admitted to hospital survived to 
30 days or to hospital discharge, with a variability from less than 5.0% to 30.0% due to 
differences in emergency system structures and CPR practices patients (Gräsner 2016). This 
is due to the complex pathophysiological processes that occur following whole-body 
ischemia during CA and the subsequent reperfusion response during CPR. This condition 
has been termed the post CA syndrome. The reflow after the whole-body ischemia might 
in fact activate detrimental pathways during reperfusion, causing tissue injury, particularly 
to the brain (Neumar 2008). Investigating the effect of a specific treatment option for post-
CA syndrome represents the focus of the experimental studies described in this thesis 
work. 
In the early 1970s, Dr. Vladimir Negovsky firstly described the pathology caused by 
complete, whole-body ischemia and reperfusion as “a second, more complex phase of 
resuscitation beginning when patients regain spontaneous circulation after CA”. Negovsky 
named this state “post resuscitation disease” (Negovsky 1972 and 1988 and 1995). However, the 
term “resuscitation” is now used broadly to include treatment of various shock states in 
addition to CA, in which circulation has not ceased. So, in 2008 Neumar and Nolan 
proposed the modern term “post CA syndrome”, that sounds more appropriate to identify 
patients who regain spontaneous circulation after CA (Neumar 2008). 
The 3 key components of this syndrome are: 1) post CA brain injury; 2) post CA 
myocardial dysfunction; 3) systemic ischemia/reperfusion response. This state is often 
complicated by a fourth component: the unresolved pathological process that caused the 
CA (Neumar 2008, Nolan 2008). Pathophysiology, clinical manifestations and potential 
treatments of the post CA syndrome are summarized in Table 2. Investigating the effect of 
Argon as a potential treatment option for post-CA brain injury represents the focus of the 
experimental studies described in this thesis work. 
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Table 2. Post CA syndrome: pathophysiology, clinical manifestations, and potential treatments. From 
Nolan 2008. 
 
Post CA syndrome would be described also by a time-based definition of 4 phases, with a 
more treatment-orientated approach (Figure 1). Indeed, 4 phases are recognized: 1) the 
immediate post-arrest phase, including the first 20 min after ROSC; 2) the early post-arrest 
phase, defined as the period between 20 min and 6-12 hr after ROSC, when early 
interventions might be most effective; 3) the intermediate, between 6-12 and 72 hr, when 
injury pathways are still active and aggressive treatment is typically instituted; and 4) the 
period beyond 3 days after ROSC, considered the recovery phase when prognostication 
becomes more reliable and ultimate outcomes are more predictable.  
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Figure 1. Temporal phases of the post-CA syndrome. From Neumar 2008. 
 
Within the first 24 hr post-arrest, a microcirculatory dysfunction from the multifocal 
ischemia/reperfusion leads to rapid release of toxic enzymes and free radicals into the 
cerebrospinal fluid and blood. Over the next 1-3 days, cardiac and systemic functions 
improve, but intestinal permeability increases, predisposing the patient to sepsis and the 
multiple organ dysfunction syndrome. During the subsequent days, a serious infection may 
occur causing rapid clinical deterioration. The patient either dies of a complication or of 
the primary disease that caused the CA, or undergoes a partial or complete recovery. 
The mechanisms responsible for post CA myocardial and cerebral injury are not well 
understood, although several events have been described.  
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At cellular level, the CA-induced whole-body ischemia causes hypoxia, conversion to 
anaerobic metabolism, intracellular acidosis, adenosine triphosphate (ATP) depletion, ion 
pump failure, intracellular calcium ions (Ca2+) accumulation, and cellular and 
mitochondrial edema (Chalkias A, 2012, Adrie 2004, Neumar 2008,  Reis 2017). At systemic level, 
release of catecholamines, tumor necrosis factor alpha (TNFα), interleukin (IL) 1 β, 
complement and polymorhponuclear (PMN) leukocyte activation, endothelial damage with 
increased microvascular permeability, coagulation cascade activation, and PMN release of 
reactive oxygen species (ROS) and cytokines (Chalkias A, 2012, Adrie 2004, Neumar 2008,  Reis 
2017,  Lindner 1992). CPR results in partial restoration of organ perfusion and triggering of 
reperfusion injury mechanisms. Global reperfusion injury is further amplified by the 
subsequent ROSC. At cellular level, reperfusion injury (Madathil 2016, Yellon 2007), causes 
enhanced ROS production, intracellular nitric oxide (NO) depletion, myocardial 
contracture and interstitial edema, excessive brain glutamate release, activation of 
intracellular proteases and phospholipases, cell membrane damage, impaired glucose 
utilization, opening of the mitochondrial permeability transition pore, and activation of 
apoptotic pathways. At systemic level, activated PMNs and platelets interacting with an 
injured and dysfunctional endothelium induce widespread microvascular plugging termed 
as the “no-reflow” phenomenon (Chalkias 2012). Activated PMNs further boost the cytokine 
storm and infiltrate damaged tissues causing cell death (Adams 2006). The ongoing 
endothelial injury further impairs microvascular permeability contributing to intravascular 
volume depletion, while the concurrent, immune cells’ inducible NO synthase-related 
overproduction of NO promotes peripheral vasodilation (Adrie 2002). The inflammatory 
cascade is amplified by nuclear factor kappa β activation. Furthermore, a potential 
ischemia/reperfusion injury-associated disruption of the intestinal mucosal barrier (Chalkias 
2016) may cause acute increases of pathogen-associated molecular patterns such as 
endotoxins in the systemic circulation, with further amplification of the systemic 
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inflammation, and predisposition to multiple organ failure and “endogenous 
immunosuppression” (Kakihana 2016). 
2.1 Post CA brain injury  
Post CA brain injury manifests as coma, seizures, myoclonus, varying degrees of 
neurocognitive impairment and brain death. It is the responsible of death of the majority of 
patients after out-of-hospital CA (Lemiale 2013). 
The unique vulnerability of the brain is attributed to its limited tolerance to ischemia as 
well as its unique response to reperfusion. The mechanisms of brain injury triggered by CA 
and resuscitation are complex and include excitotoxicity, disrupted Ca2+ homeostasis, free 
radical formation, pathological protease cascades, and activation of cell death signaling 
pathways (Lipton 1999, Neumar 2000 and 2008, Nolan 2008, Polderman 2009).  
Levels of high-energy metabolites such as ATP and phosphocreatine decrease within 
seconds when oxygen supply to the brain is interrupted (Small 1999. Cavus 2006). Once the 
storage of ATP is completely consumed, the switch of intracellular metabolism to 
anaerobic glycolysis leads to an increase in intracellular levels of inorganic phosphate, 
lactate, and hydrogen ion, resulting in both intra- and extracellular acidosis (Figure 2). 
 
 
Figure 2. Source of hydrogen ions (H+) during low-flow states. H+ derived from the anaerobic oxidation 
of glucose and from the hydrolysis of high-energy phosphates. ATP, adenosine 5' triphosphate; ADP, 
adenosine 5' diphosphate; AMP, adenosine monophosphate. From Ristagno 2006. 
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Consequently, the blood-brain barrier (BBB) of different brain areas breaks down, 
allowing for serum proteins to enter the brain microfluid environment (Sharma 2011). 
The passage of large molecules through the BBB enhances the passage of sodium ions 
(Na+) and water from blood to brain compartment, altering the osmolality between them. 
These water and electrolyte changes following cell membrane damage and BBB 
breakdown result in cell swelling and brain edema formation. Brain edema contributes to 
the development of post CA intracranial hypertension, which further augments brain 
damage. 
Ischemia/reperfusion can also lead to significant disruptions in the BBB, which can 
facilitate the subsequent development of brain edema (Chi 2001, Huang 1999). In fact, 
inflammatory cytokines and vascular endothelial growth factor (Kaur 2008), via release of 
NO (Fischer 1999) mediate decreased fluidity and integrity of cell membranes and increased 
vascular permeability of microvascular endothelial cells in the brain. More specifically, 
NO can interact with ROS producing peroxynitrite radicals, which activate matrix 
metalloproteinases (MMPs) that ultimately disrupt BBB junctions. Recently, perivascular 
pool of aquaporin-4 has been suggested as a key mechanism because this brain 
predominant water channel controls the rate limit of water influx during cerebral edema 
formation and it is the regulatory site of osmotic agents for brain water efflux (Zeng 2012).  
The disruption of Ca2+ homeostasis due to a progressive increase in cell membrane 
permeability and to the derangements of intracellular electrolytes represents another 
important mechanism of brain damage. First, intracellular Ca2+ exerts cytotoxic effects 
leading to free radical production. Second, a massive cytosol Ca2+ accumulation is 
followed by the release of intracellular excitatory amino acids such as glutamate. When 
activated by glutamate, N-methyl-D-aspartate (NMDA) receptors activate Ca2+ ion 
channels and further increase Ca2+ conductance into the intracellular space (Siesjo 1995, 
Polderman 2009). In addition, the excess of in Ca2+ induces mitochondrial dysfunction, 
overwhelming the endogenous mitochondrial scavenging systems leading to mitochondrial 
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dysfunction and cell death. Indeed, mitochondrial Ca2+ overload causes the induction of 
inner mitochondrial membrane permeability transition, which then leads to disruption of 
mitochondrial membrane integrity, irreversible oxidative damage, and the loss of ATP 
production, finally resulting in cell death (Polderman 2009). 
Post CA brain injury can also be followed by failure of cerebral microcirculation. During 
CA, in response to the stress of global ischemia, various cytokines are synthetized and 
released, resulting in activation of blood coagulation, platelets activation and decreased 
regional blood flow. Furthermore, with the onset of CPR, marked activation of blood 
coagulation occurs, which can lead to microthrombi, while the activated neutrophils and 
platelets accumulate in the microvasculature. This impaired reflow can cause persistent 
ischemia and small infarctions in some brain regions. The cerebral microvascular occlusion 
that causes no-reflow may further be compromised by the α1- adrenergic agonist of 
endogenous or exogenous adrenaline, which reduces capillary blood flow (Ristagno 2009). 
Other phenomena may be involved in cerebral perfusion disturbances, which include not 
only no-reflow events but also hyperemia episodes following ischemia: increased blood 
viscosity and perivascular edema, as well as possible down-regulation of NO synthesis, 
expression of endothelial adhesion molecules and generation of free radicals (Bottiger 1997, 
Donadello 2011, Hossmann 1993, Liachenko 2001, van Genderen 2012). 
Histologically, both neuronal necrosis and apoptosis have been reported after CA. 
Selectively vulnerable neuron subpopulations in the hippocampus, cortex, cerebellum, 
corpus striatum, and thalamus, degenerate over hours to days (Brierley 1973, Blomqvist 1985, 
Hossmann 2001, Neumar 2000, Nolan 2008, Polderman 2009, Pulsinelli 1985, Taraszewska 2002). 
2.2  Post CA myocardial dysfunction  
The myocardial dysfunction observed after CA is a transient phenomenon known as 
myocardial stunning initially described 28 years ago by Braunwald and Kloner (Patel 1988). 
Post CA myocardial dysfunction contributes to the early deaths after resuscitation from CA 
(Lemiale 2013, Herlitz 1995, Laurent 2002, Laver 2004, Neumar 2008, Nolan 2008). However, it 
19 
 
represents areversible dysfunction, responsive to therapy, characterized by normal or near-
normal coronary flow (Ruiz-Bailén 2005) and usually spontaneously disappears within the 
following 2-3 days (Tang 2006, Neumar 2008, Lemiale 2013).  
Knowledge regarding the myocardial dysfunction after CA has grown dramatically over 
the years thanks to preclinical and clinical studies. Development of contracted LV, namely 
“stone heart”, is characterized by reduced LV end-diastolic volume, stroke volume and 
increased LV wall thickness (Figure 1) (Klouche 2000 and 2002). After the onset of 
contracture, successful DF becomes unlikely. 
 
Figure 3. Development of the stone heart with reduced LV end-diastolic volume, stroke volume and 
increased LV wall thickness over 8 min of cardiac arrest in pigs. Modified from Klouche 2002. 
 
In a model of CA and CPR in rats, significant reductions in post CA left ventricle ejection 
fraction (LVEF) was observed, at 2 and 4 h following ROSC, with a subsequent recovery 
72 h later. A strong relationship between LVEF and circulating high sensitivity cardiac 
troponin T (hs-cTnT) was confirmed at different time points following ROSC. Normal LV 
function at 72 h post ROSC indicates that myocardial viability was preserved even in the 
presence of previous hs-cTnT release. This suggests that post-resuscitation myocardial 
dysfunction is largely reversible (Hackenhaar 2014). 
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In a pig model of myocardial infarction and CA, LV EF was deeply depressed during the 
first 4 h post-resuscitation (Babini 2017). 
Repetitive defibrillations are known to increase the severity of post-resuscitation 
myocardial dysfunction (Tang 2006). It has been reported that the longer was the duration of 
no-flow, the greater was the number of defibrillation attempts and such a number of 
electrical countershocks was significantly related with the systolic dysfunction, represented 
by the LVEF impairment, and with the myocardial injury (i.e. hs-cTnT release), (Babini 
2017).  
Immediately after ROSC, heart rate (HR) and blood pressure are extremely variable and 
this is mainly caused by a transient increase in myocardial and circulating catecholamine 
concentrations (Prengel 1992, Rivers 1994). Premature ventricular beats and episodes of 
ventricular tachicardia and VF commonly occur during the early minutes after resuscitation 
and account for early death. Furthermore, an overall condition of severe myocardial 
dysfunction, including variable degrees of systolic and diastolic dysfunction, is present. 
In one series of 148 patients who underwent coronary angiography after CA, 49% of 
subjects had myocardial dysfunction manifested by tachycardia and elevated LV end-
diastolic pressure, followed approximately 6 hr later by hypotension and low cardiac 
output (CO) (Kern 1996, Laurent 2002). This global dysfunction was transient, and full 
recovery occurred. In a swine model with no antecedent coronary or other LV dysfunction 
features, the time to recovery appeared to range between 24 and 48 hr. Several case series 
have described transient myocardial dysfunction after human CA. Cardiac index values 
reached their nadir at 8 hr after resuscitation, improved substantially by 24 hr, and almost 
uniformly returned to normal by 72 hr in patients who survived out-of-hospital CA. This 
trend in arterial pressure, cardiac index and other hemodynamic parameters are described 
in Table 3 from Dr. Laurent’s work (Laurent 2002), where clinical data over the 72 h post 
CA are reported.  
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Table 3. Hemodinamic during the first 72 h after CA. Reproduced from Laurent 2002. 
 
Among the mechanisms underlying early post-resuscitation arrhythmia and myocardial 
dysfunction, cytosolic and mitochondrial Ca2+ overload following CA and CPR has been 
recognized as a determinant in several preclinical studies (rats and pigs) (Ayoub 2008, 
Gazmuri 2012). Ca2+ overload after CA is related to myocyte Na+ content alteration. Under 
normoxic conditions the late Na+ current (INaL) contributes very little to the total Na
+ 
content of the myocardial cell. However, during ischemia the INaL channel does not close 
properly. Under this condition, the influx of Na+ becomes substantial (Kloner 2011). Indeed, 
Na+ influx through the late Na+ channel appears to be the major contributor to the rise of 
cardiomyocyte intracellular Na+ concentration observed during ischemia (Zaza 2008). It has 
been shown, in fact, that ischemia increases the amplitude of INaL in rat ventricular 
myocytes, from 50–100 pA up to 180–205 pA. Furthermore, following reperfusion, 
production of ROS is known to further increase INaL (Ma 2005, Slezak 1995, Song 2006). 
In the setting of CA and CPR, main routes for cardiomyocyte Na+ entry include the Na+-
hydrogen exchanger isoform-1, the voltage-gated Na+ channel, and the Na+-bicarbonate 
co-transporter. This cytosolic Na+ accumulation, further augmented by the concurrent 
ischemia-induced Na+-K+-ATPase inability to extrude Na+, represents an important 
pathophysiological mechanism responsible for cell injury (Wang 2007). Cytosolic Na+ 
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causes, in fact, a subsequent increase in myocyte intracellular Ca2+ via the activity of Na+-
Ca2+ exchanger (Figure 8) (Ayoub 2008).  
 
 
Figure 4. Events leading to cardiomyocyte Ca2+ overload during ischemia/reperfusion. NHE = Na+/ H+ 
exchanger; NBC = Na+/ HBO3-- exchanger; NCX = Na+/ Ca2+ exchanger; Ch = channel. From Ayoub 
2008. 
 
Post-resuscitation cytosolic Ca2+ accumulation in cardiomyocytes has, indeed, several 
deleterious consequences, including: electrical instability with ventricular arrhythmias 
early after resuscitation, i.e. premature ventricular complexes, VT and VF; varying degrees 
of mechanical LV dysfunction that can compromise hemodynamic function, i.e. reduced 
contractility and increased diastolic tension; and mitochondrial dysfunction (Ayoub 2008 and 
2010, Gralinski 1996).  
Mitochondria are the major contributors in many cellular as well as extracellular regulatory 
functions that affect survival following an ischemic insult. In the setting of CA, 
mitochondria are thought to be progressively damaged during ischemia and further injured 
when reperfusion resumes. This leads to important alterations of the function of this 
organelle. Specifically, the dysfunction has been shown to be mainly associated with 
impaired complex activities that begin to deteriorate within the initial 15 min of ischemia. 
Nevertheless, ultrastructural changes of mitochondria during ischemia, including swelling, 
loss of matrix density and cristae disintegration, have been also demonstrated to correlate 
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well with the duration of CA (Yeh 2009, Xu 2010). More specifically, within the first hours 
during the early recovery phase, a greater decrease in respiratory control ratio has been 
observed. In addition to its bioenergetic function, mitochondria also participate in 
processes leading to cell death via necrosis or apoptosis. Various distinctive mechanisms 
have been identified including opening of the so called mitochondrial permeability 
transition pore (leading to collapse of proton motive force and uncoupling of respiration) 
(Halestrap 2004) and release of various pro-apoptotic proteins, including cytochrome c, 
apoptosis-inducing factor, Smac/DIABLO, endonuclease G, and a serine protease 
Omi/HtrA2 (Cai 1998, Green 1998, Radhakrishnan 2007 and 2009).  
2.3 Post CA systemic inflammatory response  
The whole-body ischemia and reperfusion occurring during CA and CPR triggers a 
systemic inflammatory response, which increase the risk of multiple organ failure and 
infection (Adams 2006, Cerchairi 1993, Esmon 2003). More specifically, this inflammatory 
response includes endothelial activation, plasma cytokine elevation with deregulated 
cytokine production, presence of endotoxin in plasma, coagulation abnormalities, and 
adrenal dysfunction (Adrie 2002, Ristagno 2014, Nolan 2008, Peberdy 2010). Accordingly, this 
systemic inflammatory response brings evident similarities with sepsis and septic shock, 
and is generally described as a “sepsis-like” syndrome (Adrie 2002).  
Soluble intercellular adhesion molecule-1, soluble vascular-cell adhesion molecule-1, and 
P- and E-selectins are inc-reased during and after CPR, suggesting leucocyte activation and 
endothelial injury (Adrie 2002 and 2004, Geppert 2000, Gando 2000).  
In addition, high levels of circulating cytokines, dysregulated production of cytokines 
found in CA patients resemble the immunological profile of patients with sepsis (Adrie 2002 
and 2004). 
Specifically, levels of IL-6 and IL-10 at baseline were significantly higher in non-survivors 
compared with survivors, whereas baseline levels of IL-1β, IL-2, IL-4, IL-5, IL-9, IL-12, 
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IL-13, TNF-α, interferon-γ, C reactive proteine, and procalcitonin were similar in survivors 
and non-survivors at 30 days, (Fig. 5 and 6), (Bro-Jeppesen 2015). 
As early as 3 hours after CA, endotoxin increase (figure 7) was observed. The hypo-
responsivness of circulating leucocytes to endotoxin increase named “endotoxin 
tolerance”, as observed in severe sepsis (Munoz 1991). Endotoxin tolerance after CA may 
protect against an overwhelming proinflammatory process, but may induce 
immunosuppression with increased risk of nosocomial infection (Adrie 2002, Figure 7). 
 
 
Figure 5. From Bro- Jeppesen 2015. 
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Figure 6. From Bro- Jeppesen 2015. 
 
 
Figure 7. Measurement of endotoxin levels (endotoxin units [EU]/mL) in plasma of 35 resuscitated 
OHCA patients on admission (day 0) and the 2 days after (days 1 and 2). dl indicates detection limit 
(0.02 EU/mL). From Adrie 2002. 
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Activation of blood coagulation is an important pathophysiological mechanism that may 
contribute to microcirculatory reperfusion disorders (Adrie 2005, Böttiger 1995). Coagulation 
profile in CA patients undergone to CPR has been addressed by a number of studies over 
the last decade. Gando et al. was among the first studying coagulation during and after 
CPR, finding massive fibrin generation especially in the first 24 hours in 63 OHCA 
patients (Gando 1997). Similarly, increased levels of thrombin-antithrombin complexes were 
observed by Hostler et al. in patients affected by OHCA (Hostler 2007). Increased activation 
of blood coagulation without inadequate activation of endogenous fibrinolysis represents 
one of the main pathophysiological mechanism involved in post CA syndrome. Indeed, this 
leads to disseminated intravascular coagulation (DIC), which clinically manifests as 
obstruction of microcirculation and multiple organ dysfunction In particular, thrombotic 
occlusion in the brain vessels due to DIC causes the “no-reflow phenomenon” responsible 
of the microcirculatory failure occurring after CA and CPR. Altered coagulation in patients 
with post CA syndrome is characterized by tissue factor-dependent coagulation, which is 
accelerated by impaired anticoagulant mechanisms, including antithrombin, protein C, 
thrombomodulin, and tissue factor pathway inhibitor (Wada 2017).  
Finally, the stress of total body ischemia/reperfusion affects adrenal function. Relative 
adrenal insufficiency is common following cardiac arrest and seems to be related to the 
severity of the ischemic insult (Kim 2011). Although an increased plasma cortisol level 
occurs in many patients after out-of-hospital CA, relative adrenal insufficiency, defined as 
failure to respond to corticotrophin, is common (Hekimian 2004, Schultz 1993).  
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3 Circulating biomarkers in CA 
Circulating biomarkers have become an increasingly important tool in clinical practice, 
useful for diagnosis, risk stratification, monitoring, and prognosis of patients. Predicting 
survival and especially the neurological outcome after ROSC in victims of cardiac arrest 
remains a difficult challenge. The decision to continue, limit or stop intensive care is a 
major problem for deep ethical implications and for resources allocation. Accurate 
prediction of the neurologic outcome of comatose patients following cardiac arrest is 
therefore essential to establish the model of care (Thenayan 2008). Prognostication of 
outcome in cardiac arrest is of importance because it could help physicians to make 
decisions and enhance therapeutic efforts in patients with predictable overall good 
recovery and to re-address the overall management or ultimately to make a decision on 
withdrawal of care in those with expected poor outcome (Bouwes 2012). A procedure used to 
support no-treatment decisions, however, should ideally have no false-positive results 
(Wijdicks 2006, Zandbergen 2001) reaching a specificity of 100% for poor outcome. A false 
prediction of a poor outcome may cause the patient to be denied life-supporting treatment. 
On the other hand, a falsely optimistic prediction, although less serious from an ethical 
point of view, may lead to unnecessary prolongation of costly therapy. With the help of the 
most sophisticated and highly accurate methods measuring biomarkers, high serum 
concentrations of biomarkers are associated with false positive rates close to 0% in cardiac 
arrest patients; however, the thresholds used in the reports are inconsistent. This is partly 
because measuring techniques vary among studies, and it is an obstacle to widespread 
clinical implementation of biomarkers for prognostication (Nolan 2017).  
Due to the heterogeneity of cardiac arrest population and scenarios, no single factor has 
been identified as a reliable predictor of outcome. In addition, with recent advances in the 
use of therapeutic hypothermia (TH), prediction of patients’ outcome has become even 
more challenging. In fact, there is evidence that TH makes the well-established tests in 
normothermic patients less reliable. Early assessment of patient brain damage remains 
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quite difficult in the intensive care unit (ICU), and could be actually reachable only 
through the integration of the answer given by clinical examination, neuro-functional and 
neuro-imaging evaluation, and biochemical markers dosing (Sandroni 2014). This evaluation 
should be carried out after the initial 72 h post-ROSC. Normothermic and hypothermic 
patients with a favorable prognosis predominantly regain consciousness within 3 days 
(Fugate 2011). A reliable prediction in TH is, however, quite difficult. Likewise, a residual 
effect of sedative and analgesic substances must be excluded, due to longer drugs’ half-life 
during TH. Indeed, a significantly delayed awakening in patients treated with TH could be 
observed (Lurie 2011). For this reason, the early termination of life support 72 hr after re-
warming needs to be reconsidered critically and is not indicated. 
The current clinically used biomarkers to predict outcome of cardiac arrest are cTn and 
creatine kinases (CKs) for the heart, and NSE and S-100b, for the brain (Peberdy 2010, 
Scolletta 2012). Nevertheless, evidence does not support the use of these serum biomarkers 
alone as predictors of outcome in the setting of cardiac arrest (Neumar 2010, Nolan 2010). 
Furthermore, the use of the above markers is depending from conditions of “localized” 
myocardial or brain ischemic insults, while cardiac arrest is a wider and more complex 
event, involving the whole body. Accordingly, research in this domain extends from 
localized to generalized ischemic injury, a condition of “global” ischemia and reperfusion 
(Becker 2002).  
Experimentally, both brain and cardiac injury biomarkers mainly allow evaluating the 
severity of the injury. Indeed, biomarkers plasma levels correlate with the extent of anoxic-
ischaemic neurological and cardiac injury from cardiac arrest. Furthermore, biomarkers are 
able to provide feedback regarding the effects of treatment, and the progress of the disease. 
Finally, biomarkers level adds information about mechanisms of injury and preservation. 
Up to date cardiac, neurological and inflammatory biomarkers, as potential predictors of 
outcome after cardiac arrest, are summarized in Supplemental Table 1 (see appendix 2), 
(Scolletta 2012). 
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3.1 Circulating biomarkers of cardiac injury 
Within the last decade a broad range of circulating markers associated with an increased 
risk for death and cardiovascular endpoints have been identified (Supplemental Table 2, 
Appendix 2). Adding to markers of cell necrosis are markers of ischemia, inflammation, 
plaque destabilization or rupture, myocardial dysfunction, and stress. Most of these 
markers have demonstrated at least some prognostic value (Hochholzer 2010). 
For patients resuscitated from cardiac arrest, it is important to determine a definite cause, 
that is, myocardial ischemia vs. primary ventricular arrhythmia, owing to the risk of 
recurrence and the different therapeutic approaches available. Acute myocardial infarction 
(AMI) may account for up to 50% of out-of-hospital cardiac arrest, ischemic heart disease 
without AMI for one-third of cases and non-ischemic cardiomyopathy for nearly 10% of 
all arrests (de Vreede-Swagemakers 1998, Voicu 2012). 
Troponins are the most used biomarkers of myocardial injury/dysfunction. Troponin I, C, 
and T form a complex that regulates the Ca2+-modulated interaction of actin and myosin in 
striated muscle. Among the cardiac markers, cTn I and T are sensitive and specific markers 
of myocardial injury and are used routinely for the diagnosis of acute coronary syndromes. 
They provide prognostic information and are of great value for risk stratification of 
patients (Antman 1996, Apple 2005, Aviles 2002, Donnelly 1998, Lindahl 2000). Elevated cTn blood 
levels have been reported in several cohorts of patients with heart failure, and the 
magnitude of elevation has been correlated with the severity of the disease and with 
adverse outcomes (Ishii 2002, Setsuta 1999, Sato 2001). Because of their high cardiac specificity, 
elevated blood cTn may suggest ongoing myocardial damage and may serve as a marker 
for the progression of disease during the post reperfusion recovery. Currently, for every 
patient who has suffered a myocardial ischemic event or who has been resuscitated from 
cardiac arrest, cTn T or I are considered the first-line test (Williams 2005). Cardiac troponin T 
has been investigated extensively and has been found to be a sensitive marker of 
myocardial necrosis (Katus 1991 and 1992, Mair 1992). The presence of elevated levels of cTnT 
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in the general population has a prevalence of less than 1% and this condition is commonly 
associated with an underlying cardiovascular disease or high-risk phenotypes for cardiac 
accidents, especially in persons with chronic heart failure. Currently, new highly sensitive 
assays for determination of cTn are available and have shown that cTnT retains a 
prognostic value at previously undetectable concentrations (Latini 2007). When cTnT levels 
were investigated in more than 4.000 patients with a LV ejection fraction (EF) of <40% 
using both the standard assay and the high sensitivity assay, cTnT detection increased from 
approximately 10% of the population to more than 90%. The circulating concentration of 
this highly sensitive (hs) cTnT showed even greater prognostic accuracy in association 
with increases of another biomarker, namely brain natriuretic peptide (BNP). In 658 
patients who presented with BNP above the normal median concentration and cTnT below, 
mortality was 14%. However, in an additional 632 patients with BNP below the median 
and cTnT above, mortality was 20%. Finally, in the 1.331 patients with both markers 
above their respective median concentrations, mortality increased to 32% (Latini 2007). A 
continuous, slow release of cTn from the myocardium might reflect an ongoing cardiac 
myocyte cell death. This condition has been associated with the condition of LV 
dysfunction following myocardial ischemia in both animal models and humans patients 
suffering with chronic heart failure (Narula 1999, Olivetti 1997). If ongoing cardiac damage at 
a very low rate is the determinant of these circulating troponins, other mechanisms may, 
however, account for this phenomenon, such as stretching of cardiac myocytes with 
transient loss of cell membrane integrity. There are few investigations on the role of cTn 
for the differential diagnosis of AMI in patients successfully resuscitated after out-of-
hospital cardiac arrest. Early studies reported a substantial lack of sensitivity and 
specificity (Müllner 1996). This might have been because procedures used for CPR (CC or 
DF) or persistent circulatory shock might have directly provoked myocardial damage and 
the release of cardiac markers, in the absence of a coronary artery occlusion (Müllner 1998). 
Troponin elevation in patients resuscitated from cardiac arrest but who do not have AMI is 
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however lower and normalizes faster than after AMI (Oh 2012). In a recent, single-centre 
study, 163 patients resuscitated from cardiac arrest were assessed with coronary 
angiography on admission for AMI, that was diagnosed in 37% of the cases (Voicu 2012). 
High circulating cTn concentrations were measured very early after cardiac arrest, even in 
patients with normal angiograms (median cTnI was 0.6 ng/mL in the latter group), 
indicative of non-ischemic myocardial injury during CC. However, combined with ST-
elevation on ECG, elevated cTn concentration on admission (cTnI> 2.5 ng/mL) showed a 
good performance to exclude the diagnosis of AMI (sensitivity 93%, negative predictive 
value 94%). The specificity remained low even in combination with ST-elevation on ECG 
(64%). 
International guidelines recommend considering emergent coronary angiography and 
percutaneous coronary intervention in cardiac arrest patients after ROSC, even in the 
absence of ST elevated myocardial infarcton (STEMI) (Peberdy 2010). Since clinical 
findings such as chest pain are often lacking and the predictive value of ECG for AMI is 
poor, cTn testing may provide a simple and objective selection of post-resuscitation patient 
candidate for immediate coronary angiography. This triage strategy has recently been 
tested in 422 cardiac arrest survivors without obvious extra-cardiac causes (Dumas 2012). In 
this large study, a coronary angiography was systematically performed and cTn measured 
on admission. However, even if independently associated with coronary occlusion, 
elevation of cTn levels had a poor accuracy to identify a recent coronary lesion, precluding 
its use as the sole criteria for the decision to perform or not early coronary angiography in 
these patients (Supplemental Figure 1). 
Acute coronary artery occlusion is therefore difficult to diagnose in survivors of cardiac 
arrest using circulating markers alone, especially in case of ambiguous ECG. There are no 
data available to date on the diagnostic performance of cTn after cardiac arrest, when using 
high sensitivity assays that may readily detect concentrations in the order of few 
nanograms per liter, ten to hundred times lower than the conventional assays. However, 
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one may speculate that specificity will become an even more critical issue since the recent 
introduction of this new generation of high sensitivity reagents has led to a substantial 
increase in the proportion of detectable cTn levels attributable to conditions distinct from 
acute coronary syndromes (de Lemos 2013). Moreover, the diagnostic value of cTn could be 
altered by CPR. Increased cTn levels were, in fact, reported in approximately 40% of 
cardiac arrest patients, when samples were drawn during CPR (Lai 2004).  
3.2 Circulating biomarkers of brain injury 
Biochemical markers of brain injury are logical choices as prognostic markers of 
neurological outcome. Of these biomarkers neuron specific enolase (NSE) and S-100b are 
among the most widely studied and used. Considering the different characteristics of these 
two biomarkers, a possible rationale for analyzing both molecules in patients after cardiac 
arrest is their different distribution within the grey (NSE) and white (S-100b) matter. 
NSE is a neuron-derived enzyme, which is released after stroke and cardiac arrest and can 
be detected in the blood. Its level in serum correlates with the extent of the neurological 
damage. NSE is a 78-kDa with a half-life of 24 hr, intracellular enzyme found in neurons 
and other cells of neuroectodermal origin. Elevation of serum NSE 1–3 days after cardiac 
arrest is regarded as a severity marker of post-anoxic neuronal injury. The American 
Academy of Neurology, which considered studies from the pre-hypothermia era, suggested 
a cutoff of > 33 ug/L at days 1–3 after ROSC as a robust predictor for poor outcome 
(Wijdicks 2006); the reported false positive rate (FPR) varied from 0 to 3%. Cerebral hypoxia 
causes death of neuronal cells as well as damage to the BBB, resulting in an elevation of 
the serum levels of this and other markers. The serum levels often correlated with the 
extent of brain damage and in some studies with the prognosis of the patients. The 
predictive value of NSE in patients with ROSC has been shown in several trials prior to the 
use of TH (Reisinger 2007, Zandbergen 2006). An elevation of NSE was associated with poor 
outcome for comatose patients after cardiac arrest (Auer 2006, Grubb 2007, Meynaar 2005, Roine 
1989). Fogel et al. (Fogel 1997) reported that NSE concentrations exceeding 33 μg/l at any 
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time within a week since arrest had a sensitivity of 80% and specificity of 100% to predict 
persistent coma. In addition, Zandbergen et al. (Zandbergen 2006) found in a large cohort of 
resuscitated patients that NSE concentrations above 33 μg/l within 72 hr after arrest 
predicted poor outcome with a FPR of 0%. However, a subgroup analysis of the 
Hypothermia after Cardiac Arrest trial (Tiainen 2003) showed a decreased prognostic value 
of NSE in patients treated with TH. Since the introduction of the 2010 guidelines, various 
studies have dealt with NSE during TH. Although an elevated NSE predicts a poor 
outcome, there are case reports of good neurological survival despite extremely high NSE 
levels in serum (Grubb 2007, Krumnikl 2002). In a prospective observational study on 97 
patients, patients with poor outcome at 3 months had significantly higher NSE levels at 24 
and at 72 hr than those with good neurological. A peak NSE level of 47 μg/l had the 
highest specificity (84%) and sensitivity (72%) to predict poor outcome, with a positive 
predictive value (PPV) of 93%. A cutoff value for NSE of 97 μg/l predicted a poor 
neurological outcome with a specificity of 100% and a sensitivity of 49% (Daubin 2011), 
NSE levels >33 μg/l resulted in a rate of false prediction of poor outcome ranging from 7% 
for measurements taken 48 hr after arrest to 10% if NSE was assessed during TH (Bouwes 
2012). Other cutoffs have been also reported, widely ranging from 9 to 91 μg/l (Reisinger 
2007, Zingler 2003). It is therefore difficult to identify a specific cut off predictive of 
neurological outcome.  
In addition, there is also evidence for a constant turnover of NSE in blood, making changes 
specifically associated with brain damage in serum levels difficult to evaluate. For 
example, hemolysis caused by invasive procedures might produce a false rise in NSE 
(Zandbergen 2001). Moreover, it is well known that platelets are markedly activated and 
hemolysis may occur during early reperfusion after cardiac arrest. Therefore, even though 
at least a proportion of NSE is released from neurons, the determination of NSE, 
particularly during early reperfusion after cardiac arrest, may not be brain-specific. More 
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recently, increases of NSE levels over time, i.e. 2 to 6.4 ug/L during the initial 24 and 48 hr 
after ROSC, have shown better predictivity for poor outcome (Oksanen 2009, Rundgren 2009).  
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4 Post CA syndrome current treatments 
The treatment that patients receive during the post resuscitation period depends on the 
severity of the post CA syndrome, as well as on the cause of the arrest, and influences 
significantly the quality of life (Nolan 2015). Specifically, during years, it has become clearer 
that the management of these patients once ROSC is achieved can affect substantially their 
ultimate neurological outcome. For this reason, great emphasis has been given to the first 
European Guidelines on post-resuscitation care, produced in 2015 and resulting from a 
collaboration between the European Resuscitation Council (ERC) and the European 
Society of Intensive Care Medicine (ESICM), where the key interventions required to 
optimize outcome for these patients are set out.  
The management of the post-CA patients is complex and must address multiple major 
problems simultaneously. The main critical interventions in post CA management are 
highlighted below. 
Immediately following ROSC, the earliest threat to survival is cardiovascular collapse. 
Interventions to optimize blood pressure and maintain end-organ perfusion (fluids, 
vasopressors and inotropes) helps to avoid hypotension. Additional goals in the short-term 
post resuscitation care include optimizing oxygenation and ventilation.  Determination of 
the etiology of CA and the initiation of relevant treatments are performed concurrently in 
order to prevent recurrent arrest and to optimize outcomes. Finally, evidence supports the 
use of targeted temperature management (TTM) to minimize brain injury, together with 
seizures prevention and control and glucose control.  
4.1 Hemodynamic management 
Post-resuscitation myocardial dysfunction causes hemodynamic instability, which 
manifests as hypotension, low cardiac index and arrhythmias (Laurent 2015). For this reason, 
an adequate blood pressure must be maintained in the post CA patients. However, the 
optimal targets for mean arterial pressure and/or systolic arterial pressure remain unknown. 
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In general, when determining blood pressure goals, clinicians must balance the metabolic 
needs of the ischemic brain with the potential of the decompensated heart. So, mean 
arterial pressure (MAP) should be above 65 mmHg to maintain the end-organ perfusion 
(Kern 1997), and preferably 80 to 100 mmHg to optimize cerebral perfusion and optimize 
neurological outcome (Kilgannon 2014). Inotropic and vasopressor support can mitigate the 
myocardial dysfunction during the first hours after CA. Inotropic support (i.e. dobutamine) 
is often required, at least transiently, even if tachycardia may be caused by dobutamine and 
was associated with bad outcome in one retrospective study (Torgersen 2013). Inotropic 
agents are usually administered in association to vasoactive drugs (i.e. noradrenaline). 
Indeed, the systemic inflammatory response that occurs frequently in post CA patients may 
also cause vasoplegia and severe vasodilation (Laurent 2002). Infusion of relatively large 
volumes of fluid is tolerated remarkably well by patients with post-cardiac arrest syndrome 
(Gaieski 2009). Immediately after CA, there is typically a period of hyperkalaemia. 
Subsequent endogenous catecholamine release and correction of metabolic and respiratory 
acidosis promotes intracellular transportation of potassium, causing hypokalemia. 
Hypokalemia may predispose to ventricular arrhythmias. Potassium administration to 
maintain the serum potassium concentration between 4.0 and 4.5 mmol l−1 may be helpful 
(Nolan 2015).  
4.2 Oxygen and carbon dioxide target 
Guidelines indicates to maintain oxygen saturation > 94%, avoiding hyperoxia which has 
been associated with worse outcomes. Indeed, one of the major events characterizing the 
ischemia/reperfusion injury is the generation of oxygen free radicals that are known to 
injure cells. Supplementary oxygen increases their production. However, the importance of 
avoiding hyperoxia in the post arrest patients remains an area of debate. Whereas animal 
studies always supports the hypothesis that hyperoxia is harmful, differing conclusions 
emerged from clinical studies comparing hyperoxia with normoxia in post CA patients. 
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Several observational studies showed an association between hyperoxia and poor outcome 
(Janz 2012). In contrast, an observational study of over 12,000 post-cardiac arrest patients 
showed that after adjustment for sickness severity, hyperoxia was no longer associated 
with mortality (Bellomo 2011). The heterogeneity across studies could be because, in the 
animal studies, the relationship between hyperoxia and worse neurological outcome after 
CA have generally evaluated in the first hour after ROSC. Clinically, there are significant 
practical challenges with the titration of inspired oxygen concentration immediately after 
ROSC, particularly in the out-of hospital setting. The only prospective clinical study to 
compare oxygen titrated to a target range (in this case 90–94 % oxygen saturation) versus 
giving 100% oxygen after out of hospital cardiac arrest was stopped because of unreliable 
pulse oximetry readings (Young 2014). Further studies involving titration of oxygen to a 
target oxygen saturation of 94 % as soon as possible after ROSC are advocated. 
Hypocapnia causes cerebral vasoconstriction and a decreased cerebral blood flow (Menon 
2004). After CA, hypocapnia induced by hyperventilation may exacerbate cerebral ischemia 
and impair neurological outcome (Bouzat 2013, Buunk 1998). In contrast, two observational 
studies have documented an association with mild hypercapnia and better neurological 
outcome among post-CA patients in the ICU (Schneider 2013, Vaahersalo 2014). Until 
prospective data are available, it is reasonable to adjust ventilation to achieve normocapnia. 
4.3 Temperature control 
Mild induced hypothermia initiated within minutes to hours after ROSC and maintaining a 
temperature range of 32–34°C for 12–24 h was recommended from 2003 as the unique 
effective neuroprotective strategy improving outcome of CA. In fact, cooling suppresses 
many of the pathways leading to delayed cell death, including apoptosis (programmed cell 
death) and reduces the release of excitatory amino acids and free radicals (Gunn 2006, 
McCullough 1999). Furthermore, hypothermia blocks the intracellular consequences of 
excitotoxin exposure (high calcium and glutamate concentrations) and reduces the 
38 
 
inflammatory response associated with the post-CA syndrome (Bro-Jeppesen 2014). At that 
time, the supporting evidence was based on experimental animal data, non-randomized 
clinical trials and two small randomized trials. Furthermore, hypothermia presented several 
well-recognized physiological side effects, that need to be taken into consideration 
clinically. First, despite shivering is a sign of a normal physiological response and its 
presence is associated with a good neurological outcome, it will increase metabolic and 
heat production, thus reducing cooling rates. Second, mild induced hypothermia increases 
systemic vascular resistance and causes bradycardia that may be beneficial; it reduces 
diastolic dysfunction and its occurrence has been associated with good neurological 
outcome. Moreover, mild induced hypothermia causes a diuresis and electrolyte 
abnormalities (i.e. hypophosphataemia, hypokalaemia, hypomagnesaemia and 
hypocalcaemia), decreases insulin sensitivity and insulin secretion, and causes 
hyperglycaemia, which will need treatment with insulin. Importantly, hypothermia can 
impair the immune system and increase infection rates. It is associated with an increased 
incidence of pneumonia even if this seems to have no impact on outcome (Nolan 2008).  
Studies supporting the use of mild therapeutic hypothermia presented several limitations 
and data are extremely difficult to interpret because of other changes in post cardiac arrest 
care that occurred simultaneously. Specifically, it was not clear if the potential benefits of 
cooling on brain injury due to circulatory arrest would be the same irrespective of the 
cause of arrest. In addition, the most beneficial target temperature for therapeutic 
hypothermia remained unknown. The recommended temperature of 32° to 34°C has been 
extrapolated from experiments in animals but similar results have been observed with 
milder cooling. 
In the Targeted Temperature Management (TTM) trial, 950 all-rhythm OHCA patients 
were randomized to 36 h of temperature control (comprising 28 h at the target temperature 
followed by slow rewarm) at either 33 or 36 °C (Nielsen 2013). There was no difference in 
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all-cause mortality, and neurological outcome at 6 months was also similar. Importantly, 
patients in both arms of this trial had their temperature well controlled so that fever was 
prevented in both groups.  
After the neutral results of the TTM Trial, current recommendations have been modified to 
include a broader range of target temperature (Nolan 2015).  
Optimum timing and duration of for mild induced hypothermia and TTM are still unknown 
but some trials are ongoing. Both are currently most commonly used for 24 h.  
Prior recommendations suggest that cooling should be initiated as soon as possible after 
ROSC, but this recommendation was based only on preclinical data indicating that earlier 
cooling after ROSC produces better outcomes (Kuboyama 1993, Colbourne 1995). 
Observational studies are confounded by the fact that there is an association between 
patients who cool faster spontaneously and worse neurological outcome (Haugk 2011, Benz-
Woerner 2012, Perman 2015).  It is hypothesized that those with the most severe neurological 
injury lose their ability to control body temperature easier. 
TTM can be induced and maintained using cold intravenous fluids after ROSC (Kim 2007,  
Kamarainen 2009, Bernard 2010, Kim 2014) or during resuscitation (Debaty 2014); however, in one 
prehospital randomized controlled trial this intervention was associated with increased 
pulmonary edema and an increased rate of re-arrest during transport to hospital (Kim 2014). 
Based on this evidence, prehospital cooling using a rapid infusion of large volumes of cold 
intravenous fluid immediately after ROSC is not recommended. Additional methods of 
inducing and/or maintaining TTM include ice packs and/or wet towels application, water 
or air circulating blankets, water circulating gel-coated pads, transnasal evaporative 
cooling to obtain local cooling of the brain, intravascular heat exchanger, placed usually in 
the femoral or subclavian veins and extracorporeal circulation (e.g. cardiopulmonary 
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bypass, ECMO). There are no data indicating that any specific cooling technique increases 
survival when compared with any other cooling technique. 
To date, neuroprotective treatments, pharmacological or not, other than hypothermia, used 
alone or in association, failed to improve neurologically intact survival when clinically 
tested.  
The overall scenarios makes the the use of inhaled noble gases (Argon, helium and 
particularly xenon) a promising research option, wich need a consistent rigorous testing in 
different animal experimental models, providing sufficient informations on the efficacy 
and safety aspect needed to proceed to clinical application.   
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5 Medical uses of noble gases  
The inert or noble gases helium, neon, Argon, krypton and xenon exist as monatomic gases 
with low chemical reactivity due to the full electron valence shell which avoids covalent 
bindings with other elements. However, the noble gases cannot be defined as a 
“biologically” inert gas, despite their chemical profile. The potential for noble gases to 
produce a biological effect was firstly suggested 70 years ago by Behnke and Yarbrough, 
who reported the development of progressive “narcosis” in United Stated Navy divers 
exposed to 80% Argon or krypton in 20% oxygen under hyperbaric conditions (10 atm), 
(Behnke 1939). The narcotic effect was not observed for helium and neon, that appeared both 
chemically and biologically inactive, at least at tolerable pressures (Miller 1967,  Koblin 1998). 
Radon instead might be predicted to be an anesthetic; it is radioactive, however, and 
exposure to radon – even at very low levels – is a health risk (Gray 2009). Particular 
attention has been focused on the potential use of xenon as a general anesthetic. Indeed, 
xenon in contrast to Argon and krypton, exerts anesthetic and analgesic effects under 
normal (as opposed to hyperbaric) atmospheric pressure conditions. Its physical properties 
and clinical characteristics suggest that xenon may be especially useful as an inhaled 
anesthetic; in fact, xenon produces rapid induction of and emergence from anesthesia, does 
not cause teratogenic effects or undergo biotransformation, and is essentially devoid of 
cardiovascular effects (Lockwood 2006, Wappler 2007).  
At molecular level, xenon anesthetic effect is mediated by the NMDA; Franks et al. in the 
1998 demonstrated firstly that xenon inhibited NMDA-evoked currents in cultured 
hippocampal neurons by ~60% at a clinically relevant concentration of 80% xenon (Franks 
1998). 
The discovery that xenon is an NMDA-receptor antagonist led to the idea that xenon may 
be neuroprotective. Indeed, it is well-known that one of the mechanisms of injury activated 
under conditions of energy substrate depletion (i.e. after different kinds of ischemic 
injuries) is the glutamate excitotoxicity, exerted by the excessive activation of NMDA 
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receptors. Xenon exerts a NMDA receptor antagonism at non-anesthetic concentrations 
avoiding or reducing adverse side effects and potential neurotoxicity associated with the 
NMDA receptor stimulation (Lipton 2004, Palmer 2000).  
The purpose of the majority of the studies involving xenon was the neuroprotection after 
different kinds of ischemic injuries. Nevertheless, the effects as cardioprotective and 
nephroprotective agent have been investigated in animal and human studies as well.  
Among the noble gases, xenon has been the most widely studied either in preclinical and 
clinical models. For this reason, the organ- protective properties of xenon will be addressed 
in the following section. 
Thereby, the evidence for the organ-protective properties of xenon has prompted interest in 
investigating whether other inert gases have similar potential in ischemia reperfusion 
injury. 
Briefly, neon was only explored in myocardial ischemia reperfusion injury in rabbits and 
showed a reduced infarct size when administered as preconditioning (Pagel 2007).  
The organ protection by helium was explored in different model of ischemia reperfusion 
injury. More specifically, helium was shown to be neuroprotective in rodents subjected to 
cerebral ischemia (Liu 2011, Pan 2011, David 2009, Pan 2007, Zhuang 2012), and cardioprotective 
in rabbit model of myocardial infarction (Pagel 2009 and 2008). These studies explored three 
windows of protection (pre-, post- and reconditioning), and all these administration 
regimens have been demonstrated to be effective. Furthermore, there were few data on 
renal and hepatic ischemia reperfusion injury, where helium administration did not 
improve outcomes significantly (Voss 1970, Braun 1973, Braun 2014). 
 The organ protection by Argon will be discussed separately. 
5.1 Organ protection by xenon 
In order to evaluate its neuroprotective effects, xenon was administered either as 
precondition, recondition and postcondition treatment, to evaluate the cerebral damage in 
vitro and in vivo after ischemic stroke, asphyxia (both neonatal and intrauterine), 
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cardiopulmonary bypass and cardiac arrest. Rodent models were employed very 
frequently, both adult and neonatal. Swine model were employed as well, but the results 
were less straightforward at least in models of postconditioning after cardiac arrest. 
Interestingly, attempts to administer Xenon through echogenic liposomes were reported 
and the results were encouraging (Britton 2010, Peng 2013). 
Overall, the results were in favor of the administration of Xenon as neuroprotective agent 
and the beneficial effect seemed to be equally exerted to both genders. Optimal timing and 
concentration of Xenon have not been determined yet although the neuroprotective effect 
seemed to be dose – dependent, with a more pronounced effect when administered within 8 
hours after the insult (Ma 2005, David 2008, Peng 2013).  
Models of neonatal asphyxia in rats to induce brain damage were employed in different 
experiments. Xenon at a concentration of 70% was evaluated as preconditioning before the 
right common carotid artery ligation followed by hypoxia (90 minutes): while a 2-h 
exposure before injury had no effects on ischemic brain injury, exposure 4-, 8-, or 24- h 
before ischemia reduced infarct volumes. A time point (4 h before hypoxia–ischemia) was 
chosen to investigate whether the morphologic improvement by xenon preconditioning 
extended to a long-term improvement in neurologic function. Authors found that, 30 days 
after the injury, the impairments in neurologic motor function and coordination were both 
significantly improved by xenon preconditioning. The same group performed a dose-
response study and found that higher Xenon doses were more effective, as 75% xenon but 
not 30% reduced infarct size. Postconditioning with Xenon after both moderate and severe 
hypoxia–ischemic brain injury provides neuroprotection. Moreover, postconditioning with 
hypothermia were tested, as described in the dedicated section (Hobbs 2008). Another group 
used the same model of 90-minute hypoxic insult after unilateral carotid ligation in 7 days-
old rats. Rats were then randomized to breathe 1 of 2 gas mixtures for 3 hours: 50% 
Xenon/30% O2/20% N2 or 30% O2/70% N2. One week after hypoxic-ischemic survival, 
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significant global protection was seen in the Xenon group (Dingley 2006). The neurologic 
improvement was seen even 10 weeks after the injury (Hobbs 2008). The effects of xenon on 
the neonatal hypoxic-ischemic encephalopathy was evaluated in a model of intrauterine 
perinatal asphyxia, where the treatment of the mother with subanesthetic doses of xenon 
(35%) provided both analgesia and neuroprotection, less neurologic deficit, neural loss, 
cellular disorganization, and cell shrinkage. A clinical application of these favorable 
preclinical evidences in birth asphyxia has been recently published. In this multicenter 
randomized, open-label, parallel-group trial. Infants (92) were included if: 36-43 weeks of 
gestational age, had signs of moderate to severe encephalopathy and moderately or 
severely abnormal background activity for at least 30 min or seizures and had one of the 
following: Apgar score of 5 or less 10 min after birth, continued need for resuscitation 10 
min after birth, or acidosis within 1 h of birth. Participants were randomized within 12 h of 
birth to cooling at 33·5°C for 72 h (standard treatment) or to cooling in combination with 
30% inhaled xenon for 24 h started immediately after randomization. This study 
demonstrated how the administration of xenon is feasible and apparently safe, but 
unfortunately is unlikely to enhance the neuroprotective effect of cooling after birth 
asphyxia (Azzopardi 2016). 
Transient middle cerebral artery occlusion in mice was used to evaluate the treatment with 
Xenon in the setting transient focal cerebral ischemia. 70% Xenon administration during 
the injury improved both functional and histologic outcomes. In rats with transient brain 
ischemia through middle cerebral artery occlusion, exposure to Xenon at subanesthetic 
doses (50%) provided global neuroprotection up to at least 2 h after induction of ischemia. 
However, at a higher concentration (75%), Xenon exhibits potentially neurotoxic effects 
(David 2008and 2003). Using a similar model of transient focal ischemia, authors couldn’t 
confirm the benefit at 28 days when a subanesthetic Xenon concentration was used. A 
better outcome was also described in models of intracerebral hemorrhage. 
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In a global cerebral ischemia through bilateral common carotid artery occlusion in rats, 50 
% Xenon administration for 45 minutes was neuroprotective 1 hour after the injury. 
Studies on neuroprotection after cardiac arrest, mainly performed in swine models, paved 
the way to a study in the clinical scenario (De Deken 2016). Models of cardiac arrest of 8 to 
10 minutes were employed to determine the effects of Xenon postconditioning. 70% 
Xenon administered 1 hour after resuscitation improved short-term neurologic and 
neurocognitive recovery whereas ventilation with Xenon 10 minutes after the cardiac arrest 
did not improve neurologic dysfunction. The combination of either a short (1 hr) or a long 
(18–24 hr) period of xenon administration and mild hypothermia immediately after 
resuscitation improved functional recovery and histologic injury.  
The feasibility and cardiac safety of inhaled Xenon treatment in a clinical setting were 
firstly investigated through an open controlled and randomized single-centre clinical trial 
involving 36 out-of-hospital cardiac arrest patients, with ventricular fibrillation or pulseless 
ventricular tachycardia as initial cardiac rhythm. Patients were randomly assigned to 
receive either mild therapeutic hypothermia treatment with target temperature of 33°C 
alone or in combination with 40% Xenon for 24 hours. The frequency of serious adverse 
events, including in-hospital mortality, status epilepticus, and acute kidney injury, was 
similar in both groups and there were no unexpected serious adverse reactions to xenon 
during hospital stay. In addition, xenon did not induce significant conduction, 
repolarization, or rhythm abnormalities. Xenon treatment in combination with hypothermia 
showed favorable cardiac features in survivors, as median dose of norepinephrine during 
hypothermia was significantly lower, heart rate was significantly lower and post hospital 
arrival incremental change in troponin-T at 72 hours was significantly less in the Xenon + 
mild therapeutic hypothermia group. 
A randomized single-blind phase 2 clinical trial randomized 110 comatose patients who 
had experienced out-of-hospital cardiac arrest to receive either inhaled Xenon (40% end-
46 
 
tidal concentration) combined with hypothermia (33°C) for 24 hours or hypothermia 
treatment alone. The effect of inhaled Xenon on ischemic white matter damage was 
assessed with magnetic resonance imaging between 36 and 52 hours after cardiac arrest 
(by fractional anisotropy from diffusion tensor magnetic resonance imaging). Inhaled 
Xenon combined with hypothermia compared with hypothermia alone resulted in less 
white matter damage but no statistically significant difference in neurological outcomes or 
mortality at 6 months was demonstrated. Later, the same group assessed the effect of 
inhaled Xenon on myocardial ischemic damage in the study population (Arola 2017). 
Myocardial ischemic damage was assessed by Troponin-T levels at hospital admission, and 
at 24 h, 48 h, and 72 h post-cardiac arrest. After adjustments for age, sex, study site, 
primary coronary percutaneous intervention (PCI), and norepinephrine dose, the post-
arrival incremental change of the ln-transformed troponin-T at 72 h was significantly 
reduced in the group treated with Xenon. The effect of Xenon on the change in the 
troponin-T values did not differ in patients with or without PCI or in those with a diagnosis 
of ST-segment elevation myocardial infarction (Arola 2017). 
Based on evidences of cardioprotection in a variety of preclinical models, (rat, ex-vivo 
rabbit heart, pig, and dog) a recent randomized trial evaluated the effects of Xenon 
anaesthesia in 492 low-risk elective, on-pump coronary artery bypass graft surgery patients 
in 17 university hospitals in Europe. Patients were randomized to receive Xenon, 
sevoflurane, or propofol-based total intravenous anesthesia for anesthesia maintenance. 
Authors found that in postoperative cardiac troponin I release, Xenon was non-inferior to 
sevoflurane and that cardiac troponin I release was less than with total intravenous 
anesthesia. Moreover, Xenon anesthesia appeared safe and feasible, as previously 
demonstrated for other surgical settings. 
Experiments on nephroprotection showed improved kidney function with Xenon 
administration, in animal models of rat transplant with Xenon preconditioning, 
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postconditioning, and reconditioning of the kidney graft, stored in a Xenon-saturated 
preservation solution (De Deken 2016). 
Surgical patients undergoing partial nephrectomy were included in a small randomized 
trial to receive xenon or isoflurane, with the aim to explore whether Xenon anesthesia 
could reduce renal damage and to gather pilot data of possible nephroprotection. Xenon 
anesthesia was feasible and safe with regard to postoperative renal function, but no 
significant effect on early renal function were found (Stevanovic 2017). 
The combination of Xenon and hypothermia was tested in many preclinical models. The 
majority of results suggest that the administration of these two treatments, both 
simultaneously or delayed, potentiate the neuroprotection provided by Xenon even if a low 
concentration is used; this additive effect seem to be conserved either in case of short or 
long period of xenon administration (Ma 2005 Hobbs 2008, Sheng 2012, Martin 2007, Fries 2012, 
Chakkarapani 2010, Faulkner 2011,  Schwiebert 2010). Given these preclinical evidences, the 
association of Xenon and hypothermia has been evaluated as potentially beneficial in a 
population of out-of-hospital cardiac arrest patients in two recent trials (Arola 2017, Laitio 
2016) and in infants affected by birth asphyxia. 
Anesthetic properties of Xenon were discovered more than 60 years ago, and since then, a 
variety of clinical experiences demonstrated that it is a safe drug. Thanks to its small 
blood-gas partition, Xenon offers a rapid onset and offset of its action. It can produce 
profound analgesia and hypnosis without producing hemodynamic instability as described 
in various clinical experiences involving different surgical settings, either non-cardiac or 
cardiac surgery, and in patients with impaired cardiac function (Arola 2017, Laitio 2016). 
Xenon production is highly energy-consuming requiring a fractional distillation process of 
liquid air. Moreover, a special equipment is required to deliver Xenon. As a result, Xenon 
treatment is very expensive, from 3 to 10 folds more than other anesthetic agents 
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(sevoflurane, isoflurane, propofol) and 100 folds more than Argon. As a future perspective, 
the use of microbubbles and liposomes to deliver Xenon could allow a cheaper and more 
efficient way to treat selected patients.  
5.2 Argon 
Argon belongs to the noble gas group, discovered by the British physicist Lord Rayleigh 
and the chemist Sir Ramsay, in 1894 (Ramsay 1984). Argon is colorless, tasteless, odorless, 
noncorrosive, noninflammable and nontoxic (Material Safety Data Sheet Gaseous Argon, Universal 
Industrial Gases, Inc. Retrieved 14 October 2013. http://www.uigi.com/MSDS_gaseous_Ar.html). It is the 
most abundant noble gas, and the third major component of the air, with a concentration of 
0.93%. From a physical point of view, Argon’s density is 38% higher than air’s one, the 
solubility in water and plasma is 24-fold lesser than that of carbon dioxide (CO2), but 5-
fold greater in oil compared to water (Roberts 1997).  
Like the other noble gases, Argon has a full electron valence shell which avoids covalent 
bindings with other elements; for this it is usually considered a non-reactive chemical gas, 
as pinpointed by its Greek name “αργός”, meaning “inert” (Ulbrich 2016). But, as mentioned 
above, starting from the evidence of the narcotic effects of Argon in divers in 1939 (Behnke 
1939), it became evident that it is able to exert biological effects. Further confirmatory 
evidences of such a Argon’s property were added over time (Taylor 1976, Sauter 1979, Smith 
2010, Rostain 2011, Clark 2015). 
Argon showed narcotic effects only under hyperbaric conditions (Balon 2002, Fowler 1972). 
Different theories have been proposed to explain this property (Rostain 2011). Most likely, 
the increase of the inert gas pressure induces modification on cytoplasmic membrane 
and/or receptor condition, subsequently modifying the neurotransmission. Indeed, when 
rats were exposed to Argon at ≈ 19 atm for 2 h, dopamine release from striatum decreased 
by approximately 10% compared to animals that were not exposed to the gas (Balon 2002). 
Since the striatum coordinates different aspects of motor planning and motivation, a 
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subsequent study investigated the relationship between motor activity and dopamine 
release in rats exposed to Argon in a pressurized chamber for 100 min. During the 
compression period, a transient phase of hyperactivity was observed, followed by a 
decrease in the motor activity. More specifically, exposure to Argon at a pressure of ≈ 10 
atm, showed motor hyperactivity, probably related both to the higher pressure and to the 
narcotic potency of the gas, dependent on its lipid solubility. When the pressure raised to ≈ 
20 atm, loss of righting reflex appeared, indicating the onset of the anesthetic effect. This 
subsequent decrease of behavioral activity could be ascribed to the decrease of dopamine 
release from the striatum that occurred when the 20 atm pressure was achieved and was 
kept constant for at least 10 min (Balon 2003). 
 Another study concerning Argon anesthetic properties analyzed the contribution of GABA 
transmission as a possible mechanism of action for narcosis. Rats were treated with 
different GABA receptor antagonists (i.e. gabazine and flumazenil, as GABAA antagonists, 
and 2-idrossisaclofene, as GABAB antagonist) and then exposed to Argon in a pressurized 
chamber. Pretreatment with GABAA inhibitors increased significantly the Argon threshold 
pressure for the loss of righting reflex. Instead, pretreatment with GABAB inhibitor showed 
no significant effects on narcosis (Abraini 2003)  
Besides narcosis, evidence of neuroprotection played by this noble gas has been arising 
during the last 20 years, since the first Russian report in a rodent model of hypoxic brain 
injury, in 1998 (Soldatov 1998). Recently, Argon’s protective effects after ischemia became 
more and more evident preclinically. 
5.2.1 In vitro studies 
The protective effects of Argon on cell damage were investigated in several in vitro studies 
together with potential pathways activated after Argon exposure and involved in cell 
protection. These studies were performed in different cell types (i.e. rodent 
cardiomyocytes, rat neurons or hippocampal slices, human neuroblastoma, kidney, airway 
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epithelium, and osteosarcoma cell sand in whole blood from rodents) and the models for 
inducing cell damage were different, including oxygen-glucose deprivation (OGD); 
hypoxia/reoxygenation injury (H/R); peroxide-induced oxidative stress; and mechanical 
means to simulate a traumatic brain injury. In these studies, cells and/or tissues were 
incubated in chambers containing Argon atmosphere in a concentration varying from 25% 
to 75% in air and/or O2. The average Argon exposure was 90 min, ranging from a 
minimum of 5 min in the H/R study (Lemoine 2017) up to 72 hrs in the traumatic brain injury 
simulation (Loetscher 2009). In the majority of the studies, Argon was applied as a potential 
treatment and thus administered either immediately after the onset of the insult or delayed, 
up to 3 hrs later. In only 3 studies, targeting specific protective pathways, Argon was 
administered before the insult, as a preconditioning agent (Mayer 2016, Hafner 2016, Ulbrich 
2016) 
 Overall, the in vitro studies showed improved cell survival and viability when Argon was 
used both before and after the insult. More specifically, Argon appeared to be capable to 
reduce apoptosis in neuronal, tubular kidney, and airway epithelial cells (Hafner 2016, Ulbrich 
2016).  
5.2.2 In vivo studies 
The majority of in vivo studies are focused on neuroprotection after a variety of brain 
damages; from these studies, combining different neurological, behavioral, and behavioral 
tests with histological and biochemical assays, evidence in favor of a beneficial effect of 
Argon treatment emerged. In all these studies, Argon was administered by inhalation, at a 
concentration varying from 25% up to 88% in air or in a mixture of Nitrogen (N2)/O2. 
Focusing on the use of Argon as neuroprotective agent, 4 studies (David 2012, Höllig 2016,  
Zhuang 2012, Ryang 2011) evaluated the post-insult neurological recovery and in half of them 
(Zhuang 2012, Ryang 2011) there was evidence for a better outcome after inhalation of this 
noble gas when compared to the control ventilation.  
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All the investigations performed a histological evaluation, including various essays in 
different brain areas. Overall, there was evidence for a mitigation of the brain tissue injury 
as represented by increased cell viability and reduced neuronal necrosis and apoptosis and 
infarct size. In one study on a rat model of MCAO (David 2012). Argon had contrasting 
effects, with a reduced infarct size in the cortical area, but an increased injury in the 
subcortical ones, compared to sham animals. However, in this study, animals treated with 
Argon had a significantly higher body temperature (average of 38.5°C), which could 
explain the greater brain damage compared to the controls (David 2012).  
The cardioprotective effects of Argon were investigated in three in vivo studies and are 
commented in details in the Discussion as well as studies focused on neurological injury 
following resuscitation from CA. 
Overall, both the in vitro and in vivo studies provided evidence in support of a protective 
role of Argon, independently of the disease model and of the duration and onset of 
exposure to the treatment (i.e. pre- or post-acute event).  
5.2.3 Clinical uses of Argon 
Since the Sixties, Argon was applied clinically for the measurement of lung volumes, i.e. 
total lung capacity (TLC) (Black 1984), functional residual capacity (FRC) (Ozanne 1981), 
and closing volumes (McCarthy 1972). For these measurements, the re- breathing/gas-
dilution technique was used. Healthy volunteers were exposed to a known volume of 
Argon 50% in O2, that was re- breathed in a closed system. After a few breaths the new 
Argon concentration was detected and lung volumes derived (Black 1984, Ozanne 1981). 
A single breath method, instead, was applied to measure the lung closing volumes 
(McCarthy 1972). Considering the non-invasive estimation of CO, Argon 6-7 %, as inert 
and insoluble gas, has been used as part of a mixture along with other inert but soluble 
gases, i.e freon-22 (or acetylene), O2 and N2. This mixture was re- breathed by the patient 
through a re- breathing bag and, at the same time, a mass spectrometer measured the 
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concentration curve of the inert gases and calculated the wash-out rate, which is 
proportional to the CO (Henrghan1981, Bonde-Petersen 1980). Another use of Argon 
inhalation in humans was the estimation of global myocardial blood flow (MBF) through 
the measure of the difference of Ar concentration in the arterial and the coronary sinus 
blood during inhalation of a mixture of Ar 75% in O2 (Kotzerke 2001). In these studies, 
focused on evaluating lung and cardiac functions, subjects were exposed to a single or a 
few breaths of an isobaric mixture of Argon; therefore, no conclusions on effects of Argon 
or potentials safety issues may be extrapolated. 
Of different value were instead the studies conducted on divers with the intent to 
investigate the feasibility of Argon use in the diving mixture in place of N2. In these 
studies, divers breathed Argon mixtures for long periods and in hyperbaric conditions. In 
1939, motor and cognitive impairment, such as slowed mental activity, inability to perform 
efficient manual work and emotional disturbances, which might lead to loss of 
consciousness, were described in divers breathing a mixture of 69% Argon, 20% O2 and 
11% N2 from 1 to 10 atm. It was the first report on Argon’s narcotic properties under 
hyperbaric conditions (Behnke 1939). In another study, 10 subjects performed mental 
arithmetic tasks while exposed to Argon 80% in O2 at 1, 4 and 7 atm. Again, Argon under 
hyperbaric condition showed more narcotic effects (Fowler 1972).   
The longest exposure to Argon under hyperbaric condition was in 1998 (Pavlov 1999). 
Four male volunteers participated in a simulated diving at 10 meters for 7 days to 
determine effects on physiological variables of to the following gas mixture: O2 0.2 ± 
0.005 kg/cm2, N2 0.8 ± 0.01 kg/cm
2 and Argon 1.0 ± 0.01 kg/cm2. No effects on central 
nervous system electrophysiology and functional test, cardiopulmonary system, i.e. ECG, 
oxihemometry, and biochemical analysis of urine, were detected. All measured data did 
not exceed physiological range. Thus, the prolonged normoxic exposure to Argon was 
safe. Under hyperbaric pressure a workload of 100 Wt was performed 62% higher when 
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breathing Ar 15% in O2 than N2 15% in O2. Moreover, the exposure to a hypoxic Argon-N2 
mixture containing O2 0.15 ± 0.005 kg/cm
2, instead of O2 0.2 ± 0.005 kg/cm
2, determined 
an increase in the performed work volume, showing that Argon causes a positive effect on 
organism adaptation to hypoxia. 
Another study performed in 8 human volunteers investigated the possible adverse effects 
from breathing isobaric mixture of 80% Argon and 20% O2 for 30 min to determine if 
Argon might cause neurological impairment or embolism. The authors did not report 
narcosis or coagulation and fibrinolytic abnormalities, which would have been present in 
case of gas embolism (Horrigan 1979).  
More recently, Argon inhalation has been proposed as a new method to measure the global 
cerebral blood flow (CBF), by a modification of the Kety-Schmidt inert gas saturation 
technique. Patients were exposed to Argon 70% in O2 and during a 10-min wash-in period, 
blood samples from the arterial and the jugular bulb catheter were withdrawn 
simultaneously at a constant rate. Then, Argon concentration in the samples was measured 
through gas chromatography and CBF was calculated (Mielck 1999). To establish this new 
method, the presence of any potential influence of Argon inhalation on cerebrovascular 
and cerebro-metabolic variables needed to be excluded. Thus, additional 30 anesthetized 
patients undergoing cardiovascular surgery were subjected to ventilation with 70% Ar in 
O2 for 15 min, prior to the surgical procedure (Grüne 2017). Argon ventilation did not 
show any influence on cerebrovascular circulation or metabolism, evaluated by 
transcranial Doppler sonography nor difference in content between arterial and jugular-
venous lactate, glucose and oxygen, respectively.   
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6 Aims and hypothesis 
The aim of my PhD studies was to investigate the neuroprotective and cardiacprotective 
effects of the noble gas Argon using preclinical models of CA and CPR. 
The overall aim of my studies was to identify a novel treatment option and provide solid 
efficacy and safety data, requested for future clinical investigation. The consequent 
research programme included complementary experiments with specific aims, which I 
have detailed in the experimental design section. 
The overreaching hypothesis was that Argon treatment would ameliorate post-resuscitation 
neurological dysfunction in different animal models of CA and CPR.  
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Material and methods 
1 Experimental design 
Procedures involving animals and their care were performed in accordance with the 
institutional guidelines in compliance with the national and international law and policies. 
The protocols were reviewed and approved by the Animal Care and Use Committee of the 
IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milano and by the Italian 
Health Ministry (Legislative Decree n° 76/2014- B). 
The thesis work includes a spectrum of different experiments with specific aims, 
performed in three different animal models of both CA and CPR and myocardial ischemia 
reperfusion injury in order to investigate the potential protective neuro- and myocardial 
effect of Argon. 
The experimental design, together with the experimental groups are schematically detailed 
in the table 4. 
The overall aim of my studies was to identify a novel treatment option and provide solid 
efficacy and safety data, requested for future clinical investigation. The consequent 
research programme included complementary experiments both in pig (efficacy and safety) 
and rats (mechanism of action). 
Specifically, the effects of post-resuscitation treatment with inhaled Argon on outcome of 
CPR were initially investigated in a porcine model of short duration of no flow time (i.e. 6 
minutes of ventricular fibrillation) and CPR (Experiment 1). The protective effects of  
observed in experiment 1 were subsequently validated in the more severe model of CA (i.e. 
12 minutes of ventricular fibrillation) and CPR in pigs (Experiment 2). A model of 
prolonged untreated CA was used to obtain greater ischemic injury and worse outcome. In 
addition, the experiment 2 aimed to optimize the Argon treatment in the same model of 
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severe CA, by testing the effects of different Argon concentrations in the inhaled mixture 
on brain injury. 
Finally, in order to investigate the safety of Argon ventilation, anesthetized domestic 
healthy pigs were ventilated with Argon and potentially harmful adverse effects were 
evaluated (Experiment 3). 
The effect of different no-flow durations on post-resuscitation myocardial and neurological 
injury and survival in a pig model have been investigated with the aim to identify an 
optimal duration that adequately reflects the clinical scenario. This experiment is fully 
described in the Appendix 3. A duration of untreated CA of 12-13 min may be an optimal 
choice for clinically relevant CA models. 
National laws about experimental research are changed over time. For this reason 
anesthesia and drugs administration during experiments changed among different 
experiments. All the doses of anesthetic and analgesic drugs are due to minimize pain and 
are imposed by the national restrictive policy regulating experimental research in animals. 
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Experiment Experimental 
model 
Argon 
treatment 
duration 
Observation Experimental 
groups 
Endpoint 
1 
Pigs, CA 8 
mins and CPR 
5 mins 
4 h 72 h 
70% N2- 30% 
O2 
Efficacy 
70% Ar- 30% 
O2 
2 
Pigs, CA 12 
mins and CPR 
5 mins 
4 h 96 h 
70% N2- 30% 
O2 
Efficacy 
50% Ar- 30% 
O2- 20% N2 
70% Ar- 30% 
O2 
3 Healthy pigs 4 h 72 h 
70% Ar- 30% 
O2 
Safety 
4 
Rats, CA 7 
mins and CPR 
5 mins 
2 h 2 h 
70% N2- 30% 
O2 
Mechanism 
of action-  
brain 
injury 
70% Ar- 30% 
O2 
5 
Rats, 
Coronary 
artery 
occlusion 30 
mins and 
reperfusion 
1 h 6 h or 24 h 
70% N2- 30% 
O2 Mechanism 
of action-  
myocardial 
injury 
70% Ar- 30% 
O2 
 
Table 4. Experimental design. Ar, Argon. N2, nitrogen. O2, oxygen. CA, cardiac arrest. CPR, 
cardiopulmonary resuscitation. H, hours. 
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2 Pig model of short duration CA and CPR- Experiment 1 
2.1 Animal preparation 
Twelve male domestic pigs (38 ± 1 kg) were supplied by a single-source breeder and were 
housed in a conditioned room with a 12-h light-dark cycle. Pigs were fasted the night 
before experiment except for free access to water. Anesthesia was induced by 
intramuscular injection of ketamine (20 mg/kg) and completed by ear vein injection of 
sodium pentobarbital (30 mg/kg). Additional doses of pentobarbital (8 mg/kg) were 
administered at intervals of approximately 1 hr or when necessary (if response to painful 
stimuli or awakening signs were present) to maintain anesthesia. Animals were placed on a 
V- board and secured with rope before starting the surgical procedures. Animals received 
500 ml of fluids before the induction of VF and 500 ml after ROSC. A cuffed tracheal tube 
was inserted and animals were mechanically ventilated with a volume-controlled ventilator 
(Servo 300, Siemens, Sweden), with a tidal volume of 15 mL/kg, peak flow of 40 L/min, 
and FiO2 of 0.21. End-tidal CO2 (EtCO2) was monitored with an infrared capnometer 
(MRx, Philips Medical Systems, Andover, MA). Respiratory frequency was adjusted to 
maintain EtCO2 between 35-40 mmHg prior to inducing cardiac arrest and post-
resuscitation (Ristagno 2007 and 2008). No positive end expiration pressure (PEEP) was 
applied. 
 
A fluid filled 7-Fr catheter (Edwards Lifesciences, Irvine, CA) was advanced from the 
right femoral artery into the thoracic aorta to measure aortic pressure. For measurements of 
right atrial pressure (RAP), core temperature, and thermodilution CO, a 7-Fr, 5-lumen, 
thermodilution-tipped catheter was advanced from the right femoral vein into the 
pulmonary artery. Conventional pressure transducers were used (Medex TranStar, Monsey, 
NY). Myocardial infarction was induced in a closed-chest preparation by intraluminal 
occlusion of the left anterior descending (LAD) coronary artery between the first and 
second diagonal branches. Briefly, a 6-Fr balloon-tipped catheter was inserted from the 
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right common carotid artery and advanced into the LAD; its position was confirmed with 
contrast medium (Renografin-76, Squibb Diagnostics, New Brunswick, NJ). For inducing 
VF, a 5-Fr pacing catheter (EP Technologies, Inc., Mountain View, CA) was advanced 
from the right subclavian vein into the right ventricle (Ristagno 2008). The position of all 
catheters was confirmed by characteristic pressure morphology and/or fluoroscopy  before 
and after CPR. For recording the frontal plane ECG, three adhesive electrodes were 
applied to the skin of the proximal right and left upper and lower limbs. 
Experimental procedures 
Fifteen min prior to inducing cardiac arrest, the animals were allocated into one of the two 
study groups: 1) “Argon treatment” (n=6), in which animals were mechanically ventilated 
with an experimental inhalation mixture of 70% Argon – 30% oxygen for 4 hr post-
resuscitation; or 2) “Control treatment” (n=6), in which animals were mechanically 
ventilated with a control inhalation mixture of 70% nitrogen – 30% oxygen for 4 hr post-
resuscitation. 
The balloon of the LAD catheter was then inflated with 0.7 mL of air to occlude the flow. 
If VF did not occur spontaneously after 10 min of LAD occlusion, it was induced with 1–2 
mA alternating current delivered to the right ventricle endocardium. Ventilation was 
discontinued after onset of VF. After 8 min of untreated VF, CPR was initiated. Precordial 
compressions were performed with the LUCAS 2 compressor (PhysioControl Inc., 
Sweden). Coincident with the start of precordial compressions, the animals were ventilated 
with a tidal volume of 500 mL, 10 breaths/min, and FiO2 of 1.0. After 2 min of CPR, 
adrenaline (30 μg/kg) was administered via the right atrium. After 5 min of CPR, 
defibrillation was attempted with a single biphasic 150-J shock, using a MRx defibrillator 
(Philips Medical Systems). During CPR manuevres, pigs were stabilized using a custom 
made V- board. If resuscitation was not achieved, CPR was immediately resumed and 
continued for 1 min prior to a subsequent defibrillation. Pads with latero-lateral placement 
were used for defibrillation. Additional dose of adrenaline was given after 7 min of CPR. 
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Successful resuscitation was defined as restoration of an organized cardiac rhythm with a 
mean arterial pressure (MAP) of more than 60 mmHg, which persisted for more than 1 
min. If a recurrent VF occurred after successful resuscitation, it was treated with 
immediate delivery of biphasic 150-J shocks. 
Immediately after ROSC, the LAD catheter placement was reconfirmed by fluoroscopy 
and then the experimental or control inhalation was started. Anesthesia was maintained and 
animals were invasively monitored during the 4-h treatment. Forty-five min after 
resuscitation, the balloon was deflated and the LAD catheter withdrawn. Temperature of 
the animals was maintained at 38°C ± 0.5°C during the whole experiment, with the aid of 
infrared lamps. After 4 hr of treatment, catheters were removed, wounds were repaired 
surgically, and the animals were extubated and returned to their cages. Analgesia with 
butorphanol (0.1 mg/kg) was administered by intramuscular injection. At the end of the 72 
hr post-resuscitation observation, animals were reanesthetized reanesthetized as described 
before (ketamine and pentobarbital)for echocardiographic examination and blood sample 
withdrawn. Animals were then sacrificed painlessly with an intravenous injection of 150 
mg/kg pentobarbital, before heart and brain were harvested. Autopsy was performed 
routinely for documentation of potential injuries during CPR or due to obfuscating disease. 
2.2 Measurements 
Hemodynamics, EtCO2, and ECG were recorded continuously on a PC-based acquisition 
system (CODAS hardware/software). The coronary perfusion pressure (CPP) was 
computed from the differences in time-coincident diastolic aortic pressure (DAP) and 
RAP. CO was measured by thermodilution technique after injection of 5 mL of saline at 0-
5 °C (COM-2, Baxter, IL). Echocardiography was performed at baseline and at 2, 4, and 72 
hr post-resuscitation using a phase-array multifrequency 2.5-5 MHz probe (MyLab 
30Gold, Esaote S.p.A., Italy). Parasternal long-axis, short axis at base, mid papillary and 
apical level, and 2&4 apical chamber views were obtained. LV end-systolic, end-diastolic 
volumes and EF were calculated by the Simpson’s method (Ristagno 2007). 
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Arterial blood gases were assessed with i-STAT System (Abbott Laboratories, IL, USA), 
at baseline, and at 2 and 4 hr post-resuscitation. Plasma hs-cTnT was measured with an 
electrochemiluminescence assay (ECLIA, Elecsys 2010 analyzer, Roche Diagnostics, 
Germany), at baseline and 2, 4, and 72 hr post-resuscitation. Serum neuron specific enolase 
(NSE) was also measured with an electrochemiluminescence assay (Roche Diagnostics), at 
baseline and 72 hr post-resuscitation. 
The neurological alertness score (NAS) was used for evaluating neurological recovery at 
24, 48, and 72 hr post-resuscitation. Briefly, the test consisted of five items: level of 
consciousness, respiration, posture, feeding, and self care behavior. Each of the items was 
graded by severity contibuting to a final score ranging from 100 (normal) to 0 (brain 
death). The swine neurologic deficit score (NDS) that included evaluation of 
consciousness, breathing, motor/sensory function, and behavior, was also assessed. A score 
of 0 was considered normal and a score of 400 was brain death. Finally, 72 hr performance 
was evaluated according to overall performance categories (OPC) as follows: 1) normal 
(able to walk and eat); 2) slight disability (able to sit but not stand or walk); 3) severe 
disability (unaware of surroundings, withdraws to pain); 4) coma (some reflexes or 
pathologic movements, but no response to pain); and 5) brain death or death. Scores were 
assessed by veterinarian doctors blinded to treatment. No inter-rater test was performed. 
At sacrifice, the brains were carefully removed from the skulls and fixed in 4% buffered 
formalin. Standardized 5-mm coronal slices were taken. The hippocampus was chosen as 
region of interest and was paraffin embedded. Five μm-thick sections were then obtained 
and stained with hematoxylin-eosin. An 8-mm tract of the CA1, including the layer of 
pyramidal cells, was considered. The proportion of neuronal loss and degeneration 
(shrunken neurons with deeply acidophilic cytoplasm and pyknotic nucleus) was quantified 
as absent (0), rare (1), few (2), and numerous (3), in relation to the total amount of cells. 
Immunohistochemistry with antibody against microglia-specific ionized calcium binding 
adaptor molecule-1 (Iba1) was used to detect reactive microglia activation. Iba1 stained 
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sections were analyzed with ImageJ software (http://rsb.info.nih.gov/ij/). The extent of 
reactive microglia was quantified and expressed as percentage of the layer of pyramidal 
cells involved by reactive microglial activation. An experienced pathologist, blinded to 
treatment, performed the assessments. 
Myocardial infarct was assessed by tetrazolium chloride (TTC) staining. The LV was 
sliced into 5-mm thick transverse sections which were incubated (20 min) in a solution of 
TTC and then transferred to 4% formalin overnight before image analysis (Analytical 
Imaging Station 3.0, Imaging Research, Canada). The pale area (TTC-negative) was 
considered dead tissue. Infarct size was reported as percentage of TTC-negative area 
relative to LV area. 
2.3 Statistical analyses 
For comparisons between time-based measurements within the two groups, Repeated 
Measures Analysis of Variance (ANOVA), which enabled time and treatment effects and 
their interaction to be evaluated, was used. The same analysis allowed for within-subjects 
comparison between two subsequent times. Non parametric Mann-Whitney U-test was 
used for variables that were not normally distributed. For comparisons between groups at 
the given time points, one-way ANOVAwas used. When the dependent variable was 
categorical, χ2 test was performed. Statistical analysis was performed using SPSS 16.0 
software (SPSS, Inc., Chicago, IL). A value of p < 0.05 was regarded as statistically 
significant. 
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3 Pig model of prolonged CA and CPR- Experiment 2 
3.1 Animal preparation 
Thirty-six male domestic pigs (39 ± 2 kg) were fasted the night before experiment except 
for free access to water. Anesthesia was induced by intramuscular injection of ketamine 
(20 mg/kg) followed by intravenous administration of propofol (2 mg/kg) and sufentanyl 
(0.3 μg/kg) through an ear vein access. Anesthesia was then maintained by continuous 
intravenous infusion of propofol (4-8 mg/kg/h) and sufentanyl (0.3 μg/kg/h). A cuffed 
tracheal tube was placed, and animals were mechanically ventilated with a tidal volume of 
15 mL/kg and FiO2 of 0.21. Respiratory frequency was adjusted to maintain the EtCO2 
between 35 and 40 mmHg, monitored with an infrared capnometer (Ristagno 2014). No 
PEEP was applied. For measurement of aortic pressure, a fluid-filled 7F catheter was 
advanced from the right femoral artery into the thoracic aorta. For measurements of RAP, 
core temperature, and CO, a 7F pentalumen thermodilution catheter was advanced from the 
right femoral vein into the pulmonary artery. Conventional pressure transducers were used 
(MedexTransStar, Monsey, NY). Myocardial infarction was induced in a closed-chest 
preparation by intraluminal occlusion of the LAD coronary artery. More in details, a 6F 
balloon-tipped catheter was inserted from the right common carotid artery and advanced 
into the aorta and then into the LAD, beyond the first diagonal branch, with the aid of 
image intensification and confirmed by injection of radiographic contrast media. A 5F 
pacing catheter was advanced from the right subclavian vein into the right ventricle to 
induce VF (Babini 2017). The position of all catheters was confirmed by characteristic 
pressure morphology and/or fluoroscopy. Frontal plane electrocardiogram was recorded. 
3.2 Experimental procedures 
Fifteen minutes before inducing CA, the animals were allocated  using the evelop method 
into one of the following study groups: (1) Control: post- resuscitation 4 hours ventilation 
with 70% nitrogen- 30% oxygen (n=12); (2) Argon 50%: post- resuscitation 4 hours 
ventilation with 50% Argon- 50% oxygen (n=12); (3) Argon 70%: post- resuscitation 4 
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hours ventilation with 70% Argon- 30% oxygen (n=12). Argon or control treatments were 
initiated within 5 min following resuscitation, after hemodynamic stabilization. 
The balloon of the LAD coronary artery catheter was then inflated with 0.7 mL of air to 
occlude the flow. Occlusion was confirmed by the rapid occurrence of progressive 
electrocardiographic ST segment elevation. If VF did not occur spontaneously, after 10 
min it was induced with 1 to 2 mA AC current delivered to the right ventricular 
endocardium. Ventilation was discontinued after onset of VF. After 12 min of untreated 
VF, CPR, including chest compressions with the LUCAS 2 (PhysioControl Inc, Lund, 
Sweden) and ventilation with oxygen (tidal volume of 500 mL, 10 breaths/min), was 
initiated. After 5 min of CPR, defibrillation was attempted with a single biphasic 150-J 
shock, using an MRx defibrillator (Philips Medical Systems, Andover, MA). If 
resuscitation was not achieved, CPR was resumed and continued for 1 min before a 
subsequent defibrillation. Adrenaline (30 µg/kg) was administered via the right atrium 
after 2 and 7 min of CPR. Successful resuscitation was defined as restoration of an 
organized cardiac rhythm with a MAP of more than 60 mmHg, which persisted for more 
than 1 min. After that, if VF reoccurred, it was treated by immediate defibrillation. During 
CPR, the LAD occlusion balloon was deflated to avoid possible rupture during mechanical 
chest compression, but the catheter was left in place in order to maintain a partial occlusion 
of the LAD, which was approximately 75% of the internal lumen (Babini 2017). After 
successful resuscitation, anesthesia was maintained, and animals were monitored during 
the 4-h treatment. Forty-five minutes after resuscitation, the LAD coronary artery catheter 
was withdrawn. Temperature of the animals was maintained at 38°C ± 0.5°C during the 
whole experiment. After 4 h of treatment, catheters were removed, wounds were repaired, 
and the animals were extubated and returned to their cages. Analgesia with butorphanol 
(0.1 mg/kg) was administered by intramuscular injection. At the end of the post-
resuscitation observation period, up to 96 h, animals were re- anesthetized as described 
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before (ketamine and propofol) for echocardiographic examination and blood sample 
withdrawn. Animals were then sacrificed painlessly with an intravenous injection of 150 
mg/kg tiopenthal, and heart and brain were harvested. Autopsy was performed routinely 
for potential injuries due to CPR or obfuscating disease. 
3.3 Measurements 
Hemodynamics, EtCO2, and electrocardiogram were recorded continuously on a personal 
computer-based acquisition system (WinDaq DATAQ Instruments Inc, Akron, OH). The 
coronary perfusion pressure was computed from the differences in time-coincident 
diastolic aortic pressure and right atrial pressure. CO was measured by thermodilution 
technique (COM-2; Baxter International Inc, Deerfield, IL). Transthoracic 
echocardiography was performed using a phase-array multifrequency 2.5- to 5-MHz probe 
(CX50, Philips, The Netherlands). Two-dimensional apical four chamber view was 
acquired to determine LV volumes and EF, calculations were computed using the modified 
single-plane Simpson’s rule (Babini 2017). Arterial blood gases were assessed with i-STAT 
System (Abbott Laboratories, Princeton, NJ), at baseline and at 2 and 4 h post- 
resuscitation. Plasma hs-cTnT at baseline and 2, 4, and 96 h postresuscitation and NSE at 
baseline and 96 h post- resuscitation were measured with electrochemiluminescence assays 
(Roche Diagnostics Italia, Monza, Italy). 
As previously described (Ristagno 2014), neurologic recovery at 24, 48, and 96 h post- 
resuscitation was assessed with the NAS, ranging from 100 (normal) to 0 (brain death), and 
with the swine NDS, ranging from 0 (normal) and 400 (brain death). Finally, the functional 
recovery was evaluated prior to sacrifice according to OPC as follows: 1 = normal, 2 = 
slight disability, 3 = severe disability, 4 = coma, and 5 = brain death or death. Outcome 
was defined poor when OPC was ≥ 3. Scores were assessed by veterinarian doctors blinded 
to treatment. 
Brain and heart histology were evaluated as described above. 
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3.4 Statistical analysis 
One sample Kolmogorov–Smirnov Z test was used to confirm normal distribution of the 
data. For comparisons of time-based variables, two-wayANOVA with the Tuckey’s 
multiple comparisons test was used. Time- based variables not normally distributed were 
corrected by logarithmic transformation before the analysis. For comparisons between 
groups at the given time points, one-way ANOVA with Tukey’s multiple comparison was 
used for parametric variables, while Kruskal-Wallis test with Dunn’s multiple comparison 
was used for not normally distributed variables. Paramentric variables are expressed as 
mean ± SEM, whereas non parametric variables and presented as median [Q1-Q3]. When 
the dependent variable was categorical, χ2 test for trend test was performed. Statistical 
analyses were performed using GraphPad Prism 7.02 (GraphPad Software Inc.). A p value 
≤ 0.05 was considered statistically significant. 
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4 Safety- Experiment 3 
4.1 Animal preparation 
Five pigs (361 kg) were anesthetized by intramuscular injection of ketamine (20 mg/kg) 
followed by intravenous administration of propofol (2 mg/kg) and sufentanyl (0.3 μg/kg) 
through an ear vein access. Anesthesia was then maintained by continuous intravenous 
infusion of propofol (4-8 mg/kg/h) and sufentanyl (0.3 μg/kg/h). Animals were , 
orotracheally intubated and mechanically ventilated (tidal volume 15 mL/kg, positive end-
expiratory pressure (PEEP) 5 cmH2O, Inspired O2 fraction (FIO2) 0.21, and respiratory 
frequency adjusted to maintain the EtCO2 between 35-40 mmHg. An arterial line was 
introduced in Aorta through the femoral artery to monitor arterial pressure.  
4.2 Experimental procedures and measurements 
After recording baseline variables, the anesthetized animals were ventilated with a mixture 
of 70% Argon in O2 for 4 h. Arterial pressure and ventilatory parameters were 
continuously monitored and recorded (WinDaq DATAQ Instruments Inc, Akron, OH), 
together with hourly blood samples for blood gas analysis, including also hemoglobin 
(Hb), hematocrit (Ht) and electrolytes with i-STAT System (Abbott Laboratories, 
Princeton, NJ), and assessment of circulating markers of cardiac, liver and renal injury, i.e. 
plasma hs-cTnT (electrochemiluminescence assay, Roche Diagnostics Italia, Monza, Italy), 
and serum alanine aminotransferase (ALT) and creatinine (colorimetric assays, Cayman 
Chemical). 
At the end of the 4 hrs of observation, animals were weaned and returned to their cages. 
They were observed up to 72 hrs, after which another blood sample was obtained and 
animals were then sacrificed painlessly.  
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5 Rat model of CA and CPR- Experiment 4 
5.1 Animal preparation 
Thirty- seven male Sprague Dawley rats (500 g) were anesthetized by intraperitoneal 
injection of pentobarbital (50 mg/kg). Additional doses (10 mg/kg) of pentobarbital were 
administrated at intervals of approximately 1 h or when necessary to maintain anesthesia. 
The trachea was orally intubated with a 14-gauge cannula as previously reported (Fumagalli 
2014). A PE-50 catheter was advanced into the descending aorta from the left femoral 
artery for measurement of arterial pressure and blood sampling. Through the left external 
jugular vein, another PE-50 catheter was surgically advanced into the right atrium with 
reference to midchest for measurement of RAP and for the administration of drugs. Aortic 
and right atrial pressures were measured with reference to the mid-chest with conventional 
external pressure transducers. A 3-Fr PE catheter was advanced through the right external 
jugular vein into the right ventricle. A pre-curved guide wire supplied with the catheter 
was then advanced through the catheter into the right ventricle and confirmed by 
endocardial electrocardiogram, for inducing VF. All catheters were flushed intermittently 
with saline containing 2.5 IU/mL of bovine heparin. A conventional lead II ECG was 
continuously monitored. Temperature was continuously monitored with the aid of a rectal 
probe and maintained at 37±0.5 ºC. 
5.2 Experimental procedures 
VF was electrically induced with progressive increases in 60-Hz current to a maximum of 
4 mA delivered to the right ventricular endocardium. The current flow was maintained for 
3 min to prevent spontaneous defibrillation. Precordial compression was begun after 7 min 
of untreated VF with a pneumatically driven mechanical chest compressor as previously 
described (Fumagalli 2014). Coincident with the start of precordial compression, animals 
were mechanically ventilated at a frequency of 50/min in order to maintain chest 
compression/ ventilation ratio of 2:1, and with a tidal volume 0.6 ml/100g and a FiO2 of 
1.0. A single dose of epinephrine (0.02 mg/kg) was injected into the right atrium 2 min 
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after the start of precordial compression. After 5 min of CPR, resuscitation was attempted 
with up to three 2 joule defibrillations (CodeMaster XL, Philips Heartstream). Successful 
resuscitation was defined as the return of supraventricular rhythm with a mean aortic 
pressure > 50 mmHg for a minimum of 5 min. After resuscitation animals were 
randomized to a 2 hours ventilation with: (1) an experimental inhalation mixture of 70% 
Argon - 30% oxygen (n=14); or (2) a control inhalation mixture of 70% nitrogen - 30% 
oxygen (n=23). The non balance in the number of animals per group is because additional 
animals were needed in order to set up the experimental procedures. 
In vivo micro-dialysis was performed as described below during all the experimental 
phases and samples of perfusate were collected from the dorsal hippocampus because of its 
marked susceptibility to ischemic injury. Extracellular concentrations of glutamate (GLU), 
gamma-amino butyric acid (GABA), as indicators of excitatory or inhibitory 
neurotransmission, were measured by high performance liquid chromatography (HPLC) as 
well as lactic acid and piruvic acid concentration as indicators of anaerobic metabolism. 
Heart rate, arterial and right atrial pressures were invasively monitored and CPP calculated 
till 2 hrs following ROSC. After the two hours observation period, plasma was collected 
and hs-cTnT assayed. Animals were then sacrificed. 
5.3 Microdialysis procedure 
Microdialysis is a well-established technique allowing in vivo monitoring of extracellular 
neurotransmitters. The basic principle is the positioning of probe made with a membrane 
that allows free diffusion of water and low molecular weight solutes between the brain 
interstitial space and a solution lacking the substance of interest continuously flowing into 
the probe lumen. The membrane made of Cuprophan (Sorin Biomedica, Italy) acts as a 
mechanical barrier to turbulence in the fluid flow reducing the mechanical stimulation of 
the tissue. Furthermore, it acts as a filter against the large molecules and proteins present in 
the extracellular fluid.  
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One week before induction of CA, rats were anesthetized with ketamine (80 mg/kg) and 
xylazine (10 mg/Kg) and a guide cannula for the microdialysis probe was implanted into 
the brain parenchyma using a stereotaxic frame (model 900, David Kopf, CA), after the 
surgical exposure of the skull. The guide cannula for the microdialysis probe was secured 
to the skull with two stainless steel screws and dental cement (Paladur, New Galetti e 
Rossi, Milan, Italy). 
Twenty-four hours before the induction of CA, the dialysis probe was perfused with 
artificial cerebrospinal fluid (aCSF, composition in mM: NaCl 145, CaCl2 1.26, KCl 3, 
MgCl2 1, Na2HPO4 1.4, pH 7.4 with 0.6 M NaH2PO4) at a constant flow of 1 µL/min with 
a microinfusion pump and was lowered slowly into the dorsal hippocampus. The day of 
CA, the probe was connected by polythene tubing (about 50-60 cm; Portex Ltd., Hythe, 
UK) to a 2.5 mL syringe (Icogamma plus, Novico spa, Ascoli Piceno, Italy) with a 26-
gauge needle, mounted on a CMA/100 microinjection pump (CMA Microdialysis, 
Stockholm, Sweden) containing aCSF and perfused at a constant flow-rate of 1 µL/min. 
After 1 h washout, perfusate was collected every 15 min with a microsampler (Univentor, 
Zeitun, Malta) and samples were stored at -20°C. 
GABA and GLU were measured after derivatization with o-phthalaldehyde (OPA; Sigma-
Aldrich, Milan, Italy) based reagent according to Donzanti and Yamamoto (1988). Stock 
derivatizing reagent was prepared by dissolving 27 mg OPA in 1 mL methanol, followed 
by 5 µL -mercaptoethanol and 9 mL 0.1 M sodium tetraborate buffer (pH 9.3) prepared 
by dissolving 0.62 g boric acid in about 80 mL ultrapure water (MilliQ, Millipore, USA). 
pH was adjusted to 9.3 with 2-3 mL 5 M NaOH and the final volume brought to 100 mL 
with water. Stock reagent solution was maintained at room temperature in a darkened 
bottle for one week. Derivatizing reagent was prepared by diluting stock solution 1:4 with 
0.1 M sodium tetraborate buffer, 24 h before use. Five µL of derivatizing reagent were 
added to 5 µL sample to measure GLU or GABA, thoroughly mixed and immediately 
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injected into the HPLC by a refrigerated Midas autosampler (Spark-Holland, Emmen, The 
Netherlands) set at 4°C.  
GABA and GLU were separated through a 4.6 x 80 mm C18 reverse-phase column (HR-
80, ESA, Chelmsford, MA). New Guard RP-18 guard column (3.2 x 15 mm; Perkin-Elmer, 
USA) was used to protect the analytical column. The mobile phase for GABA was as 
follows: 0.05 M Na2HPO4, 35% methanol, pH 6.25 with 85% phosphoric acid, pumped at 
1.2 mL/min with a LC10-ADvp HPLC pump (Shimadzu, Milan, Italy). 
The mobile phase for GLU separation contained 0.05 M Na2HPO4, 28% methanol, pH 6.4 
with 85% phosphoric acid at a flow rate of 1 mL/min with a LC20-AD HPLC pump 
(Shimadzu, Milan, Italy). 
GABA and GLU were measured by a fluorescence detector (Jasco SP2020, Tokyo, Japan). 
Excitation and emission wavelengths were 335 and 450 nm for both aminoacids. Assays 
were calibrated daily by injecting 0.2, 0.4 and 0.8 pmol/20 L GABA or 1, 5 and 10 pmol/5 
L GLU, made up freshly in aCSF. Detection limits were 0.025 pmol/20 L for GABA 
and 0.1 pmol/5 L for GLU (signal-to-noise ratio = 2). 
Lactate and pyruvate were measured by HPLC associated with ultraviolet detection 
(wavelength, 220 nm) essentially according to the method described elsewhere (Biagi 2012) 
using a Synergi RP-18 Hydro 250 x 4.6 mm (Phenomenex) column in combination with a 
mobile phase composed by 30 mM NaH2PO4, pH 2.4 with 85% phosphoric acid. Pyruvate 
and lactate concentrations were determined by comparison to a standard calibration curve 
freshly prepared daily. 
5.4 Statistical analysis 
Comparisons between the two groups were analyzed by repeated measure ANOVA with 
Sidack’s or Tuckey’s multiple comparisons test and data are reported as mean ± SEM. 
Comparison between variables at distinct time point were analyzed with Student t-test, 
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with the exception of hs-c TnT, reported as median and analyzed using non parametric 
Mann-Whitney U test and interquartile range. When the dependent variable was 
categorical, Fisher’s exact test was performed. Statistical analysis was performed using 
GraphPad Prism 6.0 software or SPSS for Analytics Software. A value of p < 0.05 was 
regarded as statistically significant.  
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6 Rat model of myocardial ischemia-reperfusion injury- Experiment 5 
6.1 Animal preparation and experimental procedures 
Fifty-nine Sprague Dawley rats weighting 305 ± 6 were anesthetized by intraperitoneal 
injection with ketamine (75 mg/kg) and medetomidine (0.5 mg/kg), intubated and 
ventilated at a frequency of 98/min with a tidal volume 0.6 ml/100g, positive end 
expiratory pressure of 2 cmH2O and a FiO2 of 0.21. The heart was surgically exposed and 
a 7.0 silk suture was passed under the left anterior descending coronary artery and tied over 
two pieces of suture to produce the occlusion. After 30 minutes of ischemia, the occlusion 
was removed by pulling on the two pieces of suture to allow the reperfusion, under 
continuous electrocardiographic monitoring. The chest was then closed under negative 
pressure. Five minutes before reperfusion, animals were randomized to a 1 hour ventilation 
with: (1) 70% Argon - 30% oxygen; or (2) 70% nitrogen - 30% oxygen. One hour after 
reperfusion, post surgical analgesia was achieved by buprenorphine (0.1 mg/kg 
subcutaneous). Rats were weaned from mechanical ventilation and returned to their cages. 
Six or 24 hours after reperfusion plasma samples were collected for hs-cTnT 
electrochemiluminescence assay (Roche Diagnostics Italia, Monza, Italy) and animals 
were sacrificed. Myocardial infarct size was assessed as follow. Six or twenty-four hours 
after the onset of reperfusion, blue particles (Unisperse Ciba) suspension was injected into 
the inferior vena cava, after retying the ligature around the coronary artery. The heart was 
excised, blotted and weighed. The heart was sliced into 1-mm thick transverse sections 
which were incubated (20 min, 37°C) in a solution of tetrazolium chloride (TTC), then 
transferred to 4% formalin overnight before image analysis (Analytical Imaging Station, 
version 3.0, Imaging Research, St. Catherine’s, ON, Canada).  The area lacking blue 
particles was considered the AAR. Within the AAR, the pale area (TTC-negative) was 
considered dead tissue (i.e. infarct) by TTC staining and inflammatory response was 
evaluated in terms of neutrophil infiltration by naphtol staining (Sigma-Aldrich).  
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6.2 Statistical analysis 
Comparisons between the two groups were analyzed by unpaired T test and data reported 
as mean ± SEM for variables normally distributed. Non-parametric Mann-Whitney U test 
was used for variables that were not normally distributed and data are reported as median ± 
interquartile range. When the dependent variable was categorical, Fisher’s exact test was 
performed. Statistical analysis was performed using GraphPad Prism 7.0 software. A value 
of p < 0.05 was regarded as statistically significant. 
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Results 
1 Pig model of short duration CA and CPR- Experiment 1 
There were no differences in the weight of the animals and in the baseline values of blood 
gases, heart rate (HR), SAP, MAP, DAP, RAP, EtCO2, CO, and EF between the two 
groups (Table 5 and Figure 8).  
No statistical differences in the duration of LAD occlusion prior to onset of VF, CPP and 
amount of adrenaline administered during CPR were observed between the two groups 
(Table 5). Animals in the Argon group received a greater number of defibrillations in 
comparison to control animals (Table 5, p not significant).  
All the animals were successfully resuscitated. No significant differences in post-
resuscitation hemodynamics, including SAP, MAP, DAP, and RAP, EtCO2 and 
myocardial function, were observed between the two groups (Table 5 and Fig. 8). 
Nevertheless, animals receiving Argon showed a trend toward a better post-resuscitation 
arterial pressure (p not significant, Fig. 8) and 72 h LVEF (p, not significant, Table 5). 
Animals in the Argon group presented a transient significantly higher HR at 2 hr post-
resuscitation in comparison to those in the control group (p < 0.05, Table 1). However, this 
higher HR was mainly due to two animals in the Argon group that received a large number 
of defibrillations.  
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 Control (n=6) Argon (n=6) 
Time from LAD occlusion and onset of VF, min 9 ± 2 9 ± 1 
Coronary perfusion pressure, mmHg 
CPR 1 min 
CPR 3 min 
CPR 5 min 
 
33 ± 5 
44 ± 4 
35 ± 3 
 
25 ± 4 
47 ± 11 
42 ± 7 
Total dose of adrenaline administered, mg 1.5 ± 0.3 1.3 ± 0.2 
Total defibrillations delivered, n 6 ± 2 12 ± 6 
Successful Resuscitation, n 6/6 6/6 
72 hr survival, n 5/6 6/6 
72 hr survival with OPC score = 1, n 2/6 * 6/6 
Serum NSE increase from baseline, %  234 # 12 
Heart rate, beat/min 
Baseline 
PR 2 hr 
PR 4 hr 
 
106 ± 12 
129 ± 6* 
136 ± 9 
 
118 ± 11 
156 ± 9 
138 ± 6 
Right atrial  
pressure, mmHg 
Baseline 
PR 2 hr 
PR 4 hr 
 
5 ± 1 
7 ± 1 
6 ± 1 
 
4 ± 1 
5 ± 1 
5 ± 1 
EtCO2, mmHg 
Baseline 
PR 2 hr 
PR 4 hr 
 
35 ± 0 
36 ± 0 
36 ± 1 
 
36 ± 1 
36 ± 0 
38 ± 1 
LV cardiac output, l/min 
Baseline 
PR 2 hr 
PR 4 hr 
 
4.2 ± 0.6 
3.3 ± 0.4 
3.3 ± 0.3 
 
4.5 ± 0.3  
3.6 ± 0.6 
3.9 ± 0.5 
LV ejection fraction, % 
Baseline 
PR 2 hr 
PR 4 hr 
PR 72 hr 
 
69 ± 2 
35 ± 6 
46 ± 5 
61 ± 2 
 
69 ± 2 
39 ± 2 
48 ± 7 
67 ± 5 
 
Table 5. Resuscitation outcome, hemodynamics and myocardial function. CPR, cardiopulmonary 
resuscitation; LAD, left anterior descending coronary artery; VF, ventricular fibrillation; PR, post 
resuscitation; OPC, overall performance category; EtCO2, end tidal PCO2; LV left ventricle. All data 
are reported as mean ± S.E.M., except for NSE increase that is reported as median. * p < 0.05 vs. 
Argon; # p < 0.05 vs. baseline. 
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Figure 8. Systolic, mean, and diastolic arterial pressures (SAP, MAP, and DAP) in Argon treated 
animals and controls, at baseline and during the 4 h post-resuscitation period. Repeated measures  
ANOVA and unpaired t test for comparison at each time-point. Mean ± S.E.M. 
 
Ventilation with Argon did not impair respiratory gas exchange and acid-base homeostasis, 
as reflected by EtCO2 and arterial blood gases (Tables 5 and 6). No differences in arterial 
pH, PO2, PCO2, HCO3, and BE, were observed between the two groups during the 4 h 
post-resuscitation treatment (Table 6).   
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 Argon (n=6) Control (n=6) 
pH 
Baseline 
PR 2 h 
PR 4 h 
 
7.469 ± 0.02 
7.458 ± 0.06 
7.451 ± 0.02 
 
 7.509 ± 0.02 
7.449 ± 0.03 
7.473 ± 0.02 
PO2, mmHg 
Baseline 
PR 2 h 
PR 4 h 
 
79 ± 5 
83 ± 9 
76 ± 9 
 
82 ± 15 
90 ± 8 
88 ± 4 
PCO2, mmHg 
Baseline 
PR 2 h 
PR 4 h 
 
38 ± 1 
39 ± 1 
39 ± 1 
 
38 ± 2 
40 ± 2 
42 ± 1 
HCO3, mmol/L 
Baseline 
PR 2 h 
PR 4 h 
 
28.8 ± 1.2 
24.8 ± 1.1 
27.8 ± 1.5 
 
30.4 ± 0.9 
27.9 ± 1.1 
30.8 ± 1.1 
BE, mmol/L 
Baseline 
PR 2 h 
PR 4 h 
 
5.3 ± 1.5 
0 ± 1.5 
3.8 ± 2 
 
7.7 ± 1 
4.2 ± 1.6 
7.3 ± 1.4 
 
Table 6. Arterial blood gases. PR, post-Table 5. Resuscitation outcome, hemodynamics and myocardial 
function. PR, post resuscitation; PO2, oxygen partial pressure; PCO2, carbon dioxide partial pressure; 
HCO3, bicarbonate; BE, base excess. 
 
Each of the six resuscitated animals in the Argon group survived for 72 hr and had a 
complete neurological recovery, represented by an OPC = 1 (Table 5). Five of the six 
resuscitated animals in the control group survived for 72 hr. However, among them, only 
two animals achieved a complete neurological recovery, i.e. OPC = 1 (p < 0.05 vs. Argon, 
Table 5). More specifically, animals treated with Argon presented a significantly higher 
NAS and a significantly lower NDS compared to control animals, already 24 hr after 
resuscitation (p < 0.01, Fig. 9). These differences persisted up to 72 hr post-resuscitation (p 
< 0.01, Fig. 9). Brain histology of the CA1 hippocampal sector showed the presence of 
lesser, although not statistically significant, neuronal loss and degeneration and microglia 
activation in animals that received Argon in contrast to those that received the control 
ventilation (Fig. 11). These functional and histological results were paralleled by the 
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increases in serum NSE levels at 72 hr post-resuscitation, that were minimal in the Argon 
treated animals, while were statistically significant in the control ones (Table 5). 
 
Figure 9. Neurological alertness score and neurological deficit score in Argon treated animals (n=6) 
and controls (n=5), at 24, 48, and 72 hr post-resuscitation. Repeated measures ANOVA and unpaired t 
test for comparison at each timepoint. Mean ± S.E.M. * p < 0.05 and ** p < 0.01 vs. Argon treated 
animals. 
 
Neither the total dose of administered sodium pentobarbital nor the duration of CPR prior 
to resuscitation affected the above results on neurological function and injury. The average 
amount of sodium pentobarbital administered to the animals during the whole experimental 
procedure was equivalent in the two groups (Tab. 5. 1.606 ± 95 mg in the Argon group and 
1.613 ± 120 mg in the control one, p NS). The duration of CPR prior to resuscitation was 
also equivalent in the two groups (Tab 5. 337 ± 24 secs in the Argon group and 353 ± 42 
secs in the control one, p not significant).  
Heart gross anatomy showed a slightly smaller (p NS) infarct size, reported as percentage 
of TTC-negative area relative to LV area, in animals that received Argon in comparison to 
those that received the control ventilation (Fig. 10). These histological findings were 
80 
 
paralleled by a three-fold lower post-resuscitation increases in plasma hs-cTnT in pigs that 
received Argon in comparison to control animals (p NS, Fig. 10). 
 
Figure 10. Part a: Left ventricular (LV) infarct size. On the left: 2,3,5-Triphenyl-2H-tetrazolium 
chloride (TTC) staining of the upper and lower faces of one LV slice. Vital myocardium is TTC-
positive (red), while infarcted myocardium is TTC-negative (white). On the right: infarct size, reported 
as percentage of TTC-negative area relative to LV area, in animals treated with Argon in comparison 
to controls (Mean ± S.E.M.). Part b: Plasma high sensitive cardiac troponin T in Argon treated 
animals and controls, at baseline, during the 4 hr post-resuscitation period, and 72 hours later 
(Repeated measures ANOVA. Mean ± S.E.M.). 
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Figure 11. Histology of brain hippocampal CA1 sector. A, Neuronal loss and degeneration. 
Hematoxylin-eosin staining, original magnification X100, showing intact neurons in an Argon-treated 
animal, in contrast to ischemically damaged neurons in a control (arrows). On the right, proportion of 
neuronal loss and degeneration in animals treated with Argon in comparison to controls 
(Nonparametric Mann-Whitney U test, dot-plot and median). B, Microglia activation. 
Immunohistochemistry for microglia-specific ionized calcium-binding adaptor molecule 1 (Iba1), 
original magnification X100, showing morphology typical for normal, resting microglia in an Argon-
treated animal, in contrast to activated microglia in a tract of pyramidal cells in a control (arrow). On 
the right, extension of microglia activation in the brain hippocampal CA1 sector, in animals treated 
with Argon in comparison to controls (Nonparametric Mann-Whitney U test, dot-plot and median).  
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2 Pig model of prolonged CA and CPR- Experiment 2 
No differences in body weight, HR, hemodynamics, EtCO2, and myocardial function, 
arterial blood gases and biomarkers were observed between the three groups at baseline 
(Table 7 and Fig. 12). 
No differences in CPP during CPR (Table 7) were observed among the 3 groups. Ten 
animals of 12 were successfully resuscitated in each group.  
The duration of CPR prior to ROSC and the number of total defibrillations delivered were 
greater in the Argon treated animals compared to controls (Table 7, p=0.056); specifically, 
the animals treated with Argon 50% presented the longest duration of CPR and the highest 
number of defibrillations (Table 7). 
After resuscitation, animals treated with Argon 70% showed a significantly higher systolic, 
mean and diastolic arterial pressure compared to controls and to the Argon 50% treated 
animals (p=0.008, p=0.001, p=0.0015 respectively, Figure 12). Moreover, animals treated 
with Argon 70% presented a significantly lower post resuscitation heart rate compared to 
controls (p<0.0001, Table 7). No differences were observed in other hemodynamic 
variables between groups (Table 7). 
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 Control (n=12) Argon 50% 
(n=12) 
Argon 70% 
(n=12) 
Body weight, kg 38 ± 0.7 40 ±0.6 39 ± 0.5 
Coronary perfusion pressure, mmHg 
CPR 1 min 
CPR 3 min 
CPR 5 min 
 
19 ± 4 
35 ± 3 
22 ± 4 
 
25 ± 6 
39 ± 6 
26 ± 4 
 
22 ± 5 
38 ± 5 
27 ± 3 
Time to ROSC, s 341[301.0-366.0] 371.5 [325.3-
430.3] 
301.5 [301.0-
358.9] 
Total defibrillations delivered, n 5 [2.5-11.7] 18 [7.0-24.8] 11.5 [6.5-15.0] 
Successful resuscitation, n 10/12 10/12 10/12 
96 h Survival, n 6/10 7/10 9/10 
96 h Neuronal Specific Enolase, 
ng/ml 
21.15 [16.21-
60.51] 
8.26 [1.19-
18.07] 
16.42 [2.52-
22.14] 
Heart rate, beats/min 
Baseline 
PR 2 h 
PR 4 h 
 
102 ± 9 
173 ± 7 
  165 ± 14 
 
  95 ± 4 
  154 ± 12 
135 ± 9 
 
82 ± 7 
   131 ± 5 ** 
   120 ± 9 ** 
Right atrial pressure, mmHg 
Baseline 
PR 2 h 
PR 4 h 
 
5 ± 1 
7 ± 1 
7 ± 1 
 
8 ± 1 
8 ± 1 
9 ± 1 
 
  5 ± 1 † 
6 ± 1 
7 ± 1 
EtCO2, mmHg  
Baseline 
PR 2 h 
PR 4 h 
 
          36 ± 0 
36 ± 0 
36 ± 0 
 
36 ± 1 
35 ± 0 
36 ± 0 
 
36 ± 1 
36 ± 0 
37 ± 0 
Pulmonary arterial pressure, mmHg 
Baseline 
PR 2 h 
PR 4 h 
 
19 ± 2 
20 ± 1 
21 ± 1 
 
22 ± 1 
19 ± 2 
21 ± 1 
 
18 ± 1 
19 ± 2 
21 ± 2 
Pulmonary capillary wedge pressure, 
mmHg 
Baseline 
PR 2 h 
PR 4 h 
 
  9 ± 1 
11 ± 1 
12 ± 1 
 
11 ± 1 
12 ± 1 
12 ± 1 
 
9 ± 0 
9 ± 1 
           10 ± 1 
LV cardiac output, L/min 
Baseline 
PR 2 h 
PR 4 h 
 
4.4 ± 0.2 
3.2 ± 0.3 
3.0 ± 0.2 
 
 
3.9 ± 0.2 
2.9 ± 0.3 
2.5 ± 0.1 
 
4.0 ± 0.2 
3.0 ± 0.3 
2.6 ± 0.2 
 
Table 7. Resuscitation outcome and hemodynamics. All data are reported as mean ± SEM, except for 
duration of CPR before resuscitation, total defibrillations delivered, defibrillations to ROSC and NSE 
levels, reported as median. PR indicates post resuscitation. * p< 0.05, ** p< 0.01 Controls vs. Argon 
70%. † p< 0.05, †† p< 0.01 Argon 50% vs. Argon 70%. 
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The 4-h ventilation with Argon did not impair respiratory gas exchange and acid-base 
homeostasis regardless to the Argon concentration administered, with the exception of a 
decreased BE and HCO3
- in animals treated with Argon 50% compared to other groups 
(p=0.0015 and p=0.0011 respectively, Tables 8).  
 
 
 
Table 8. Arterial Blood Gases. PR indicates post- resuscitation; PO2, oxygen partial pressure; PCO2, 
carbon dioxide partial pressure; HCO3, bicarbonate; BE, base excess. Data shown as mean  SEM. †† 
< 0.01 Argon 50% vs. Argon 70%. 
  
 Control (n=12) Argon 50% (n=12) Argon 70% (n=12) 
pH 
BL 
PR2 
PR4 
 
7.487  0.02 
7.373  0.02 
7.424  0.03 
 
7.459 0.01 
7.325 0.03 
7.408 0.02 
 
7.500  0.03 
7.398  0.02 
7.439  0.02 
PCO2 
BL 
PR2 
PR4 
 
38  1 
40  1 
40  1 
 
37  1 
38  1 
39  1 
 
36  1 
40  1 
40  1 
PO2 
BL 
PR2 
PR4 
 
  80  4 
110  6 
103  8 
 
  83  3 
113  7 
111  8 
 
  88  4 
112  8 
114  9 
BE 
BL 
PR2 
PR4 
 
 5.4  1.4 
-1.8  1.6 
 2.3  1.5 
 
 2.3  0.7 
-6.1  1.3 
    0  1.2 
 
4.8  1.3 
   -0.1  1.4 †† 
3.0  1.1 
HCO3- 
BL 
PR2 
PR4 
 
28.9  1.1 
23.3  1.3 
26.4  1.2 
 
26.5  0.6 
19.9  1.2 
24.6  0.9 
 
28.1  1.0 
    24.9  1.1 †† 
27.3  0.9 
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Post resuscitation myocardial function was significantly impaired in each animal (Table 9), 
with LV volumes increases and LVEF decreases. Although absolute mean values between 
groups were not significantly different, animals treated with Argon 70% achieved a faster 
myocardial function recovery. In fact, as shown in Table 10, LVEF from 4 to 96 h 
increased more in Argon 70% compared to Argon 50% and to Control animals (28.5±6.1% 
vs 5.3 ± 7.4 and 18.5 ± 7.0 % respectively, p < 0.01). Moreover, LV systolic volume at 96 
h normalized in animals treated with Argon 70% (Table 10).  
 
 Control  
(n=8) 
Argon 50%  
(n=9) 
Argon 70%  
(n=9) 
LVEF, % 
Baseline 
PR 2 h 
PR 4 h 
PR 96 h 
 
 
76.6 ± 2.3 
35.7 ± 3.1 
36.6 ± 3.5 
55.1 ± 7.4 
 
 
69.5 ± 3.9 
46.8 ± 8.2 
45.6 ± 7.1 
 50.9 ± 5.9† 
 
 
72.7 ± 3.1 
34.6 ± 3.3 
39.0 ± 4.5 
67.5 ± 2.6 
EDV, mL 
Baseline 
PR 2 h 
PR 4 h 
PR 96 h 
 
 
33.7 ± 3.0 
35.4 ± 3.3 
42.5 ± 5.7 
41.3 ± 4.3 
 
 
31.5 ± 1.8 
27.3 ± 2.3 
36.6 ± 6.1 
36.2 ± 2.4 
 
 
39.5 ± 3.5 
31.5 ± 2.9 
39.4 ± 2.6 
37.1 ± 4.8 
ESV, mL 
Baseline 
PR 2 h 
PR 4 h 
PR 96 h 
 
 
7.8 ± 0.9 
22.8 ± 2.6 
26.4 ± 4.2 
18.2 ± 3.5 
 
 
9.8 ± 1.4 
14.3 ± 2.8 
21.3 ± 5.6 
17.8 ± 2.3 
 
 
13.3 ± 1.8 
20.4 ± 2.4 
23.0 ± 2.3 
12.4 ± 2.1 
 
Table 9. Echocardiographic data. Left Ventricle Ejection Fraction, End-Diastolic and End-Systolic 
Volumes. All data are reported as mean ± SEM. p value from two-way ANOVA. Tukey’s multiple 
groups comparisons: † p< 0.05 Argon 50% vs. Argon 70%.  
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Control 
(n=8) 
Argon 50% 
(n=9) 
Argon 70% 
(n=9) 
LVEF, %  
 
PR2 h vs Baseline 
PR 4 h vs Baseline 
PR 96 h vs Baseline 
PR 4 h vs PR 2 h 
PR 96 h vs PR 2 h 
PR 96 h vs PR 4 h 
 
-40.9 ± 6.8** 
-40.0 ± 6.5** 
-21.5 ± 6.8* 
0.9 ± 7.0 
19.3 ± 7.3* 
18.5 ± 7.0* 
-22.7 ± 6.3** 
-23.9 ± 7.0** 
-18.6 ± 6.3* 
-1.2 ± 7.4 
4.1 ± 6.7 
5.3 ± 7.4 
-38.1 ± 5.9** 
-33.6 ± 5.9** 
-5.1 ± 6.1 
4.4 ± 5.9 
32.9 ± 6.1** 
28.5 ± 6.1** 
EDV, mL 
PR2 h vs Baseline 
PR 4 h vs Baseline 
PR 96 h vs Baseline 
PR 4 h vs PR 2 h 
PR 96 h vs PR 2 h 
PR 96 h vs PR 4 h 
 
1.77 ± 5.1 
8.9 ± 5.1 
7.6 ± 5.1 
7.1 ± 5.5 
5.9 ± 5.5 
-1.3 ± 5.3 
-4.2 ± 4.6 
5.0 ± 5.3 
4.7 ± 4.7 
9.2 ± 5.4 
8.9 ± 4.9 
-0.3 ± 5.5 
-8.1 ± 4.6 
-0.2± 4.5 
-2.4 ± 4.6 
7.9 ± 4.6 
5.6 ± 4.7 
-2.3 ± 4.6 
ESV, mL 
PR2 h vs Baseline 
PR 4 h vs Baseline 
PR 96 h vs Baseline 
PR 4 h vs PR 2 h 
PR 96 h vs PR 2 h 
PR 96 h vs PR 4 h 
 
15.0 ± 3.8** 
18.6 ± 3.8** 
10.4 ± 3.8* 
3.6 ± 4.0 
-4.6 ± 4.0 
-8.2 ± 4.0 
4.6 ± 3.4 
11.5 ± 3.9* 
8.0 ± 3.5 
6.9 ± 4.0 
3.5 ± 3.6 
-3.5 ± 4.1 
7.1 ± 3.4 
9.8 ± 3.3* 
-0.9 ± 3.4 
2.6 ± 2.1* 
-8.0 ± 3.5 
-10.7 ± 3.4 
 
Table 10. Echocardiographic data. Left Ventricle Ejection Fraction, End-Diastolic and End-Systolic 
Volumes. All data are reported as mean ± SEM. p value from two-way ANOVA. Tukey’s multiple 
comparisons within each group: * p< 0.05; ** p< 0.01. 
Animals treated with both Argon concentrations presented a significantly higher NAS and 
a significantly lower NDS compared with control animals, markedly at 72 hrs after 
resuscitation (p=0.028 an p=0.021 respectively, Figure 13).  
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Figure 12. SAP, MAP, and DAP in Argon-treated animals and controls, at baseline and during the 4-h 
post- resuscitation period. Ordinary two-way ANOVA and Tuckey’s multiple comparison test. Mean ± 
SEM. * p< 0.05, ** p< 0.01 Ar 70% vs Control; † p< 0.05, †† p< 0.01, Ar 70% vs Ar 50%. 
There was no statistically significant difference in the number of the resuscitated animals 
surviving up to 96 h (p=0.3, Table 7). Respectively 6 (60 %) and 8 (80 %) resuscitated 
animals in the Argon 50% and Argon 70% groups achieved a complete neurological 
recovery (OPC=1 or 2), whereas only 3 (30%) animals survived up to 96 hours with a 
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complete neurological recovery in the Control group (Figure 14, p<0.0001). The better 
neurological condition of the treated animals at 96 hrs is accompanied by a trend towards 
lower plasma levels of NSE at the same time- point in these two groups of treated animals 
compared to controls (p=0.21, Table 7).  
 
Figure 13. Neurologic alertness score and neurologic deficit score in Argon-treated animals and 
controls, at 24, 48, and 72 h post- resuscitation. Ordinary two-way ANOVA and Tuckey’s multiple 
comparison test. Data shown as mean with SEM.  
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Figure 14. 96 hrs survival with Overall Performance Category (OPC). 
 
.  
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Table 11. Histology of brain cortex and hippocampal CA1 sector. Perivascular cuffing, neuronal 
degeneration and microglia activation in animals treated with Argon in comparison to controls. Data 
shown as median [Q1-Q3]. * p< 0.05, ** p < 0.01 Argon 70% or Argon 50% vs Controls. 
 
Brain histology showed reduced neuronal loss and degeneration, perivascular cuffing and 
microglia activation in animals that received Argon in contrast to controls. These lesions 
were found both in cortex and in hippocampus (Table 11).   
Heart gross anatomy showed no statistically significant differences in infarct size between 
groups. However, there was a trend towards to a reduction in infarct size in animals that 
received Argon 70% in comparison to Controls and an increased infarct size in animals 
treated with Ar 50% (p=0.064, Figure15. A). The reduction in the infarct size in Argon 
70% treated group is reflected in a statistically significant lower 96-h post-resuscitation 
plasma level of hs-cTnT observed in pigs that received Argon 70% in comparison to 
controls (p=0.001, Figure 15.B).  
 
 
 
 
 
Control (n=6) Argon 50% (n=7) Argon 70% (n=9) 
Cortex Hippocampus Cortex Hippocampus Cortex Hippocampus 
Perivascular 
cuffing, score 
0.25[0-1] 0.75[0.5-1] 0[0-0]   0[0-0]*    0[0-0]* 0[0-1] 
Neuronal 
degeneration, 
score 
1[0.3-1] 2.5[2-3]    0[0-0]* 3[0.5-3] 0[0-1] 2[2-2] 
Microglia 
activation, %  
µm2 
- 24.3[20-25.5] -     13.1[5.9-14-
6]** 
- 23.1[18.1-
23.6] 
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Figure 15. A. Left ventricular infarct size, reported as percentage of TTC-negative area relative to LV 
area in animals treated with Argon in comparison to controls. Data shown as median and interquartile 
range. Kruskal-Wallis test, p = 0.0637. B, Plasma hs-cTnT in Argon-treated animals and controls, at 
baseline, during the 4-h post- resuscitation period, and 96 h later. Data shown as median and 
interquartile range. Two- ways ANOVA and Tuckey’s multiple comparisons test on values corrected 
by logarithmic transformation.  * p< 0.05 Ar 70% vs Control; †† p< 0.01, Ar 70% vs Ar 50%.  
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3 Safety- Experiment 3 
All the animals survived without any apparent behavioral changes and/or impairment over 
the 3 days of observation. Overall, no adverse events during and after Argon ventilation 
were reported. No significant changes in hemodynamics were observed; similarly, blood 
gas variables, Hb, Ht, and serum electrolytes remained in the physiological range (Figure 
16, Table 12). Hs-cTnT, ALT, and creatinine values were also stable during the whole 
period of observation (Table 12). Of interest, it was noticed that airways peak pressure 
(Ppeak) value after 4 h of Argon ventilation was comparable to baseline.  
 
Figure 16. Heart rate (HR), mean arterial pressure (MAP) and peak airways pressure (Ppeak), after a 
4-h ventilation with Argon 70%. BL, baseline; Mean  SEM.  
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Baseline Argon 70% - Oxygen 30% Sacrifice 
0 h 1 h 2 h 3 h 4 h 72 h 
HR 
(bpm) 
80 ±10 75 ±9 75 ±9 73 ±11 71 ±6 n.a. 
MAP 
(mmHg) 
83 ±10 105 ±9 105 ±8 105 ±5 104 ±4 n.a. 
Ppeak 
(cmH2O) 
18 ±0 18 ±0 19 ±0  19 ±0  19 ±0 n.a. 
pH 
7.511  
± 0.021 
7.521  
± 0.006 
7.538  
± 0.010 
7.532  
± 0.011 
7.530  
± 0.007 
n.a. 
PaO2 
(mmHg) 
80 ± 3 133 ± 4 130 ± 8 121 ± 8 123 ± 9 n.a. 
SaO2  
(%) 
97 ± 0 99 ± 0 99 ± 0 99 ± 0 99 ± 0 n.a. 
PaCO2 
(mmHg) 
34.9 ± 0.5 35.5 ± 0.3 35.3 ± 0.7 36.3 ± 1.0 36.1 ± 0.4 n.a. 
HCO3- 
(mmol/L) 
28.1 ± 1.5 29.2 ± 0.4 30.2 ± 0.4 30.2 ± 0.6 30.1 ± 0.5 n.a. 
Hb  
(g/dL) 
9.0 ± 0.3 9.1 ± 0.4 9.1 ± 0.3 9.3 ± 0.4 8.8 ± 0.2 n.a. 
Ht  26 ± 1 27 ± 1 27 ± 1 27 ± 1 26 ± 0 n.a. 
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(%) 
Na+ 
(mmol/L) 
138 ± 1 138 ± 1 137 ± 1 137 ± 1 137 ± 1 n.a. 
K+ (mmol/L) 3.7 ± 0.1 4.0 ± 0.1 4.3 ± 0.1 4.4 ± 0.2 4.5 ± 0.2 n.a. 
Lac 
(mmol/L) 
2.48 ± 0.88 1.81 ± 0.63 0.95 ± 0.10 0.84 ± 0.07 0.80 ± 0.14 n.a. 
ALT  
(U/L) 
29 ± 7 26 ± 1 32 ± 2 24 ± 2 23 ± 2 26 ± 2 
Creatinine 
(mg/dL) 
3.36 ± 0.42 2.58 ± 0.29 2.41 ± 0.47 2.52 ± 0.39 2.87 ± 0.16 2.85 ± 0.94 
hs-cTnT 
(ng/L) 
8.23  
[7.76-8.7] 
7.5  
[7.76-10.92] 
6.65 
[6.47-7.66]  
 7.24  
[5.59-10.02] 
6.54 
 [5.98-8.26] 
6.33  
[4.41-6.55] 
NSE 
(ng/L) 
0.62 
[0.53-6.62] 
0.56 
[0.55-0.69] 
0.48 
[0.42-0.76] 
0.61 
[0.46-0.62] 
0.55 
[0.42-0.59] 
0.41 
[0.31-0.43] 
 
Table 12. Arterial blood gases; hemoglobin; electrolytes; lactates; liver, renal, and cardiac biomarkers 
after a 4-hr ventilation with Ar 70%. PaO2, partial arterial oxygen pressure; SaO2, arterial oxygen 
saturation; PaCO2, partial arterial carbon dioxide pressure; HCO3-, serum bicarbonates; Hb, 
hemoglobin; Ht hematocrit; Lac, serum lactates; ALT, alanine aminotransferase; hs-cTnT, high 
sensitivity cardiac troponin T. Mean ± SEM except for hs-cTnT and NSE, shows as median and 
interquartile range. 
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4 Rat model of CA and CPR- Experiment 4 
More than 85% of the rats were successfully resuscitated and no differences were observed 
in the CPR procedures between experimental groups (Table 13, p not significant).  
 
 
Vehicle Argon 
Number of animals with 
CA and CPR 
18 9 
Body Weight (g) 476 ± 29 489 ± 31 
ROSC 85% 90% 
Number of Shocks 2.6 ± 2.8 1.9 ± 1.6 
 
Table 13. Resuscitation outcome. CA, cardiac arrest; CPR, cardiopulmonary resuscitation; ROSC, 
return of spontaneous circulation. All data are reported as mean ± SEM, except for ROSC rate 
reported as percentage.  
 
Ventilation with Argon had no detrimental effects on HR, MAP and CPP during the 2-h 
observation period. Furthermore, animals treated with Argon showed a faster increase in 
MAP and CPP compared to controls (Repeated measurement ANOVA, effect of treatment: 
p< 0.0001 (Figure 17, a, b and c). 
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Figure 17. (a) HR, heart rate; (b) MAP, mean arterial pressure; (c) CPP, coronary perfusion pressure 
in Argon treated animals (n=9) and controls (n=14), at baseline and during the 4 hr post-resuscitation 
period (PR). Data are reported as mean ± SEM. Repeated measurement ANOVA with Sidak’s multiple 
comparisons test, * p < 0.05. 
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Figures 18 shows the extracellular levels of GLU and GABA in the dorsal hippocampus at 
baseline, during and after cardiac arrest in the two experimental groups. As shown, cardiac 
arrest did not affect GLU extracellular levels (Repeated measurement ANOVA, effect of 
time p=0.16), but it determined the increase in GABA from 0.6-0.7 to 4.3-6.5 pmol/20 µL 
(Fig. 18, Repeated measurement ANOVA, effect of time: p<0.0001). However, ventilation 
with Argon did not affect he extracellular levels of GLU and GABA (Fig 18) Repeated 
measurement ANOVA, effect of treatment: p=0.39 and p=0.38 respectively). 
 
Figure 18. Extracellular levels of GLU and GABA in the dorsal hippocampus at baseline, during CA 
(red line) and CPR (green line), and after cardiac arrest. The black and the blue line over the X axis 
indicates the duration of ventilation with room air (at baseline) and the Argon or control ventilation 
(post cardiac arrest). Data shown as mean and standard error.  
 
The extracellular levels of lactic acid in the dorsal hippocampus increased significantly at 
30 min after CA compared to the baseline levels (Fig 19. Repeated measurement ANOVA, 
effect of time: p=0.0003), as expected after an ischemic insult. Lactic acid levels return to 
baseline levels 2 h after CA induction. The increase in lactic acid levels after CA was more 
consistent in control ventilation group than in the Argon ventilation one, even if the 
difference was not statistically significant (Figure 19 Repeated measurement ANOVA, 
effect of treatment: p=0.5). 
The extracellular levels of pyruvic acid in the control group decreased during the first 30 
min after CA, compared to the baseline levels, then increased 1 h after cardiac arrest and 
remained higher than baseline levels till the end of the experiment. The decrease in pyruvic 
acid levels early after CA was not observed in the Argon treated animals, where levels of 
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pyruvic acid increase starting from the induction of CA (Figure 19. Repeated measurement 
ANOVA, effect of time: p=0.0006). Treatment does not affect pyruvic acid levels during 
CPR and after resuscitation (Figure 19. Repeated measurement ANOVA, effect of 
treatment: p=0.52).  
The ratios between the lacticate and pyruvate concentration are shown over time to 
highlight the effect of the Argon ventilation on anaerobic metabolism. The rise in ratio was 
significantly attenuated in rats ventilated with Argon during the first hour after cardiac 
arrest compared to controls (Figure 19. Two-way ANOVA, effect of time: p<0.0001, effect 
of treatment: p=0.001).                                                                                                                      
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Figure 19. Extracellular levels of lactate and pyruvate in the dorsal hippocampus, and ratios between 
the lactic acid and pyruvic acid concentration, at baseline, during CA (red line) and CPR (green line), 
and after cardiac arrest. The black and the blue line over the X axis indicates the duration of 
ventilation with room air (at baseline) and the Argon or control ventilation (post cardiac arrest). Data 
shown as mean and standard error. Repeated measurement ANOVA with Tuckey’s multiple 
comparisons test, * p < 0.05. 
100 
 
Finally, to assess the protective effect of Argon ventilation on the myocardium, plasma 
levels of hs-cTnT were measured. Reduction in  hs-c TnT were detected in animals 
ventilated with Argon compared to controls (Figure 20).  
 
 
 
Figura 20. Plasma hs-c TnT in Argon treated animals (n= 13) and controls (n= 18), 120 mins after 
ROSC. Data shown as median [Q1-Q3].  
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5 Rat model of myocardial ischemia-reperfusion injury- Experiment 5 
Six hours after reperfusion, ten rats survived in both groups. Ventilation with Argon did 
not affect neither infarct size nor heart weight (Table 14, Student T-test, p not significant). 
However, rats treated with Argon showed a lower plasma level of hs-cTnT compared to 
controls (Figure 21. 3128 ng/L in Ar vs. 7432 ng/L; Mann- Whitney test, p=0.046) 
together with a reduced neutrophil infiltration (Figure 21. 72 cells/mm2 in Argon animals 
vs. 92 cells/mm2 in controls, p=not significant).  
 
Table 14. Survival, Infarct size, heart weight (HW) in controls and Argon ventilated animals 6 hours 
after reperfusion. Infarct size is expressed as infarct area/ area at risk. Data shown as mean ± SEM.  
 
 
Figure 21. Plasma hs-c TnT and polymorphonuclear infiltration 6 hours after reperfusion. 
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Twenty-four hours after reperfusion, thirteen rats survived in both groups. A trend towards 
a reduction of infarct size and heart weight was observed in Argon treated animals 
compared to controls (Table 15, Student T-test, p not significant). Ventilation with Argon 
did not affect neither hs-cTnT nor cellular infiltration (Fig 22). 
 
Table 15. Survival, Infract size, heart weight (HW) in controls and Argon ventilated animals 24 hours 
after reperfusion. Infarct size is expressed as infarct area/ area at risk. Data shown as mean ± SEM.  
 
 
Figure 22. Plasma hs-c TnT and polymorphonuclear infiltration 24 h after reperfusion. 
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Discussion 
1 Main findings 
The main finding of my PhD studies is that a 4-h post-resuscitation treatment with Argon 
significantly improved neurologic recovery after CA. In details, animals that received 
Argon achieved a faster and complete neurological recovery, in contrast to controls. 
Different neurological tests together with histopathology confirmed the better recovery 
induced by Argon  in two different swine models of CA and CPR. Our results consistently 
demonstrated the efficacy of Argon treatment in a preclinical model of CA. Argon efficacy 
has been tested in the large animal for the first time, corroborating the positive results 
previously obtained in vitro and in rats and providing, providing sufficient informations on 
the efficacy and safety aspect needed to proceed to clinical application.  
 Pigs have emerged as established and widely accepted preclinical animal model for CPR 
research. This species allows for state-of-the-art measurements of myocardial and cerebral 
functions, ischemic injury, together with inflammatory, immune and oxidative stress 
reactions. Furthermore, observations on this model are comparable to those made in 
humans (Babini 2017). The efficacy of Argon in terms of neuroprotection was replicated in 
both short-duration CA and in a more severe CA model. Data obtained from the 
experiments on animals subjected to the CA of longer duration added clinical relevance to 
the experiment with shorter interval of untreated CA, which was purely descriptive. 
Indeed, clinical studies report an average emergency medical service arrival time to the CA 
scene of 6-8 min; however, considering the intervals for emergency call, ambulance 
dispatch, arrival to the patient and onset of CPR, it is reasonable that the no-flow duration 
accounts for even longer periods. Based on that, the duration of untreated CA in 
experimental models should reasonably last more than 8 min to adequately reflect the 
clinical OHCA environment (Nielsen 2013, Rea 2010, Nichol 2015, Hasselqvist-Ax 2015, Dankiewicz 
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2016).  Experimental no-flow duration may be associated with changes in severity of post 
CA syndrome. Therefore,  the studied interventions may either overestimate or fail to show 
any effect on outcome. 
The use of Ar ventilation for neuroprotection after CA was explored in studies performed 
in rats (Brücken 2013, 2014, 2015 and 2017, Zuercher 2016). All these studies reported both 
neurological recovery, evaluated with the aid of various neurobehavioral tests, and tissue 
damage, assessed by histopathology and biochemistry. Most of this studies were from the 
same research group (Brücken 2014) that investigated the effect of 1 h of ventilation with a 
mixture of 70% Ar in O2 initiated 1 hr after resuscitation. After a no-flow of 7 min, post 
resuscitation ventilation with Argon led to a better and faster neurological recovery during 
the following 7 days, assessed by a battery of tests, including the rodent neurological 
deficit score, the open field and the Morris water-maze tests, compared to the control 
ventilation (Brücken 2013). This good functional recovery was paralleled by a significantly 
lower brain damage in the neocortex and the hippocampal CA 3 and 4 regions. An 
additional study introduced further data showing that the 70% Argon-induced 
neuroprotection persisted even when the onset of the treatment was delayed up to 3 hrs 
after resuscitation (Brücken 2014 and 2015). More recently, neuroprotection of Argon was 
investigated in conjunction with mild therapeutic hypothermia, based on the hypothesis 
that the combination of these two interventions could yield to a boosted protection, further 
improving neurological outcome after CA (Brücken 2017). Thus, in the same model, rats 
were treated with mild therapeutic hypothermia at 33°C (6 hrs) and 1 hr ventilation with 
70% Argon. Surprisingly, the results showed that the combined treatment, similarly to a 
control ventilation with air/O2, generated worse neurological recovery together with 
greater neuronal degeneration in hippocampal CA1 region, when compared to mild 
therapeutic hypothermia alone. Unfortunately, in this study the treatment with Argon 
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alone, as reference, was absent and thus no further considerations on the effect of Argon 
can be made. 
A dose dependency of Argon treatment emerged from our study. Indeed, in experiment 2 
Argon treatment after CA was confirmed to improve both neurological outcome and 
histopathological brain damage compared to controls, regardless of Argon concentration in 
the inhalation mixture. However, the neuroprotective effects were more pronounced when 
the inhalation mixture contained 70% Argon in place of 50%. Interestingly, the 
hemodynamic parameters were improved in animals treated with Argon 70% compared to 
controls and to those treated with Ar 50%, suggesting that only Argon at high 
concentration affects hemodynamic. 
The dose-dependent effect observed in our study was supported by a previous study 
employing a rat model of CA and CPR, ventilated with Argon at a concentration of either 
40% or 70% after resuscitation (Brücken 2014). In addition, in mouse hippocampal slices 
subjected to a focal mechanical trauma mimicking traumatic brain injury (TBI), exposure 
to Argon also prevented neuronal injury in a dose dependent manner with a maximum at 
70% concentration (Brücken 2015). Our results corroborate these findings and suggest that 
Argon at least in vivo exerts a maximum effect at the highest concentration. 
The choice of testing the specific concentration of 50% Argon came from a previous 
publication, where Loetscher et al. investigated the effects of Argon in two distinct in vitro 
models of neuronal trauma induced by oxygen glucose deprivation (OGD) and traumatic 
brain injury (TBI) using either 25%, 50% or 75% Argon (Loetscher 2009). While there was 
no significant difference in neuroprotective efficacy between the different Argon 
concentrations in the OGD setting, a peak effect at 50% Argon was observed in the TBI 
model. A trend towards lesser neuronal damage in animals subjected to 24 hrs ventilation 
with Argon 50% after resuscitation compared to controls was reported also in a model of 
cardiac arrest in rodents induced with KCl and esmolol. As primary outcome, neuronal 
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damage was assessed by histopathology and for secondary outcome neurologic tests were 
performed (Zuercher 2016).  
Numerous signalling pathways and molecular targets appeared to be involved in the 
biological effects provided by Argon. However, the specific contribution of each pathway 
or molecule is still unclear. Potential mechanisms of action involved in the Argon 
protection are introduced and described in many in vitro studies. Thus, Argon appeared to 
possess oxygen-like properties, which could explain its neuroprotective effects against 
hypoxia and ischemia, by partially restoring mitochondrial respiratory enzyme activity and 
reducing NMDA-induced neuronal death (David 2012). Moreover, Ar plays anti-apoptotic 
effects modulating the molecular pathways involved in cell survival in the following 
manners: increasing extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, 
already after 30 min of exposure, which leads to a reduced ERK 1/2-caspase-3 cleavage, 
blocking the apoptosis cascade (Fahlenkamp 2012, Zhao 2016, Ulbrich 2015); upregulating the 
expression of the anti-apoptotic protein B-cell lymphoma-2 (BCL-2) (Zhuang 2012, Zhao 
2016); activating the toll like receptor (TLR) 2 and 4, which reduce caspase-3 activity (Zhao 
2016, Ulbrich 2015 and 2016);and mediate the intracellular signaling involved in the production 
of pro-inflammatory cytokines, growth factors, and cell survival (Ulbrich 2016). The above 
mechanisms of action have been confirmed in the in vivo studies, by either functional tests 
or histological and biochemical essays in animals subjected to a variety of injuries and 
treated with inhaled Argon as potential therapeutic agent. 
Our experiment 4 explored the effect of Argon treatment on the brain extracellular levels 
of glutamate and GABA. Indeed, brain extracellular levels of the 2 neurotransmitters was 
reported to increase rapidly following the onset of ischemia, remain elevated during 
ischemia, and then decline over 20–30 min following reperfusion (Phillis 2003). The 
elevated levels of glutamate can contribute to the demise of surrounding neurons (Rothman 
1986, Choi 1997), whereas the inhibitory amino acid  GABA is considered to be 
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neuroprotective (Lyden 1997). Regarding GLU extracellular brain level, despite what is 
described in literature, we did not observe neither increase in GLU level during CA nor 
statistically significant differences between groups in GLU level consequent to the Ar or 
control ventilation. In contrast, GABA extracellular levels increased during the ischemic 
insult, even if we did not observe any difference between groups according to treatment. It 
should be noted that this data is to be considered preliminary because of the low number of 
animals per experimental group. Moreover, we observed lower brain extracellular 
lactate/piruvate ratios in animals treated with Argon, suggesting Argon treatment can 
alleviate the deterioration of the energy supply in the brain during the early phases of 
reperfusion (Madl 2004). 
2 Hemodynamic effects and safety 
Importantly, our studies demonstrated that the improved neurological recovery provided by 
the Argon treatment is associated with no effects on hemodynamics, respiratory function 
and gas exchange in both preclinical models. The absence of detrimental effects after 
Argon inhalation was also confirmed by data obtained in anesthetized domestic healthy 
pigs subjected to 4-h ventilation with Argon (Experiment 3). Several publications support 
our observations. In fact, no study has ever reported safety concerns related to exposure to 
inhalation of Argon. Hemodynamic parameters and blood gases were monitored during 
Argon ventilation in several in vivo studies (Brücken 2013, 2014, 2015 and 2017, Zuercher 2016, 
David 2012, Alderliesten 2014, Broad 2016, Ryang 2011, Pagel 2007, Martens 2017). In all these 
studies, Ar affected neither hemodynamics nor ventilation, in terms of respiratory gas 
exchange. In addition, in three studies body weight was also reported as an indicator of 
animal’s wellbeing during the days after Ar ventilation and none of them reported 
significant changes (Zuercher 2016, Höllig 2016, Zhuang 2012). Furthermore, two studies aimed 
to specifically evaluate the safety of Argon ventilation in pigs. In one study, neonatal 
piglets were ventilated with Argon at different concentrations, ranging from 30% to 80% in 
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O2, for a total of 3 h. Again, effects on hemodynamics and blood gases were evaluated, 
together with those on electrical brain activity (Alderliesten 2014). Prolonged ventilation with 
Ar was confirmed to be safe, at each concentration, in this setting. In the other study a 6-h 
ventilation with Argon 79% in pigs, showed no toxic effects, as demonstrated by analysis 
of serum biomarkers and histological assessment of liver and kidney function and structure 
(Martens 2017). There are 3 additional studies which evaluated the safety of Argon referring 
to its use as substitute of CO2 in inducing pneumoperitoneum during laparoscopic surgery 
(Roberts 1997, Eisenhauer 1994, Mann 1997). Argon insufflations into the abdominal cavity 
produced hemodynamic modifications, mainly related to increases in abdominal pressure 
and perhaps to a potential effect on systemic vascular resistances. No significant changes 
in respiratory functions were observed. Since Argon is lesser soluble than CO2, an 
increased risk of hemodynamic instability exits in the instance of accidental gas embolism 
(Roberts 1997). Finally, because Argon is denser than air, it could be argued that ventilation 
with such a gas could increase respiratory resistances (Behnke 1939).  However, none of the 
preclinical studies have reported such a condition after prolonged exposure to Argon. 
Moreover, a study with a model of vigorous ventilation in a respiratory resistance machine, 
showed no changes in respiratory resistance at atmospheric pressure, and up to 4 atm, 
when Argon 80% was compared to air (Behnke 1939). To conclude, Argon administration 
could be considered safe and its potential use in humans should now be addressed. 
3 Cardioprotection by Argon 
Our data indicated that ventilation with Argon was associated with a slightly smaller left 
ventricular infarct size and lesser hs-cTnT release in pigs with myocardial infarction and 
CA. The presence of cardioprotective effect of Argon after myocardial 
ischemia/reperfusion was also demonstrated previously, although the number of studies 
was limited. Overall, these studies provided evidence for a reduced infarct size and an 
improved left ventricle systolic function, evaluated either by echocardiography or magnetic 
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resonance. Moreover, beside increasing cell viability (Mayer 2016), Argon also diminished 
early after depolarizations in the ventricle tissue, limiting the onset of ischemia-triggered 
arrhythmias. When Argon was applied on the human right atrial appendages after ischemia 
reperfusion injury, the recovery of contractile activity was increased compared to the 
control treatment (Lemoine 2017). To address specifically the effect of Argon inhalation on 
myocardial protection and its mechanism of action, we employed a rat model of coronary 
occlusion and reperfusion. The mechanism of cardioprotection by Argon described in two 
different paper are based on the inhibition of the opening of the mitochondrial permeability 
transition pore. Indeed, apart from ischemia, reperfusion can also contribute to cell death, 
and, particularly on cardiomyocytes, it can induce ventricular arrhythmias and contractile 
dysfunction subsequent to the opening of the mitochondrial permeability transition pore. 
Mitochondrial permeability transition pore is a non- selective channel of the inner 
mitochondrial membrane that opens at reperfusion, causing mitochondrial calcium - 
phosphate overload and alteration of mitochondrial membrane potential. For such 
pathophysiological effects, this channel could be a target in cardioprotection. 
Phosphatidylinositol-3-kinase (PI3K), ERK 1-2 and 70 kDa ribosomal protein s6 kinase 
(p70s6K) inhibit mitochondrial permeability transition pore opening by their actions on 
several downstream signaling molecules that modulate the transition state of the pore either 
directly (e.g. endothelial nitric oxide synthase, p53, glycogen synthase kinase) or indirectly 
by affecting the pro- and anti-apoptotic B cell lymphoma protein. Thus, Ar by acting on 
the same pathways, directly or indirectly, via reperfusion injury salvage kinase (RISK), 
prevents the mitochondrial permeability transition pore opening (Lemoine 2017, Pagel 2007). 
Instead, we explored the hypothesis that Argon inhalation may reduce cardiac 
ischemia/reperfusion injury and this could be due to a reduction in inflammatory response. 
Nevertheless, although ventilation with Argon reduced myocardial damage in terms of hs-c 
TnT release, we were not able to attribute this beneficial effect to the reduction of 
inflammatory response. 
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The significance and innovation of this thesis work is the characterization of a promising 
and inexpensive therapeutic approach after CA and CPR: inhalation of Argon. Although 
noble gases are known as "inert" gases, these monatomic colorless, odorless agents can 
produce biological effects. Compared to other noble gases, and especially to the most 
widely investigated xenon, Argon has many advantages. Used at normobaric pressures, 
Argon has no hemodynamic properties and lacks hypnotic and anesthetic effects, thus 
making open-circuit administration feasible. In addition, Argon is ubiquitous in the 
atmosphere, being even more common than carbon dioxide, and it is available via 
extraction from liquefied air. Thus, Argon administration might be substantially 
inexpensive. Application of this promising gas may expand the neuro- and cardiac care.  
ArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonA
rgonArgonArgonArgonArgonArgonArgonArgonArgonArgonArgonConsidering the 
promising results of Argon inhalation after CA experimentally obtained and the apparently 
safe profile of its administration, the protocol of the “CardioPulmonary Resuscitation with 
Argon” – CPAr study, an upcoming phase I clinical trial, was submitted and approved to 
the Ethical Committee and is presented in the Appendix as preliminary draft. The aim of 
the CPAr study is to evaluate safety and feasibility of Argon ventilation in patients 
resuscitated from cardiac arrest, prior to its use as therapeutic agent.  
4 Limitations 
We recognize limitations in this thesis work. First, while the principal results obtained in 
the pig model of CA and CPR are very robust, the mechanistic explanation of the positive 
actions were limited to small rodents and are still preliminary. Thus, further work to 
elucidate the mechanism of Argon’s neuroprotection is needed. Second, the effects of 
Argon were not compared with those of other noble gases. However, earlier investigations 
have reported similar neuroprotective effects of Argon and the widely studied xenon. 
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ArgonArgonFinally, different onsets and durations of treatment have to be tested. 
Accordingly, further studies will be performed to address these issues.  
5 Conclusions 
The substantial knowledge on management of Argon gained from these studies should 
facilitate its clinical testing and possible its etrance in the clinical practice. Indeed, I 
believe this project has great translational relevance. Once the therapeutic approach with 
inhaled Argon in the preclinical setting is optimized, its subsequent clinical application 
with an optimized therapeutic strategy would be the next step.  
Compared to the fragmented informations emerging from the available literature on the 
clinical use of Argon, the approach adopted in the PhD studies reported within this thesis 
represents a structured investigation of different aspects of the Argon-based treatment of 
CA, and represents a valid background in order to move into the clinical setting.  
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Appendices 
Appendix 1 
CLINICAL STUDY PROTOCOL 
Rationale  
Ar, as shown in the above discussed preclinical studies, might diminish the neurological and 
myocardial damage after any hypoxic-ischemic insult. Indeed, Ar has been tested in different 
models of ischemic insult, at concentrations ranging from 20% up to 80%. Overall, Ar emerged as 
a protective agent on cells, tissue and organs, showing less cell death, reduced infarct size and 
faster functional recovery. More specifically, encouraging data has been reported in animal studies 
on cardiac arrest in which a better and faster neurological recovery was achieved when Ar was used 
in the post-resuscitation ventilation. More importantly, these beneficial effects played by Ar have 
been replicated in different studies, enrolling both small and large animals (12–16,48). Finally, 
ventilation with Ar in O2 has been demonstrated to be safe both in animals and humans (35,60,63). 
Thus, based on this evidence, a clinical translation is advocated.  
Thus, the CardioPulmonary resuscitation with Argon – CPAr study has been conceived. The aim of 
the CPAr study is to evaluate safety and feasibility of Ar ventilation in patients resuscitated from 
cardiac arrest, prior to its use as therapeutic agent.  
Methods  
Study design  
CPAr study is phase I, open label randomized controlled intervention study performed in patients 
resuscitated from out-of-hospital (OH) CA and admitted to ICU of two tertiary hospitals in Italy. 
The study will be submitted for approval by the Institutional Ethical Committees and will be 
conducted in compliance with the World Medical Association Declaration of Helsinki. Only 
patients meeting the inclusion criteria and from whom informed consent for the use of the data are 
obtained, either directly from the patient or from her/his legal representative, are included in the 
study.   
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Inclusion and exclusion criteria 
Inclusion criteria are: ICU admission after resuscitation from witnessed non-traumatic OHCA of 
presumably cardiac etiology with a presenting shockable rhythm; age ≥ 18 years; unconsciousness 
after ROSC; duration of CPR ≤ 30 min; CPR performed according to European Resuscitation 
Council 2015 guideline (64); initiation of study intervention ≤ 2 hrs from ROSC. Exclusion criteria 
are: age < 18 years; non-witnessed CA; CA of traumatic origin or from a non-presumably cardiac 
cause; CA with a non-shockable presenting rhythm (pulseless electrical activity and asystole); 
pregnancy; presumable irreversible death or known terminal illness; pre-CA CPC ≥ 3; participation 
in another clinical trial within the previous 30 days; initiation of the study intervention > 2 hrs from 
ROSC; refused informed consent to the use of data. 
Study procedures 
Upon ICU admission, the ventilation of the eligible patients is performed with the ventilator 
Bellavista 1000, IMT, Switzerland, a CE-approved device for clinical use and compatible with the 
ventilation with Ar 70% / O2 30%. A 30-min ventilation with air 70% and oxygen 30% is begun at 
ICU admission to evaluate the capability to maintain adequate arterial saturation with such a FiO2. 
Ventilator is set with pressure control mode with a tidal volume of 6-8 ml/kg, a PEEP of 5-10 
cmH2O and a respiratory ratio (RR) adjusted to obtain an arterial carbon dioxide partial pressure 
(paCO2) of 35-40 mmHg. Normoxia with an oxygen arterial saturation (SaO2) of 95%-98% are the 
target for ventilation. After this 30-min ventilation trial: 1) if the ventilation targets are not reached 
the study is discontinued and patient care continued according to 2015 ERC guidelines; 2) if the 
ventilation targets are reached, the patient is randomized to: a 4 hrs ventilation with Ar 
70%/oxygen 30%; or a 4 hrs ventilation with oxygen 30% in room air. After completion of the 
ventilation period, ventilation is switched to regular oxygen/air ventilation and subsequent 
management is performed according to 2015 ERC guidelines and local post-resuscitation protocols. 
In both groups, blood gases are measured at hourly intervals to determine pH, PaO2, PaCO2, HCO3- 
during ventilation and till one hour after completion of the experimental treatment. Subsequent 
blood gas analyses will be performed according to the local post-resuscitation care protocols. 
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The following data are collected: age, gender, body mass index, Sequential Organ Failure 
Assessment (SOFA) score, cause of CA, characteristics of the OHCA according to Ustein style, 
post-CA interventions (i.e. coronary angiography; percutaneous coronary intervention, 
hemodynamic support), pre-existing pathological conditions.  
Blood samples at 0, 6, 24, 48, and 96 hrs post-ROSC are withdrawn for analysis of: hs-cTnT; 
creatinine; transaminases; electrolytes; and lactates. NSE is measured at 48, 72 and 96 hrs after 
hospital admission. Survival to ICU discharge, hospital discharge and 1-month is evaluated 
together with the cerebral performance category (CPC) score. The responsible physician will call 
on the phone the patient to check for his vital status and neurological recovery at 1 month since the 
inclusion.  
Study endpoints 
The primary endpoint of the study is to identify any early adverse events related to Ar inhalatory 
treatment: inability to adequately ventilate using Ar/O2 within the predetermined setting (FiO2 30% 
and PEEP 5–10 cmH2O), i.e. an arterial O2 saturation < 95%; and/or appearance of detrimental Ar-
related hemodynamic adverse effects, i.e. arterial hypotension not responsive to fluids and/or 
vasopressor/inotropic drugs and malignant arrhythmias. 
In addition, data on potential delayed effects of Ar on survival and CPC at ICU discharge and at 1 
month later, are collected. 
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Statistics 
Since there is no data on the occurrence of adverse events and/or clinical safety of Ar treatment 
after OHCA, a formal sample size calculation cannot be performed. The sample size has been 
selected in order to establish sufficiently precise measures of safety and feasibility, while it is not 
powered to address any clinical efficacy. A number of 50 patients (25 per group) has been chosen 
to be included, as considered reasonable to detect an increase in adverse events related to Ar, in 
comparison to the control treatment. For this safety study, a concurrent control group was also 
considered, in order to better discriminate any adverse event related to Ar, but also to acquire data 
to be used for a correct sample size calculation for a subsequent phase II study. 
 
CONCLUSIONS 
Cardiac arrest is a public health issue with a severe impact on mortality and morbidity. Annually 
about 275.000 people in Europe experience OHCA, with an incidence rate of 38/100000 
people/year . Approximately 70-90% of individuals with OHCA die before reaching the hospital 
and those who survive cardiac arrest are likely to suffer post-cardiac arrest syndrome. This 
syndrome has a high mortality rate due to its unique pathophysiological process involving multiple 
organs. The main four components of this syndrome are: 1) post-CA brain injury, 2) post-CA 
myocardial dysfunction, 3) systemic ischemia and reperfusion response, 4) persistent precipitating 
pathology. Moreover, as many as 30% of survivors of CA manifest permanent brain damage and in 
some instances only 2–12% of resuscitated patients have been discharged from the hospital without 
neurological impairments.  
 
Despite the efforts to reduce brain injury and cardiovascular impairment after CA, outcome results 
are controversial and further approaches need to be established. So far, many supportive measures 
have been proposed and applied in clinical practice, but only temperature management appears as a 
possible neuroprotective treatment. In order to overcome this lack of treatment option, novel 
therapeutic approaches have been conceived and tested in the last decade, including volatile 
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anesthetics and noble gases, such as Ar, to allow for cerebral and myocardial preservation after CA. 
This study, will confirm that administration of Ar is safe and feasible and would provide 
preliminary data on clinical outcome, essential to design a subsequent phase II clinical study on 
efficacy. 
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Appendix 2 
 
Supplemental Table 1. From Scolletta 2012. 
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Supplemental Table 2. From Hochholzer 2010. 
 
  
149 
 
Supplemental Figure 1. Troponin levels dispatched according to the presence of a recent coronary 
lesion. Troponin I receiving operating characteristic (ROC) curve predicting a recent coronary lesion. From 
Dumas 2012. 
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Abstract  
Introduction. Duration of untreated cardiac arrest (CA), also known as “no-flow” time, is one of 
the main determinants of the severity of post-cardiac arrest syndrome (PCAS). However, CA 
models present a large variation in the duration of untreated CA, with often limited clinical 
relevance. The present study investigated the effect of different no-flow durations on post-
resuscitation myocardial and neurological injury and survival in a pig model with the aim to 
identify an optimal duration that adequately reflects the clinical scenario. 
Methods. An established model of myocardial infarction followed by CA and cardiopulmonary 
resuscitation (CPR) was used. The left anterior coronary artery was occluded and ventricular 
fibrillation induced in 22 male pigs. Animals were divided in 3 groups of different no-flow 
durations, namely short (8-10 min), intermediate (12-13 min), and long (14-15 min), prior to 
mechanical CPR and defibrillation. Arterial and central venous pressures were invasively 
monitored. Left ventricular (LV) systolic function, expressed as ejection fraction (EF), was 
echocardiographically assessed together with thermodilution cardiac output (CO) and high 
sensitivity cardiac troponin T (hs-cTnT) assay. Neurological impairment was evaluated by 
neurological scores, serum neuron specific enolase (NSE), and histological neuronal degeneration.  
Results. All pigs were successfully resuscitated except for one in the longest no-flow group. More 
than 60% of animals survived when the duration of CA was ≤ 13 min, compared to only 20% for a 
duration ≥ 14 min. Moreover, neuronal degeneration and neurological scores showed a trend 
towards a worse recovery for longer durations of no-flow; No animals achieved a good 
neurological recovery for a no-flow ≥ 14 min, in comparison to a 56% for a duration ≤ 13 min 
(p=0.043). Serum NSE levels were significantly correlated with the no-flow duration level (r=0.892, 
p<0.001). Longer durations of CA were characterized by significantly lower LV EF and CO 
compared to short durations (p<0.05). The longer was the duration of no-flow, the higher was the 
total number of defibrillation delivered (p=0.033) and this number of defibrillations correlated 
with LV EF impairment (r=-0.523, p=0.038) and with plasma hs-cTnT release (r=0.679, p=0.002). 
Conclusion. This porcine model showed a linear relation between the duration of untreated CA 
and the severity of PCAS. Indeed, longer no-flow durations caused greater post-resuscitation 
myocardial and neurological dysfunction and reduced the survival rate, in comparison to shorter 
durations. A duration of untreated CA of 12-13 min may be an optimal choice for clinically 
relevant CA models. 
 
Key words: No-flow; cardiac arrest; outcome; post-cardiac arrest syndrome; animal model. 
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Introduction 
Cardiac arrest (CA) is burdened by high mortality and severe neurological impairment among 
survivors.1 Up to 64% of out-of-hospital (OH) CA victims die on the scene or on the way to the 
hospital during ambulance transport.2 Moreover, more than half of the successfully resuscitated 
patients die within 72 hr after hospital admission,3,4 such that final survival is approximately 8% in 
Europe, with great differences among countries.2 Patients who eventually survive to hospital 
discharge, frequently suffer of a persistent neurocognitive impairment that deeply impacts the 
quality of life.1,4,5 Post-cardiac arrest syndrome (PCAS) is the responsible for these subsequent in-
hospital mortality and poor neurological outcome.3 
 
Novel therapeutic approaches have been conceived and tested in order to improve outcome of 
CA. Indeed, experimental models represent the starting point for evaluating the effect of new 
interventions prior to their implementation into the clinical practice. However, CA models are 
often not consistent in methods and experimental designs, such that their findings might be 
hardly reproduced in human trials. An example is represented by the duration of untreated 
cardiac arrest, known as “no-flow” time, that although recognized as one of the main 
determinants of the PCAS severity,6 remains highly variable in the experimental studies.7,8,9 This 
potentially raises concerns on the adequacy of available experimental models in reflecting the 
real clinical scenario.10  
 
Clinical studies report an average emergency medical service (EMS) arrival time to the CA scene of 
6-8 min;4,11–14 however, considering the intervals for emergency call, ambulance dispatch, arrival 
to the patient and onset of cardiopulmonary resuscitation (CPR), it is reasonable that the no-flow 
duration accounts for even longer periods. Based on that, the duration of untreated CA in 
experimental models should reasonably last more than 8 min to adequately reflect the clinical 
OHCA environment. Indeed, a shorter or a longer experimental no-flow duration may be 
associated with a lesser or a more severe PCAS in the animal, respectively,6 such that the studied 
interventions may overestimate or fail to show any effect on outcome of CA. 
 
The present study investigates the effect of different durations of untreated CA on post-
resuscitation myocardial and neurological injury and survival in a pig model of CPR with the aim to 
identify an optimal no-flow interval to be used for interventional experimental studies. 
 
Materials and method 
All procedures involving animals and their care were in conformity with national and international 
laws and policies. Approval of the study was obtained by the institutional review board 
committee and governmental institution.  
 
Animal Preparation 
Twenty-two male domestic pigs (40 ± 1 kg) were fasted the night before experiment except for 
free water access. Anesthesia was induced by intramuscular injection of ketamine (20 mg/kg) 
followed by intravenous administration of propofol (2 mg/kg) and sufentanyl (0.3 μg/kg) through 
an ear vein access. Anesthesia was then maintained by continuous intravenous infusion of 
propofol (4-8 mg/kg/hr) and sufentanyl (0.3 μg/kg/hr). A cuffed tracheal tube was placed, and 
animals were mechanically ventilated with a tidal volume of 15 mL/kg and FIO2 of 0.21. 
Respiratory frequency was adjusted to maintain the end-tidal PCO2 (EtCO2) between 35 and 40 
mmHg, monitored with an infrared capnometer.8 For measurement of aortic pressure, a fluid-
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filled 7F catheter was advanced from the right femoral artery into the thoracic aorta. For 
measurements of right atrial pressure, core temperature, and cardiac output, a 7F pentalumen 
thermodilution catheter was advanced from the right femoral vein into the pulmonary artery. 
Conventional pressure transducers were used (MedexTransStar, Monsey, NY). Myocardial 
infarction was induced in a closed-chest preparation by intraluminal occlusion of the left anterior 
descending (LAD) coronary artery with the aid of a 6F balloon-tipped catheter inserted from the 
right common carotid artery.8 For inducing ventricular fibrillation (VF), a 5F pacing catheter was 
advanced from the right jugular vein into the right ventricle. The position of all catheters was 
confirmed by characteristic pressure morphology and/or fluoroscopy. Frontal plane 
electrocardiogram was recorded. Heart rate and rhythms were monitored by electrocardiograms 
(EKG). 
 
Experimental procedure 
The balloon of the LAD coronary artery catheter was then inflated with 0.7 mL of air to occlude 
the flow. If VF did not occur spontaneously, after 10 min it was induced with 1 to 2 mA AC current 
delivered to the right ventricle endocardium.8 Ventilation was discontinued after onset of VF. 
After 8 to 15 min of untreated VF, CPR, including chest compressions with the LUCAS 2 
(PhysioControl Inc, Lund, Sweden) and ventilation with oxygen (tidal volume of 500 mL, 10 
breaths/min), was initiated. More specifically, six pigs had a no-flow time of 8 min, two of 10 min, 
five of 12 min, three of 13 min, one of 14 min and five of 15 min. For homogeneous comparison, 
animals were assigned to three groups of no-flow duration: “short” 8-10 min (n=8); 
“intermediate” 12-13 min (n=8); and “long” 14-15 (n=6). After 5 min of CPR, defibrillation was 
attempted with a single biphasic 150-J shock, using an MRx defibrillator (Philips Medical Systems, 
Andover, MA). If resuscitation was not achieved, CPR was resumed and continued for 1 min 
before a subsequent defibrillation. Adrenaline (30 µg/kg) was administered via the right atrium 
after 2 and 7 min of CPR. Successful resuscitation was defined as restoration of an organized 
cardiac rhythm with a mean arterial pressure (MAP) of more than 60 mmHg. After that, if VF 
reoccurred, it was treated by immediate defibrillation. After successful resuscitation, anesthesia 
was maintained, and animals were monitored during the 4-h treatment. Forty-five minutes after 
resuscitation, the LAD coronary artery catheter was withdrawn. Temperature of the animals was 
maintained at 38°C ± 0.5°C during the whole experiment. After 4 h of treatment, catheters were 
removed, wounds were repaired, and the animals were extubated and returned to their cages. 
Analgesia with butorphanol (0.1 mg/kg) was administered by intramuscular injection. At the end 
of the post-resuscitation observation period, up to 96 h, animals were reanesthetized for 
echocardiographic examination and blood sample withdrawn. Animals were then sacrified 
painlessly with an intravenous injection of 150 mg/kg sodium tiopenthal, and heart and brain 
were harvested. Autopsy was performed routinely for potential injuries due to CPR or obfuscating 
disease. 
 
Measurements  
Hemodynamics, ETCO2, and electrocardiogram were recorded continuously on a personal 
computer-based acquisition system (WinDaq DATAQ Instruments Inc, Akron, OH). The coronary 
perfusion pressure was computed from the differences in time-coincident diastolic aortic pressure 
and right atrial pressure. Cardiac output (CO) was measured by thermodilution technique (COM-2; 
Baxter International Inc, Deerfield, IL). Echocardiography was performed using a phase-array 
multifrequency 2.5- to 5-MHz probe (CX50, Philips, The Netherlands), and left ventricular (LV) 
ejection fraction (EF) was calculated using the modified single-plane Simpson’s rule.8 Arterial 
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blood gases were assessed with i-STAT System (Abbott Laboratories, Princeton, NJ). Plasma high-
sensitivity cardiac troponin T (hs-cTnT) and serum neuron-specific enolase (NSE) were measured 
with electrochemiluminescence assays (Roche Diagnostics Italia, Monza, Italy). 
 
As previously described,8 neurologic recovery was assessed with the neurologic alertness score 
(NAS), ranging from 100 (normal) to 0 (brain death), and with the swine neurologic deficit score 
(NDS), ranging from 0 (normal) and 400 (brain death). Finally, the functional recovery was 
evaluated prior to sacrifice according to overall performance categories (OPCs) as follows: 1 = 
normal, 2 = slight disability, 3 = severe disability, 4 = coma, and 5 = brain death or death.8 
Outcome was defined poor when OPC was ≥ 3. Scores were assessed by veterinarian doctors 
blinded to treatment. 
 
At sacrifice, the brains were carefully removed from the skulls and fixed in 4% buffered formalin. 
Standardized 5-mm coronal slices were taken. The hippocampal CA1 sector and the cortex were 
chosen as regions of interest and were paraffin embedded. Five-micrometer-thick sections were 
then obtained and stained with hematoxylin-eosin. The proportion of neuronal loss and 
degeneration/necrosis (shrunken neurons with deeply acidophilic cytoplasm and pyknotic 
nucleus) was quantified as absent (0), rare (1), few (2), and numerous (3). An experienced 
pathologist, blinded to treatment, performed the assessments. For transmission electron 
microscopy (TEM) analysis, samples from hippocampus were reduced and fixed with 4% 
paraformaldehyde and 2% glutaraldehyde in phosphate buffer 0.12 mol/l pH 7.4 overnight at 4°C, 
followed by incubation at room temperature for 2 h in 2% OsO4. After dehydration in a graded 
series of ethanol preparations, tissue samples were cleared in propylene oxide, embedded in 
epoxy medium (Epoxy Embedding Medium kit; Sigma-Aldrich) and polymerised at 60°C for 72 h. 
Ultra-thin (60 nm thick) sections of areas of interest were obtained with a Leica EM UC6 
ultramicrotome (Leica Microsystems), counterstained with uranyl acetate and lead citrate and 
examined with Energy Filter Transmission Electron Microscope (EFTEM, ZEISS LIBRA® 120) 
equipped with YAG scintillator slow scan CCD camera. 
 
Myocardial infarct was assessed by tetrazolium chloride (TTC) staining. The LV was sliced into 5-
mm-thick transverse sections, which were incubated (20 min) in a solution of TTC and then 
transferred to 4% formalin overnight before image analysis. Infarct size was reported as 
percentage of TTC-negative area relative to LV area.8 
 
Statistical Analysis 
One sample Kolmogorov–Smirnov Z test was used to confirm normal distribution of the data. For 
comparisons of time-based variables, repeated measures analysis of variance (ANOVA) was used. 
For comparisons between groups at the given time points, one-way ANOVA with Tukey’s multiple 
comparison was used for normally distributed variables, while Kruskal-Wallis test with Dunn’s 
multiple comparison was used for not normally distributed variables. When the dependent 
variable was categorical, χ2 test was performed. Linear correlations between parametric variables 
were calculated using the Pearson correlation coefficient. Spearman test was performed for the 
non-parametric variable correlation analyses. For survival analysis, Kaplan-Meier survival curves 
and log-rank (Mantel-Cox) test were used. Data are expressed as mean±SEM, except for CPR 
duration, number of defibrillations delivered, hs-cTnT and NSE, presented as median [Q1-Q3]. A p 
≤ 0.05 was regarded as statistically significant. Data analyses were performed using GraphPad 
Prism (version 6.05 for Windows, GraphPad Software, USA). 
155 
 
 
Results 
No significant differences in hemodynamic parameters, EtCO2, cardiac function and blood gases 
analysis were observed between groups at baseline (Table 1). Duration of CPR was similar in the 3 
groups (p not significant) and all animals were successfully resuscitated except for 1 animal in the 
long duration group. More than 80% of animals in the short and 60% in the intermediate no-flow 
duration survived for more than 3 days, in contrast to only 20% in the long duration group 
(p=0.007 long vs. short, Table 1 and Figure 1). The longer was the duration of no-flow, the higher 
was the total number of defibrillations delivered (p=0.042), with a 5-fold difference between the 
long and the short duration groups (p<0.05, Table 1 and Figure 2).  
 
Resuscitation outcomes, post-resuscitation hemodynamics, and blood gas analyses data are 
shown in Table 1. No significant differences in MAP were observed among the groups, except for 
a trend towards a higher MAP in the short no-flow group compared to the others (Table 1). 
Animals subjected to longer durations of no-flow presented significantly higher post-resuscitation 
HR and RAP and a lower LV CO, compared to those in the shorter durations (p=0.040, p<0.001, 
and p=0.032, respectively Table 1).  
 
LV EF decreased in each group after resuscitation (Figure 3). Post-resuscitation LV EF was 
significantly lower in the long duration group compared to the short one (p<0.05). LV EF at 4 h 
post-resuscitation was inversely correlated with the duration of no-flow (r=-0.65, p=0.006, Figure 
3). Moreover, an inverse relationship between LV EF and the number of delivered defibrillations 
was observed (r=-0.52, p=0.038, Figure 2). 
 
LV infarct size was comparable after short or intermediate duration of no flow, while it was 
greater in the single animal that survived in the long duration group (Table 1). Hs-cTnT release 
significantly correlated with the LV infarct size (r=0.77, p=0.004). There was a trend towards 
higher plasma levels of hs-cTnT in the long duration group, but there was no correlation between 
hs-cTnT and the duration of no-flow (Figure 4). Nevertheless, levels of hs-cTnT were significantly 
related to the number of defibrillations received by the animals (r=0.679, p=0.002, Figure 2).  
 
Sixty-two % of the animals resuscitated in the short and 50% in the intermediate no-flow duration 
group survived with a good neurological recovery (OPC ≤ 2), in contrast to no animal in the long 
duration group, in which only one of the 5 resuscitated animals survived and had a OPC of 3 
(p=0.043, Figure 5). NAS and NDS showed a trend towards a worse recovery for longer durations 
of no-flow, with the worst scores observed in the group with the longest duration of untreated CA 
(Figure 5). NSE release paralleled the trend observed in the neurological recovery, with higher 
circulating levels in the instance of longer durations of no-flow (p=0.021 for short vs. 
intermediated group, Figure 4). Indeed, the duration of untreated CA strongly correlated with NSE 
release (r=0.892, p<0.001, Figure 4).  
 
Neurological recovery and NSE data were confirmed by the histological findings, showing greater 
neuronal degeneration/necrosis in hippocampus and in cortex for increasing no-flow durations, 
with the single animal survived in the long duration group showing the most severe neuronal 
injury with associated gliosis and perivascular inflammation (Figures 5 and 6). Ultrastructural 
imaging showed mitochondria in neurons undergoing degenerative processes of increasing 
severity, i.e. disruption of cristae and reduction of matrix density, for longer no-flow durations; 
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neuropil, normally composed by a tightly packed myriad of axons, dendrites and glial processes, 
also presented a progressive vacuolization and loss of structure (Figure 7).  
 
Discussion 
The present study systematically investigated, for the first time, the effect of different no-flow 
intervals on PCAS severity in an experimental model, describing a linear association between the 
duration of untreated CA and the correspondent heart and brain injury. Indeed, longer no-flow 
durations were associated with lower percentage of survival and worse post-resuscitation 
myocardial dysfunction and neurological recovery compared to shorter durations. These findings 
can be applied experimentally in order to design more clinically relevant studies.  
 
Duration of no-flow is one of the key features that deeply impact CA survival13,15,16 and 
neurological injury.14,17 Designing realistic models for preclinical research, with specific attention 
on the duration of untreated CA, is therefore crucial to correctly evaluate the potential benefits of 
new interventions for the treatment of CA and PCAS. For this reason, the no-flow duration should 
be wisely selected in order to obtain an experimental model that closely reflects the 
pathophysiology of CA and PCAS and whose observations might be easily translated clinically.10 In 
our model, only when the duration of no-flow exceeded 12 min, data on survival were similar to 
those observed clinically,18 while with shorter durations a survival above 80% was still present. A 
duration of untreated CA of 12-13 min showed the best compromise in terms of severity of 
myocardial and neurological injury and survival, with outcomes that resembled those observed in 
the clinical scenario.4 In our opinion the no-flow duration of 12-13 min may be an optimal choice 
for CA experimental models, while with longer no-flow intervals, i.e. ≥ 14 min, the mortality was 
unacceptably high. Moreover, in the view of using a preclinical model to investigate new 
neuroprotective interventions, a CA duration ≥ 14 min determined probably a too extensive 
neuronal and mitochondrial damage with important loss of ultrastructure, such that any potential 
benefit might be obfuscated.   
 
Surprisingly, CA duration is extremely variable in CPR models.7–9 In a review including 42 
experimental articles, significant differences in research methodology have been reported, 
highlighting a poor clinical representativeness in the majority of the studies. More specifically, the 
duration of untreated CA ranged from 0 to 15 min, with the majority of the experiments 
employing a duration as short as 3 min or even lesser.10 In other recent reviews on animal models 
of CA, longer no-flow intervals, close to 8 min, were reported.19,20 Nevertheless, in our model, an 
untreated CA with a duration up to 10 min caused a limited injury, considering that all the animals 
were easily resuscitated and almost 90% of them survived during the whole observational period.  
 
After the initial success of CPR, the majority of patients die within 72 h from hospital admission, 
due to a variable severity of PCAS.3,6 Most prominent are post-resuscitation cardiac failure and 
ischemic brain damage. In our model, when the duration of untreated CA was < 14 min, a survival 
with a good neurological recovery was observed in approximately 60% of animals, while it 
occurred in 0% for a longer duration. This was concordant with the trend observed in the 
behavioral scores used to assess the neurocognitive status during the days after resuscitation and 
with the neuronal degeneration, which paralleled the duration of untreated CA, both in the 
hippocampus and in the frontal cortex. Thus, our results suggest that a clinically relevant model of 
CA should use longer durations of no-flow, i.e. > 12-13 min, to achieve a good balance between 
post-resuscitation neurocognitive injury and mortality, with a more clinical relevance. 
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The myocardial dysfunction observed after CA is a transient phenomenon due to cell stunning 
rather than permanent injury, that usually spontaneously reverses within the following 2-3 
days.3,17,21 In our model, the post-resuscitation myocardial dysfunction, evaluated by LVEF, was 
deeply depressed in all groups of animals during the first 4 h post-resuscitation, with a greater 
impairment after a duration > 14 min. The reason for a worse myocardial dysfunction after a 
longer untreated CA may be explained as the result of a more severe ischemic insult, as supported 
by the 2-fold greater infarct size in the single animal that survived and by the higher plasma hs-
cTnTs in this group of animals. Another explanation for the greater post-resuscitation myocardial 
dysfunction after longer durations may be represented by the greater number of defibrillations 
delivered to the animals.22 Indeed, repetitive defibrillations are known to increase the severity of 
post-resuscitation myocardial dysfunction23 and in our study, the longer was the duration of now 
flow, the greater was the number of defibrillation attempts and such a number of electrical 
countershocks was significantly related with the systolic dysfunction, represented by the LVEF 
impairment, and with the myocardial injury, reported as hs-cTnT release.  
 
We recognize several limitations in the interpretation of our findings. First, the study did not 
assess the effect of different CPR or “low-flow” durations, which are known to potentially play a 
role in outcome.24 Second, the effect of body temperature on neurological outcomes was not 
evaluated, although target temperature management (TTM) is currently a standard of care after 
OHCA for its beneficial effects on survival and neuroprotection.4,25,26 Nevertheless, the quality of 
CPR was standardized and the duration of CPR was similar in all the groups. Moreover, all the 
animals received the same post-resuscitation management, with the core temperature 
maintained at normothermia during the 4 h of intensive observation. Indeed, the main focus of 
the study was to assess the impact of the sole no-flow duration on outcome of CA, excluding any 
other potential bias, i.e. TTM or duration of CPR. Therefore, our results are robust in order to 
show the direct impact of no-flow duration on the severity of PCAS and outcome of CA.  
 
Conclusions 
In this porcine model, a linear relation between the duration of untreated CA and the severity of 
PCAS was observed. Indeed, longer no-flow durations caused greater post-resuscitation 
myocardial and neurological dysfunction and reduced the survival rate, in comparison to shorter 
durations. A duration of untreated CA of 12-13 min may be an optimal choice for clinically 
relevant CA animal models, because it yields survival rates and neurological outcomes similar to 
those observed in the clinical scenario.  
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Table 1. Resuscitation outcomes, hemodynamics and blood gas analysis 
 Short 
8-10 min 
n=8 
Intermediate 
12-13 min 
n=8 
Long 
14-15 min 
n=6 
p 
value 
ANOVA 
Total defibrillations, n 3 [1;10] 10 [2;11] 15 [11;26] * 0.042 
Duration of CPR, min 315 
[300;509] 
361 [325;455] 480 [334;757] 0.307 
Successful resuscitation, n/n 
(%) 
8/8 (100) 8/8 (100) 5/6 (83) 0.247 
Long-term survival,  n/n (%) 7/8 (88) 5/8 (63) 1/5 (20) * 0.078 
Heart Rate, beat/min 
BL 
PR2h 
PR4h 
 
99 ± 10 
127 ± 6 
130 ± 8 
 
93 ± 8 
156 ± 13 
129 ± 12 
 
86 ± 8 
164 ± 11 * 
143 ± 5 
 
0.602 
0.040 
0.595 
Mean Arterial Pressure, 
mmHg 
BL 
PR2h 
PR4h 
 
99 ± 4 
82 ± 6 
92 ± 7 
 
101 ± 3 
85 ± 6 
76 ± 2 
 
96 ± 5 
92 ± 2 
78 ± 6 
 
0.702 
0.571 
0.107 
Right Atrial Pressure, mmHg 
BL 
PR2h 
PR4h 
 
5 ± 1 
7 ± 1 
7 ± 1 
 
6 ± 1 
8 ± 1 
7 ± 0 
 
8 ± 1 
9 ± 1 
12 ± 0 **## 
 
0.081 
0.346 
<0.001 
End-Tidal CO2, mmHg 
BL 
PR2h 
PR4h 
 
36 ± 0 
36 ± 0 
36 ± 1 
 
37 ± 1 
36 ± 0 
36 ± 0 
 
36 ± 0 
37 ± 1 
37 ± 0 
 
0.406 
0.302 
0.633 
163 
 
LV CO, L/min 
BL 
PR2h 
PR4h 
 
4.5 ± 0.5 
3.3 ± 0.3 
3.2 ± 0.3 
 
4.4 ± 0.3 
3.3 ± 0.3 
3.2 ± 0.4 
 
4.0 ± 0.3 
2.8 ± 0.6 
1.9 ± 0.1 * 
 
0.735 
0.604 
0.032 
LV infarct size area, % 9.7 ± 2.0 6.5 ± 0.7 13.1 § 
pH 
    BL 
    PR2h 
    PR4h 
 
7.495 ± 0.017 
7.434 ± 0.026 
7.462 ± 0.017 
 
7.519 ± 0.016 
7.394 ± 0.042 
7.429 ± 0.027 
 
7.513 ± 0.027 
7.395 ± 0.017 
7.410 ± 0.011 
 
0.636 
0.583 
0.251 
PaO2, mmHg 
BL 
PR2h 
PR4h 
 
79 ± 11 
89 ± 7 
88 ± 3 
 
83 ± 5 
109 ± 8 
100 ± 11 
 
83 ± 2 
84 ± 10 
70 ± 9 
 
0.931 
0.111 
0.074 
PaCO2, mmHg 
BL 
PR2h 
PR4h 
 
38 ± 2 
40 ± 1 
42 ± 1 
 
37 ± 1 
39 ± 1 
40 ± 1 
 
37 ± 1 
41 ± 1 
42 ± 1 
 
0.789 
0.615 
0.302 
HCO3, mmol/L 
BL 
PR2h 
PR4h 
 
29.3 ± 1.0 
27.2 ± 0.9 
29.9 ± 1.1 
 
30.3 ± 1.2 
24.5 ± 2.0 
26.8 ± 1.3 
 
29.8 ± 1.2 
25.4 ± 0.7 
26.7 ± 0.4 
 
0.828 
0.353 
0.088 
BE, mmol/L 
BL 
PR2h 
PR4h 
 
6.4 ± 1.1 
3.1 ± 1.4 
6.1 ± 1.3 
 
7.4 ± 1.5 
-0.2 ± 2.6 
2.5 ± 1.5 
 
6.7 ± 1.6 
0.5 ± 1.0 
2.0 ± 0.4 
 
0.865 
0.402 
0.089 
 
Data are expressed as mean±SEM. BL, baseline; PR2h 2 h post-resuscitation; PR4h 4 h post-
resuscitation; CO, Cardiac Output; EF, Ejection Fraction; PR, post-resuscitation; LV, left ventricle. 
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* p<0.05 and ** p<0.01 vs. “short”; # p< 0.05 and ## p<0.01 vs. “intermediate”. 
§ ANOVA was not performed due to a single animal survived in the “long” group. 
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Legend to Figures 
 
Figure 1. Kaplan–Meier of post-resuscitation survival after an untreated cardiac arrest of short, 
intermediate, and long duration.  
 
Figure 2. A. Total number of defibrillations prior to successful resuscitation after an untreated 
cardiac arrest of short, intermediate, and long duration between groups. B. Correlation between 
total number of defibrillations and duration of untreated cardiac arrest. C. Correlation between 
total number of defibrillation and left ventricular ejection fraction (LV EF) at 4 h post-
resuscitation. D. Correlation between total number of defibrillations and plasma high sensitive 
cardiac troponin T (hs-cTnT) at 4 h post-resuscitation. 
 
Figure 3. A. Left ventricular ejection fraction (LV EF) at baseline (BL), and at 2 and 4 h post-
resuscitation (PR), and at sacrifice, after an untreated cardiac arrest of short, intermediate, and 
long duration. B. Correlation between the no-flow duration and LV EF at PR 4 h. 
*p<0.05 vs. short duration group. 
 
Figure 4. A. Plasma high sensitive cardiac troponin T (hs-cTnT) levels at baseline (BL), and at 2 and 
4 h post-resuscitation (PR), and at sacrifice, after an untreated cardiac arrest of short, 
intermediate, and long duration. B. Correlation between the duration of untreated cardiac arrest 
(CA) and the release of hs-cTnT at PR 4 h. C. Serum neuronal specific enolase (NSE) levels at 
baseline and at sacrifice. D. Correlation between the duration of untreated CA and the release of 
NSE at sacrifice.  
* p < 0.05 vs. short duration group (long duration group was not included in the analysis due to 
sample size of survived animals, n=1). 
 
Figure 5. A. Overall Performance Category (OPC, upper figure), B. Neurological Alertness Score 
(NAS), and C. Neuronal Deficit Score (NDS), after an untreated cardiac arrest of short, 
intermediate, and long duration. D. Neuronal degeneration in the hippocampal CA1 sector and in 
cortex after an untreated cardiac arrest of short, intermediate, and long duration. 
* p < 0.05 vs. long duration group. 
 
Figure 6.  A. Hematoxylin-eosin staining 200x magnification of hippocampal CA1 sector (A) and 
cortex (B) after an untreated cardiac arrest (CA) of short, intermediate, and long duration. 
Short duration: hippocampus - some degenerated/necrotic neurons characterized by shrinkage, 
deeply acidophilic cytoplasm and pyknotic nucleus are intermixed with numerous normal 
neurons; cortex - normal histological appearance of the nervous tissue.  
Intermediate duration: hippocampus - numerous degenerated/necrotic neurons with some 
normal neurons still detectable (on the left side of the picture); cortex - presence of some 
degenerated/necrotic neurons. 
Long duration: hippocampus - almost all neurons are degenerated/necrotic; cortex -  severe 
damage characterized by the presence of numerous degenerated/necrotic neurons, gliosis and 
perivascular inflammatory cells cuffing. 
 
Figure 7.  Ultrastructural analysis of hippocampus. Representative images by transmission 
electron microscopy of neurons (mitochondria indicated by white arrows) and neuropil (single 
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vacuoles indicated by asterisks and agglomerated vacuoles encircled), after an untreated cardiac 
arrest (CA) of short, intermediate, and long duration. 
Short duration: mitochondria show only irregular shapes and moderate damage of inner 
membranes; neuropil normally composed by a tightly packed myriad of axons, dendrites and glial 
processes presents some vacuolated and enlarged processes. 
Intermediate duration: mitochondria show disruption of cristae and remarkable reduction of 
matrix density; neuropil shows a more evident vacuolization. 
Long duration: mitochondria show a complete loss of internal components; the confluence of 
vacuoles determines an edematous-like massive loss of the neuropil.  
  
167 
 
Figure 1 
 
  
168 
 
Figure 2 
 
  
169 
 
Figure 3  
 
 
  
170 
 
Figure 4 
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Figure 5 
 
  
172 
 
Figure 6 
 
  
173 
 
Figure 7 
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